

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Comparing biparametric to multiparametric MRI in the diagnosis of clinically significant prostate cancer in biopsynaive men (PRIME): a prospective, international, multicentre, non-inferiority, within-patient, diagnostic yield trial protocol

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-070280
Article Type:	Protocol
Date Submitted by the Author:	19-Nov-2022
Complete List of Authors:	Asif, Aqua; University College London, Division of Surgery and Interventional Science Nathan, Arjun; University College London, Division of Surgery and Interventional Science; Royal College of Surgeons of England, Clinical Effectiveness Unit Ng, Alexander; University College London, Division of Surgery and Interventional Science Khetrapal, Pramit; University College London, Division of Surgery and Interventional Science; Whipps Cross University Hospital, Department of Urology Chan, Vinson Wai-Shun; University College London, Division of Surgery and Interventional Science Giganti, Francesco; University College London, Division of Surgery and Interventional Science; University College London, Division of Surgery and Interventional Science; University College London Hospitals NHS Foundation Trust, Department of Radiology Allen, Clare; University College London Hospitals NHS Foundation Trust, Department of Radiology Freeman, Alex; University College London Hospitals NHS Foundation Trust, Department of Radiology Punwani, Shonit; University College London Hospitals NHS Foundation Trust, Department of Histopathology Punwani, Shonit; University College London Hospitals NHS Foundation Trust, Department of Radiology; University College London, Centre for Medical Imaging Lorgelly, Paula; University College London, Institute of Epidemiology and Health Care; The University College London, Research Department of Primary Care and Population Health Brew-Graves, Chris; University College London, National Cancer Imaging Translational Accelerator Muirhead, Nicola; University College London, National Cancer Imaging Translational Accelerator Emberton, Mark; Universit

	Research Centre Takwoingi, Yemisi; University of Birmingham, Test Evaluation Research Group, Institute of Applied Health Research; University Hospitals Birmingham NHS Foundation Trust, NIHR Birmingham Biomedical Research Centre Deeks, Jonathan; University of Birmingham, Test Evaluation Research Group, Institute of Applied Health Research; University Hospitals Birmingham NHS Foundation Trust, NIHR Birmingham Biomedical Research Centre Moore, Caroline; University College London, Division of Surgery and Interventional Science; University College London Hospitals NHS Foundation Trust, Department of Urology Kasivisvanathan, Veeru; University College London, Division of Surgery and Interventional Science; University College London Hospitals NHS Foundation Trust, Department of Urology Trial Group, PRIME; University College London
Keywords:	Prostate disease < UROLOGY, Magnetic resonance imaging < RADIOLOGY & IMAGING, RADIOLOGY & IMAGING, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Urological tumours < ONCOLOGY

SCHOLARONE[™] Manuscripts

2		
3	1	Comparing biparametric to multiparametric MRI in the diagnosis of clinically significant prostate
4	2	cancer in biopsy-naive men (PRIME): a prospective, international, multicentre, non-inferiority
5	3	within-patient, diagnostic yield trial protocol
6 7	4	
/ 8	5	Authors:
9	6	Aqua Asif ^{1†}
10	7	Ariun Nathan ^{1,2†}
11	, 8	Alexander Ng ¹
12	9	Dramit Khetranal ^{1,3}
13	10	Vinson Wai-Shun Chan ¹
14	11	Francosco Cigantil ⁴
15	12	
16	12	
17	13	Alex Freeman ³
18	14	Shonit Punwani ^{4,0}
19	15	Paula Lorgelly ^{7,8}
20	16	Caroline S Clarke ⁹
21	17	Chris Brew-Graves ¹⁰
22	18	Nicola Muirhead ¹⁰
25	19	Mark Emberton ^{1,11}
24 25	20	Ridhi Agarwal ^{12,13}
25	21	Yemisi Takwoingi ^{12,13}
27	22	Jon Deeks ^{12,13}
28	23	Caroline M Moore ^{1,11}
29	24	Veeru Kasivisvanathan ^{1,11}
30	25	On behalf of the PRIME Trial Group*
31	26	
32	27	[†] Joint first authors have made equal contribution to this study
33	28	
34	29	*PubMed Indexed Collaborators (PRIME Trial Group)
35	20	John Wilkinson, Marimo Rossiter, Réka Novotta, Philip Ryan, Alex Kirkham, Jouise Dickinson, Tushar
36	21	Narain, Hazel McRain, Antonetto Androws, Daniel Margelis, Valeria Danebianco, Antti Panniko, Deter
3/	27	Alberteen Janes Munderee Adam Freeming Nacki Takabasi Tristan Parrett Panbade Penard
30	52 22	Albertsen, Lance Mynuelse, Adam Floenning, Naoki Takanasi, Instali Barrett, Rapidele Kenard
39 40	33	Perina, Vibeke Løgager, Lars Boesen, Sangeet Grial, Lars Budaus, Valeria Pariebiarico, Enrique Gomez
41	34	Gomez, Jeremy Grummet, Tho Pham, Alman Halder, Jing Yi Jessica Weng, Anders Bjartell, Wim Witjes,
42	35	Christien Caris, Joke Van Egmond.
43	36	
44	37	Affiliations:
45	38	1. Division of Surgery and Interventional Science, University College London, London, United
46	39	Kingdom
47	40	2. Clinical Effectiveness Unit, The Royal College of Surgeons of England, United Kingdom
48	41	3. Department of Urology, Whipps Cross Hospital, Barts Health NHS Trust, London, United Kingdom
49	42	4. Department of Radiology, University College London Hospital NHS Foundation Trust, London,
50	43	United Kingdom
51	44	5. Department of Pathology, University College London Hospitals NHS Foundations Trust, London,
52 53	45	United Kingdom
55 54	46	6. Centre for Medical Imaging, University College London, London, United Kingdom
54 55	47	7. Institute of Epidemiology and Health Care, University College London, London, United Kingdom
56	48	8. School of Population Health, The University of Auckland. Auckland. 1023. New Zealand
57	49	9. Research Department of Primary Care and Population Health, University College London, London
58	50	United Kingdom
59		
60		

1		
2		
4	51	10. National Cancer Imaging Translational Accelerator, Division of Medicine, University College
5	52	London, London, United Kingdom
6	53	11. Department of Urology, University College London Hospital NHS Foundation Trust, London, United
7	54	Kingdom 12. Test Evolution December Crown, Institute of Applied Health December Huivensity of Directorhead
8	55	12. Test Evaluation Research Group, Institute of Applied Health Research, University of Birmingham,
9	50	Birmingham, United Kingdom
10	57	13. NIAR Birmingham Biomedical Research Centre, University Hospitals Birmingham NAS Foundation
12	58	Trust, University of Birmingham, Birmingham, United Kingdom
13	59	Corresponding Authory
14	60 61	Corresponding Author:
15	62	
16	62	Weel ukasi Division of Surgery and Interventional Science, University College London, London, United Kingdom
17	03 64	Division of Surgery and Interventional Science, University Conege London, London, Onited Kingdom
18	04 65	Konverde
19 20	05 66	Reywords:
20	67	prostate cancer, diagnostic, MRI, prostate, biopsy
22	69	Current word count: 2659
23	60	Figure limit: No limits on figures or tables
24	70	Figure count: 1
25	70	Box count: 2
26	71	Table count: 5
2/	72	Sunnlementary annendix count: 3
20 29	73	Supplementary appendix count. S
30	75	
31	75	
32	70 77	Strength: DPIME is a progratic prospective international multicentre trial being carried out
33	79	• Strength. Prime is a plagmatic, prospective, international, multicentre that being carried out
34	70	 Strength: Its within-patient design allows nations to act as their own control improving the
35	80	• Strength. its within-patient design allows patients to act as their own control, improving the
30 27	80 81	• Strength: Its within-nations design allows the impact of the dynamic contrast enhanced
38	82	sequences on staging decisions and treatment eligibility to be made at an individual nations
39	83	
40	84	• Strength: PRIME will be one of the first trials to quality control the performance of sites'
41	85	dynamic contrast enhanced sequences prior to their involvement in the trial
42	86	Limitation: as both biparametric and multiparametric targeted biopsies are carried out in the
43	87	same patient it is possible for the performance of one technique to influence the other
44	88	sume patient it is possible for the performance of one testinique to inducted the other
45 46	89	
47	05	
48		
49		
50		
51		
52 52		
55 54		
55		
56		
57		
58		
59		
60		

ABSTRACT

Introduction

Prostate MRI is a well-established tool for the diagnostic work-up for men with suspected prostate cancer. Current recommendations advocate the use of multiparametric MRI (mpMRI), which is comprised of three sequences: T2-weighted (T2W), diffusion-weighted (DWI), and dynamic contrast enhanced (DCE). Prior studies suggest that a biparametric MRI approach (bpMRI), omitting the DCE sequences, may not compromise clinically significant cancer detection, though there are limitations to these studies, and it is not known how this may affect treatment eligibility. A bpMRI approach will reduce scanning time, may be more cost effective and at a population level, allow more men to gain access to an MRI than a mpMRI approach.

Methods

PRIME is a prospective, international, multicentre within-patient diagnostic yield trial, assessing whether bpMRI is non-inferior to mpMRI in the diagnosis of clinically significant prostate cancer. Patients will undergo the full mpMRI scan. Radiologists will be blinded to the dynamic contrast enhanced sequence (DCE) and will initially report the MRI using only the bpMRI (T2W and DWI) sequences. They will then be unblinded to the DCE sequence and will then re-report the MRI using the mpMRI sequences (T2W, DWI and DCE). Men with suspicious lesion(s) on either bpMRI or mpMRI will undergo prostate biopsy. The main inclusion criteria is men with suspected prostate cancer, with a serum PSA of \leq 20 ng/mL and no prior prostate biopsy. The primary outcome is the proportion of men with clinically significant prostate cancer detected (Gleason \geq 3+4 or Gleason Grade Group \geq 2). A sample size of at least 500 patients is required. Key secondary outcomes include the proportion of clinically insignificant prostate cancer detected and treatment decision.

Ethics and Dissemination Ethical approval was obtained from the National Research Ethics Committee West Midlands, Nottingham 21/WM/0091. Results of this trial will be disseminated through peer-reviewed publications. Participants and relevant patient support groups will be informed about the results of the trial.

Registration details NCT04571840

STUDY TITLE

Long Title: A trial assessing whether biparametric MRI is non-inferior to multiparametric MRI in the diagnosis of clinically significant prostate cancer

Short Title: Prostate Imaging Using MRI +/- Contrast Enhancement

Trial Acronym: PRIME

This protocol was written according to SPIRIT guidelines (1).

INTRODUCTION

Magnetic Resonance Imaging (MRI) is widely established as the gold standard diagnostic imaging modality for detecting clinically significant prostate cancer (PCa) (2). The landmark PRECISION study established the benefit of detecting clinically significant prostate cancer using MRI and targeting biopsies based on MRI findings (3). The National Prostate Cancer Audit data from England showed that only one in two men receive an MRI before biopsy in 2019 (5).

Current recommendations for the use of MRI for detection of PCa focus on the use of multiparametric MRI (mpMRI) (3, 4). mpMRI consists of three sequences: T2-weighted (T2W), diffusion-weighted (DWI) and dynamic contrast enhanced (DCE) sequences. On the DCE sequences, cancer-suspicious areas can demonstrate early wash-in, enhancement and rapid wash-out of contrast (6-8). The DCE sequences involve administering gadolinium contrast via an intravenous cannula. Therefore, it increases scanning time and healthcare costs compared to a bpMRI approach where only T2W and DWI are used. It is also known that the gadolinium contrast material accumulates in the basal ganglia, though its clinical relevance is not fully understood (9).

Removing the DCE sequences from the MRI protocol has been suggested as a potential avenue to improve the cost-effectiveness of using MRI in the diagnostic pathway for PCa (10, 11) and the reduced scanning time required may improve the number of men with suspected prostate cancer accessing an MRI scan. Using bpMRI has demonstrated similar detection rates of PCa as mpMRI but current evidence is limited primarily to retrospective, single-centre studies (11, 12). The few prospective studies have not been typically robustly designed to evaluate the role of DCE in prostate cancer detection (12, 13).

The PRIME trial aims to assess whether bp-MRI is non-inferior to mpMRI in the detection of clinically significant prostate cancer. PRIME may redefine the standard of care diagnostic test for men with suspicion of PCa and allow many more patients who need access to an MRI to get one.

Objectives

The primary objective is to compare the detection of clinically significant PCa (Gleason \geq 3+4 or Gleason Grade Group \geq 2) using bpMRI ± targeted biopsy with mpMRI ± targeted biopsy.

Key secondary objectives include:

- To compare the proportion of men who have clinically insignificant PCa (Gleason 3+3 or Gleason Grade Group 1) detected for bpMRI versus mpMRI
- To compare the proportion of men with non-suspicious MRIs for bpMRI versus mpMRI •
- To compare the proportion of men with indeterminately-scored MRI as reported by bpMRI • and mpMRI
 - To compare the proportion of men with MRIs of adequate standard for reporting for bpMRI • versus mpMRI
 - To compare the diagnostic test performance for bpMRI versus mpMRI •
 - To compare radiological staging for bpMRI versus mpMRI •
 - To compare treatment eligibility decisions for bpMRI when compared with mpMRI
 - To compare diagnostic performance of bpMRI and mpMRI when using the Likert scoring • system in comparison to the PI-RADS v2.1 scoring system
- To compare the cost effectiveness of bpMRI when compared to mpMRI

³ 177 Trial Design

The PRIME trial is designed as a prospective, multicentre, within-patient, diagnostic yield trial, assessing whether bpMRI is non-inferior to mpMRI for the diagnosis of clinically significant PCa in biopsy-naive men. A paired cohort design was chosen rather than a randomised trial design for the following reasons:

- More efficient design (sevenfold lower sample size required) with equivalent quality of evidence in the setting of a diagnostic study
- Patients act as their own control due to the within-patient design, thus allowing us to draw
 conclusions regarding the value of DCE sequences on a per patient level
 - Allows for the evaluation of the impact of contrast on staging decisions and treatment eligibility decisions at an individual patient level
 - Patients get the benefit of having targeted biopsies based on the information from both bpMRI and mpMRI information, whereas with a randomised study, patients randomised to one technique will be denied of potential benefit of the other

192 METHODS AND ANALYSIS

21 193 Trial Setting

We expect centres who perform prostate cancer diagnostics and management from the following countries to take part: Argentina, Australia, Belgium, Brazil, Canada, Denmark, France, Finland, Germany, Italy, Netherlands, Singapore, Spain, UK and USA. Sites will be required to undergo a period of quality control prior to including patients to ensure minimum acceptable standards for the conduct of mpMRI, reporting and targeted biopsy.

200 Eligibility Criteria

Patients will be considered eligible for registration into this trial if they fulfil all of the inclusion criteria
 and none of the exclusion criteria (**Box 1**).

205		
	Box 1	Eligibility criteria
	Inclusi	on criteria
	1.	Men at least 18 years of age referred with clinical suspicion of prostate cancer
	2.	Serum PSA \leq 20 ng/mL
	3.	Fit to undergo all procedures listed in protocol
	4.	Able to provide written informed consent
	Exclus	ion criteria
	1.	Prior prostate biopsy
	2.	Prior treatment for prostate cancer
	3.	Prior prostate MRI on a previous encounter
	4.	Contraindication to MRI (e.g. claustrophobia, some pacemakers)
	5.	Contraindication to prostate biopsy
	6.	Unfit to undergo any procedures listed in protocol
204		
205	Interver	itions
206	MRI Con	duct
207	MRI will	be conducted with 1.5T or 3.0T with pelvic-phased array coils, with or without endorectal
208	coils. Th	e PRECISION study quality control highlighted that the image quality of the DCE sequences
209	was the	most variable sequence across sites (3). Therefore, to give DCE a reasonable chance of
210	demons	trating whether it has value, MRI scanner approval for use in the study will be made on the
211	basis of	central review of MRI images, utilising the Prostate imaging Quality (PI-QUAL) scoring system
212	(14). In	brief, PI-QUAL is a 5-point Likert scoring system, where 1 indicates no sequences are of
213	ulagnos	ic quality and 5 implies that each sequence individually is of optimal diagnostic quality. The
214	objectiv	e chiena used to determine PI-QUAL scores are derived from internationally published

1		
2		
5 4	215	minimum standards for MRI conduct (15). If necessary, sites will be given recommendations to
	216	improve image quality and will be re-evaluated after optimisation for participation in the study.
6	217	
7	218	Reporting of MRI
8	219	Patients will undergo (or will have undergone) standard of care mpMRI as per their local protocol. The
9	220	radiologists participating in this trial will be blinded to the DCE sequences and will report the MRI using
10	221	only the biparametric (T2W and DWI) sequences in Report 1. After reporting the bpMRI, the same
11	222	radiologist will be unblinded to the DCE sequences and will re-report the MRI using the mpMRI
12	223	sequences (T2W, DWI and DCE) in Report 2 (Figure 1).
13	224	
14 15	225	The MRIs and lesions are scored on a 1–5 scale of suspicion for the likelihood that clinically significant
16	226	PCa is present, with 5 representing the greatest score of suspicion. Both the traditional Likert and PI-
17	227	RADS v2.1 scoring systems will be used to identify any suspicious lesions in the prostate. Suspicious
18	228	areas (Likert or PI-RADS v2.1 ≥3) on either bpMRI or mpMRI will undergo targeted biopsy of the
19	229	prostate, with cores from contrast-enhanced suspicious areas stored separately.
20	230	
21	231	A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2. Please see
22	232	Supplementary Appendix 1 for our model reporting proformas, which radiologists participating in the
23	233	PRIME trial will use to label lesions.
24	234	
25 26	235	Non-suspicious bpMRI and mpMRI
20 27	236	Men whose MRIs do not show suspicious areas on bpMRI and mpMRI (i.e. scored 1 or 2 on Likert and
28	237	PI-RADS v2.1) will be stratified by PSA density. Men with PSA density <0.15ng/mL/mL will not undergo
29	238	biopsy and men with PSA density ≥ 0.15 mg/mL/mL will undergo systematic biopsy.
30	220	
	233	
31	235	Box 2 Summary of MRI reporting rules
31 32 22	235	Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI)
31 32 33 34	235	Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) 1 The radiologist reporting this will be blinded to DCE with verification of this via an
31 32 33 34 35	235	Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) 1. The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc)
31 32 33 34 35 36	235	Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) 1. The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) 2 The radiologist should then interpret the bnMRI sequences blinded to DCE
31 32 33 34 35 36 37	233	 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Un to 4 supprisious areas (score ≥ 3 out of 5 on the likert or PL-RADS v2 1 scoring system)
31 32 33 34 35 36 37 38	235	 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be
31 32 33 34 35 36 37 38 39	235	 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on
31 32 33 34 35 36 37 38 39 40	235	 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on
31 32 33 34 35 36 37 38 39 40 41	233	 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-corter diagram
31 32 33 34 35 36 37 38 39 40 41 42	233	 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram
31 32 33 34 35 36 37 38 39 40 41 42 43	233	 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after leaking at the DCE
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 	233	 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 	233	 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 	233	 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE Report 2 (multiparametric MRI: T2W, DWI and DCE)
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 	233	 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE Report 2 (multiparametric MRI: T2W, DWI and DCE) The same radiologist must report both Report 1 and Report 2 The use is the processed
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 		 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE Report 2 (multiparametric MRI: T2W, DWI and DCE) The same radiologist must report both Report 1 and Report 2 They will then be unblinded to the DCE sequence
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 		 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE Report 2 (multiparametric MRI: T2W, DWI and DCE) The same radiologist must report both Report 1 and Report 2 They will then be unblinded to the DCE sequence The radiologist should now complete Report 2
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 		 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE Report 2 (multiparametric MRI: T2W, DWI and DCE) The same radiologist must report both Report 1 and Report 2 They will then be unblinded to the DCE sequence The radiologist should now complete Report 2 The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram value area value.
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52 		 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE Report 2 (multiparametric MRI: T2W, DWI and DCE) The radiologist should now complete Report 2 The radiologist should now complete Report 2 The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 		 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W, DWI and DCE) The same radiologist must report both Report 1 and Report 2 The vill then be unblinded to the DCE sequence The radiologist should now complete Report 2 The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 		 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W, and DWI) has been done, this cannot be altered after looking at the DCE Report 2 (multiparametric MRI: T2W, DWI and DCE) The same radiologist must report both Report 1 and Report 2 They will then be unblinded to the DCE sequence The radiologist should now complete Report 2 The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above On Report 2, each of the existing lesions are additionally labelled as one of:
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56		 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE Report 2 (multiparametric MRI: T2W, DWI and DCE) The same radiologist must report both Report 1 and Report 2 They will then be unblinded to the DCE sequence The radiologist should now complete Report 2 The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above On Report 2, each of the existing lesions are additionally labelled as one of:
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 		 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE Report 2 (multiparametric MRI: T2W, DWI and DCE) The same radiologist must report both Report 1 and Report 2 The vill then be unblinded to the DCE sequence The radiologist should now complete Report 2 The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above On Report 2, each of the existing lesions are additionally labelled as one of: bpMRI positive, mpMRI positive This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on <i>either</i> Likert or PI-PADC of a content purchase.
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58		 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE Report 2 (multiparametric MRI: T2W, DWI and DCE) The same radiologist must report both Report 1 and Report 2 The vill then be unblinded to the DCE sequence The radiologist should now complete Report 2 The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above On Report 2, each of the existing lesions are additionally labelled as one of: bpMRI positive, mpMRI positive This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on <i>either</i> Likert or PI-RADS v2.1 scoring systems
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 54 55 56 57 58 59		 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE Report 2 (multiparametric MRI: T2W, DWI and DCE) The same radiologist must report both Report 1 and Report 2 They will then be unblinded to the DCE sequence The radiologist should now complete Report 2 The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above On Report 2, each of the existing lesions are additionally labelled as one of: bpMRI positive, mpMRI positive This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on <i>either</i> Likert or PI-RADS v2.1 scoring systems

This c but a	occurs when a lesion scores 3, 4 or 5 on bpMRI on <i>either</i> Likert or PI-RADS v2.1 scoring systems, Iso scores a 1 or 2 on mpMRI on both Likert and PI-RADS v2.1 scoring systems
bpMI	RI negative, mpMRI positive
	There are two instances in which new targets may be labelled and drawn onto Report 2:
1	. New lesions scoring 3, 4 or 5, identified by DCE not previously identified on bpMRI should be marked on as new lesions as DCE Targets and bpMRI negative, mpMRI positive
2	 Lesions that appear larger on DCE should be treated as 2 separate targets One target depicts the completely overlapping segment from Report 1 (bpMRI positive, mpMRI positive) The non-overlapping part which would otherwise not be sampled should be labelled as a new target (bpMRI negative, mpMRI positive). This is a subjective decision by the radiologist. A typical example of when to declare this as a separate target is if the non-overlapping part enters an adjacent sector on the PI-RADS v2.1 sector diagram
	A bionsy plan is recommended by the radiologist thereafter for the bionsy operator to
follow	A biopsy plan is recommended by the radiologist thereafter for the biopsy operator to
Men w which lesion, separa	vill undergo MRI-targeted biopsy if either their bpMRI or mpMRI identifies a suspicious lesion scores ≥3 on either Likert or PI-RADS v2.1. Four targeted cores will be taken per suspicious and these should be stored and labelled in separate containers to ensure cancer detection from te suspicious areas are ascertained.
System	natic Bionsy
System contra are bili	natic biopsies should be performed after targeted biopsies, with 6 cores taken from the lateral side of the MRI lesion, focused on sampling the peripheral zone of the prostate. If there ateral MRI lesions or midline lesions, then no systematic biopsies are necessary.
Please	
	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted.
Prosta	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted.
Both tl	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i>
cucii li	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> ne Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for ndividual target lesion.
Pre-Tri	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> he Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for idividual target lesion.
Pre-Tri For all	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> he Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for idividual target lesion. <i>al Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal
Pre-Tri For all digital	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> he Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for individual target lesion. <i>al Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal rectal examination). To confirm a patient's eligibility, screening will be undertaken. Patients can
Pre-Tri For all digital enter t	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> he Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for ndividual target lesion. <i>al Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal rectal examination). To confirm a patient's eligibility, screening will be undertaken. Patients can he trial either before or after they have had their mpMRI scan. If patients are recruited after an
Pre-Tri For all digital enter t mpMR	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> he Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for ndividual target lesion. <i>al Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal rectal examination). To confirm a patient's eligibility, screening will be undertaken. Patients can he trial either before or after they have had their mpMRI scan. If patients are recruited after an I scan has been carried out, this will only be permitted if the MRI has not been seen by any
Pre-Tri For all digital enter t mpMR clinicia	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> he Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for ndividual target lesion. <i>al Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal rectal examination). To confirm a patient's eligibility, screening will be undertaken. Patients can he trial either before or after they have had their mpMRI scan. If patients are recruited after an I scan has been carried out, this will only be permitted if the MRI has not been seen by any n.
Pre-Tri For all digital enter t mpMR clinicia	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> he Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for ndividual target lesion. <i>Cal Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal rectal examination). To confirm a patient's eligibility, screening will be undertaken. Patients can he trial either before or after they have had their mpMRI scan. If patients are recruited after an I scan has been carried out, this will only be permitted if the MRI has not been seen by any n.
Pre-Tri For all digital enter t mpMR clinicia Registri Follow	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> he Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for ndividual target lesion. <i>Cal Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal rectal examination). To confirm a patient's eligibility, screening will be undertaken. Patients can he trial either before or after they have had their mpMRI scan. If patients are recruited after an I scan has been carried out, this will only be permitted if the MRI has not been seen by any n. <i>ration Procedures</i> ing consent and confirmation of eligibility, trial processes can commence. The patient will be
Pre-Tri For all digital enter t mpMR clinicia Registi Follow registe	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> the Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for individual target lesion. <i>Tal Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal rectal examination). To confirm a patient's eligibility, screening will be undertaken. Patients can the trial either before or after they have had their mpMRI scan. If patients are recruited after an I scan has been carried out, this will only be permitted if the MRI has not been seen by any n. <i>ration Procedures</i> ing consent and confirmation of eligibility, trial processes can commence. The patient will be red and assigned a trial ID using a central online database (Marvin by XClinical)
Pre-Tri For all digital enter t mpMR clinicia Registri Follow registe	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> the Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for individual target lesion. <i>Cal Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal rectal examination). To confirm a patient's eligibility, screening will be undertaken. Patients can the trial either before or after they have had their mpMRI scan. If patients are recruited after an I scan has been carried out, this will only be permitted if the MRI has not been seen by any n. <i>ration Procedures</i> ing consent and confirmation of eligibility, trial processes can commence. The patient will be red and assigned a trial ID using a central online database (Marvin by XClinical).
Pre-Tri For all digital enter t mpMR clinicia Registri Follow registe	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> the Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for individual target lesion. <i>Cal Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal rectal examination). To confirm a patient's eligibility, screening will be undertaken. Patients can the trial either before or after they have had their mpMRI scan. If patients are recruited after an I scan has been carried out, this will only be permitted if the MRI has not been seen by any n. <i>ration Procedures</i> ing consent and confirmation of eligibility, trial processes can commence. The patient will be red and assigned a trial ID using a central online database (Marvin by XClinical). <i>ration Procedures</i>

All patients will undergo a full mpMRI scan. This includes T2W, DWI and DCE sequences. Follow-Up for Results If bpMRI and mpMRI is non-suspicious and PSA density is <0.15 ng/mL/mL, the patient will be counselled for standard of care follow-up – typically consisting of PSA surveillance. If a decision for prostate biopsy or other tests is made, these results will be recorded after which the participant completes the trial. Multidisciplinary Team Decision-Making for Treatment Eligibility Treatment decisions will be per local standard of care, based on pathology results and will be recorded. Subsequently, a virtual multidisciplinary team meeting will be conducted and treatment eligibility decisions blinded to the DCE will be recorded. Once a decision has been recorded, the clinicians will be unblinded to the DCE sequence and the impact that this information makes on treatment eligibility will be evaluated. MRI and Pathology Quality Control Quality control will be carried out at the end of the study by the PRIME chief radiologists reviewing the original MRIs, who will assess the MRI quality and re-report the MRI blinded to the study reports. Anonymised pathology slides from a proportion of patients may also be reviewed by central pathologists. Any slides assessed outside of the originating site will be returned to the original site after quality control. Quality control results will be reported but will not influence patient management or outcomes. Cost-Effectiveness A within-trial incremental cost-effectiveness analysis will be conducted to calculate the difference in mean cost per diagnosis of clinically significant prostate cancer if a strategy of bpMRI were adopted instead of the current mpMRI standard of care, over a time horizon of 30 days. The difference in cost of avoiding each additional case of clinically insignificant prostate cancer diagnosed may also be calculated. Costs of procedures will be estimated by applying standard unit costs to resource use data captured within the trial plus other procedures that would be offered to patients in either pathway. Estimates of the resources used (procedures, tests, radiotherapy, chemotherapy, other therapies, surveillance visits, and other care events) on the two treatment pathways will be obtained for the theoretical bpMRI cohort using decisions made initially by the MDT with information from the bpMRI scan and any biopsies as a result of that scan; and estimates of the treatment pathway resources used in the theoretical mpMRI cohort will be made subsequently by the MDT on viewing additional information from the mpMRI scan and any further biopsies performed as a result of that scan. This thought experiment is required due to the ethical requirement to use all available information, i.e. not just bpMRI and biopsies or just mpMRI and biopsies, when making the actual treatment decision with the patient. The analysis perspective will be that of the NHS and personal social services. Standard unit costs (e.g. NHS Reference Costs) will be supplemented by unit cost data from the participating trial sites. A microcosting study to provide this information will be undertaken in a small number of sites as part of the trial to investigate the resources employed to deliver bpMRI and mpMRI scans. This information will allow us to understand the MRI booking system, consumption of consumables, and staff time as related to delivering bpMRI and mpMRI scans. Depending on the within-trial cost-effectiveness findings, consideration will be given to extending this analysis using decision analytic modelling to estimate quality-adjusted life-years gained (QALYs) over BMJ Open

2		
3	322	a lifetime horizon. Quality of life information will be estimated from anonymised patient-level data by
4	323	the same group from an earlier study in this instance.
5	324	
0 7	325	Outcomes
/ 8	326	Primary Outcome
9	327	The primary outcome will be the proportion of men with clinically significant PCa detected – any
10	328	nattern 4 disease on any core (<i>i.e.</i> Gleason $>3+4$ or Gleason Grade Group >2). The time frame for
11	320	assessment: when bionsy results are available, at an expected average of 30 days nost-bionsy
12	220	assessment. when biopsy results are available, at an expected average of 50 days post biopsy.
13	330	Secondary Outcomes
14	222	Table 1 lists our secondary outcomes
15	332 333	Table I lists our secondary outcomes.
16	333	
17	334	sample size
18	335	The margin of clinical unimportance to allow a conclusion of non-inferiority of bpMRI to mpMRI to be
19	336	made was set at 5 percentage points – i.e. if the lower bound of the 95% confidence intervals (CIs) for
20	337	the difference in detection rates of bpMRI-targeted biopsy compared to mpMRI-targeted biopsy is
21	338	above -5 percentage points, then bpMRI will be deemed as non-inferior.
22	339	Using simulation, an mpMRI underlying probability of detecting clinically significant cancer of 38% (3)
23	340	and the following, two key probabilities were used to determine the sample size:
25	341	
26	342	A. The probability that a patient found to have no suspicious lesions on bpMRI or have no
27	343	clinically significant PCa on bpMRI-targeted biopsy will have clinically significant PCa on mpMRI-
28	344	targeted biopsy
29	345	B. The probability that a patient found to have no suspicious lesions on mpMRI or have no
30	346	clinically significant PCa on mpMRI-targeted biopsy will have clinically significant PCa on bpMRI-
31	347	targeted biopsy
32	348	
33	349	Assuming the probability of A is greater than the probability of B, and applying McNemar's test in each
34	350	of 1.000 simulation runs for each combination of probabilities A and B ranging from 0 to 0.05, a sample
30	351	size of 400 patients gives more than 90% power across these probabilities of A and B. Accounting for
30	352	20% dropout or exclusion after enrolment, at least 500 patients will be required
38	353	
39	354	Recruitment
40	355	At each narticinating site enrolment will occur at outnatient clinics. With at least 25 sites, it is
41	256	estimated that the trial will complete within 24 months of commencement. The trial opened for
42	250	recruitment in April 2022 and the estimated completion date is April 2024
43	220	recruitment in April 2022 and the estimated completion date is April 2024.
44	220	Data Collection Mathada
45	202	The electronic case report form (aCDE) system Marvin by VClinical will be used to callect data
46	300	The electronic case report form (eCRF) system Marvin by Aclinical will be used to collect data.
4/	361	
48	362	Patient-Reported Outcome Measures
49 50	363	The International Index of Erectile Function (IIEF-5) and the International Prostate Symptom Score
51	364	(IPSS) will be utilised to assess baseline erectile function and lower urinary tract symptoms,
52	365	respectively. These questionnaires will aid the multidisciplinary team decision-making for treatment
53	366	eligibility.
54	367	
55	368	Patient Retention
56	369	It is estimated that loss to follow-up will be no more than 20% due to the expected short time interval
57	370	between enrolment and end of study. It is expected that the majority of patients will complete the
58	371	trial within 4 to 6 weeks (Table 2A, Table 2B).
59	372	
60		

³ 373 Statistical Methods

A statistical analysis plan will be finalised before our database lock and before any statistical analysis occurs. A consort diagram will be presented. All continuous variables will be described using the mean and standard deviation, or median and interquartile range, as appropriate. Categorical variables will be described using frequencies and percentages. Baseline characteristics will be examined and presented for those with and those without clinically significant PCa. The assumptions underpinning the statistical methods used will be assessed. The use of transformations will be considered to satisfy statistical assumptions.

12 381

13
14382Primary Outcome Analysis

The primary outcome is the difference in the proportion of men with clinically significant PCa, as detected by bpMRI-targeted biopsy compared to mpMRI-targeted biopsy. The proportion of men with clinically significant PCa, Gleason \geq 3+4 or Gleason Grade Group \geq 2, detected by bpMRI-targeted biopsy is defined as the number of men with clinically significant PCa identified on bpMRI-targeted biopsy divided by the number of men undergoing bpMRI. Similarly, the proportion of men with clinically significant PCa detected by mpMRI-targeted biopsy is defined as the number of men with clinically significant PCa identified on mpMRI-targeted biopsy divided by the number of men undergoing mpMRI. Methods that account for the paired nature of the data such as McNemar's test will be used to compare bpMRI and mpMRI.

25 392 26 393 Secondary Outcome Analysis

The proportion of men with clinically insignificant cancer (any cancer core with Gleason 3+3 or Gleason grade group 1 detected by bpMRI-targeted biopsy will be compared to that of mpMRI-targeted biopsy. The proportion of men with clinically insignificant cancer detected by bpMRI-targeted biopsy is defined as the number of men with clinically insignificant prostate cancer identified on bpMRI-targeted biopsy divided by the number of men undergoing bpMRI. Similarly, the proportion of men with clinically insignificant cancer detected by mpMRI-targeted biopsy is defined as the number of men with clinically insignificant prostate cancer identified on mpMRI-targeted biopsy divided by the number of men undergoing mpMRI. The same analytical approach described for clinically significant PCa will be applied.

The number and proportion of men scoring 1 or 2 (non-suspicious) or 3 (indeterminate) on bpMRI and
 mpMRI will be reported. A two-way table will be produced to show the agreement between the two
 MRI results using the Likert scoring system on a scale of 1-5.

407
 42
 408 The number and proportion of men with adequate standard of reporting on bpMRI and mpMRI will
 43
 409 be reported.

A two-way table will be produced to show the number and proportion of patients with each radiological stage of bpMRI and mpMRI. Similarly, we will report the number and proportion of patients eligible for different treatment options following discussion of the bpMRI and mpMRI results in the Multidisciplinary Team meeting.

- Using histopathology as the reference standard, sensitivity, specificity, positive predictive value and negative predictive value with 95% CI of bpMRI and mpMRI will be reported. The following assumptions will be made, where non-suspicious MRI refers to a score of 1 or 2 and suspicious MRI refers to a score of 3, 4 or 5 on the Likert and PI-RADS v2.1 scoring systems and absence of clinically significant cancer refers to a combination of clinical insignificant and no cancer.
- The number and proportion of men with clinically significant cancer detected by systematic biopsy
 and not detected by bpMRI and mpMRI with targeted biopsy will be reported. A two-way table will be

BMJ Open

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

produced to show a comparison between systematic biopsy (no biopsy, clinically significant cancer, clinically insignificant cancer and no cancer) and the two MRI results with targeted biopsy (no biopsy, clinically significant cancer, clinically insignificant cancer and no cancer). Sensitivity and Other Planned Analyses The primary outcome analysis will be repeated with a definition of clinically significant PCa being any primary pattern 4 disease - Gleason 4+3 or Gleason Grade Group 3. Monitoring The NCITA Global Prostate Trial Steering Committee (TSC) is responsible for the governance of the PRIME Study. A sub-group of independent TSC members form the Data Monitoring Sub-Committee (DMSC). Roles and responsibilities of the TSC To act as the oversight body for up to five prostate cancer studies on behalf of the Sponsor and Funders. In addition, the independent members will form a DMSC to review safety. The role of the TSC is to provide oversight for the studies and provide advice through its Chair to the Chief Investigators (CI), whilst working in tandem with the DMSC, Sponsor, Funders and host institution on all aspects of the studies. The rights, safety and well-being of the study participants are the most important consideration and should prevail over the interests of science and society. Harms Adverse events (AEs) will be defined as 'any untoward medical occurrence in a clinical trial subject undergoing any intervention in the trial, which does not necessarily have a causal relationship with this treatment'. Serious adverse events (SAEs) will be defined as 'any untoward medical occurrence as a result of any intervention in the trial that: Results in death, • Is life-threatening Requires hospitalisation or prolongation of existing inpatients' hospitalisation, results in • persistent or significant disability or incapacity' AEs and SAEs will be recorded until 30 days post biopsy. In the event that the patient does not undergo biopsy, AEs and SAEs should be recorded until 30 days post-MRI. Unexpected AEs will be recorded by a member of the research team or clinical team on an AE report form eCRF. All SAEs must be recorded on an SAE report form eCRF which must be sent to the coordinating trials unit within 24 hours of knowledge of the SAE. Both AEs and SAEs should be recorded in the medical notes. Ethics and Approval The UK National REC (West Midlands – Black Country Research Ethics Committee, Nottingham) gave favourable approval for PRIME protocol version 2.0 on 26 May 2021 (Ref:21/WM/0091). All participating centres have gained local and ethical approvals prior to receiving a site initiation visit and approval by the sponsor to open for recruitment. Patient and Public Involvement Patients and public members were involved in defining the research question, evaluation of the research proposal, suggesting modifications to the trial, reviewing the patient information sheet,

	Protected by copyright, including for uses related to text and data mining, AI training, and simila	Erasmushogeschool .
9	ing, and similar technologies.	

2		
3	475	consent form and GP letter. Patient groups and charities will also be involved in the dissemination of
4	476	results.
5	477	
6 7	478	Consent
/ 8	479	The clinical teams managing patients with suspected PCa who are referred to their centre will identify
9	480	potential trial participants. Patient information sheets will be provided to patients. Members of staff
10	481	who are trained to take informed consent, as indicated by the PI on the delegation log for that site.
11	482	will take informed consent. A model patient information sheet is shown in Supplementary Appendix
12	483	3
13	484	
14	185	Confidentiality
15	405	The data of the participants will be recorded into the eCPE system and analysed without any personal
16	400	identifiers, by provide anotymiced coded information. A cite's source documents and identification
17	407 100	lists will be archived in a secured facility at that control
18	400	ists will be archived in a secured facility at that centre.
19	489	Disconsignation
20 21	490	
21	491	Results of this trial will be disseminated through national and international conferences and papers.
23	492	Authorship criteria will be based on recommendations of the International Committee of Medical
24	493	Journal Editors. The participants and relevant patient support groups will be informed about the
25	494	results of the trial.
26	495	
27	496	Access to Data
28	497	Only authorised individuals within the PRIME Clinical Operations Group have access to the final data
29	498	set. Individual PIs have access to their own data but not that of other sites.
30	499	
31	EUU	Declaration of Interacts
27	300	
32	500 501	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is
32 33 34	500 501 502	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The
32 33 34 35	501 502 503	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by
32 33 34 35 36	500 501 502 503 504	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of
32 33 34 35 36 37	500 501 502 503 504 505	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research
32 33 34 35 36 37 38	500 501 502 503 504 505 506	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical
32 33 34 35 36 37 38 39	500 501 502 503 504 505 506 507	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR
32 33 34 35 36 37 38 39 40	500 501 502 503 504 505 506 507 508	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants
32 33 34 35 36 37 38 39 40 41	500 501 502 503 504 505 506 506 507 508 509	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants from MRC, CRUK, Movember, and Prostate Cancer UK. VK is funded by Prostate Cancer UK and The
32 33 34 35 36 37 38 39 40 41 42	500 501 502 503 504 505 506 507 508 509 510	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants from MRC, CRUK, Movember, and Prostate Cancer UK. VK is funded by Prostate Cancer UK and The John Black Charitable Foundation. He receives speaker fees from the European Association of Urology,
32 33 34 35 36 37 38 39 40 41 42 43	500 501 502 503 504 505 506 507 508 509 510 511	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants from MRC, CRUK, Movember, and Prostate Cancer UK. VK is funded by Prostate Cancer UK and The John Black Charitable Foundation. He receives speaker fees from the European Association of Urology, Singapore Urology Association, The Clinical Comms Group and Got IT consulting SL. All authors declare
32 33 34 35 36 37 38 39 40 41 42 43 44	500 501 502 503 504 505 506 507 508 509 510 511 512	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants from MRC, CRUK, Movember, and Prostate Cancer UK. VK is funded by Prostate Cancer UK and The John Black Charitable Foundation. He receives speaker fees from the European Association of Urology, Singapore Urology Association, The Clinical Comms Group and Got IT consulting SL. All authors declare that there are no conflicts of interest. The views expressed in this publication are those of the authors
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46	500 501 502 503 504 505 506 507 508 509 510 511 512 513	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants from MRC, CRUK, Movember, and Prostate Cancer UK. VK is funded by Prostate Cancer UK and The John Black Charitable Foundation. He receives speaker fees from the European Association of Urology, Singapore Urology Association, The Clinical Comms Group and Got IT consulting SL. All authors declare that there are no conflicts of interest. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47	500 501 502 503 504 505 506 507 508 509 510 511 512 513 514	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants from MRC, CRUK, Movember, and Prostate Cancer UK. VK is funded by Prostate Cancer UK and The John Black Charitable Foundation. He receives speaker fees from the European Association of Urology, Singapore Urology Association, The Clinical Comms Group and Got IT consulting SL. All authors declare that there are no conflicts of interest. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care.
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48	500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 514 515	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants from MRC, CRUK, Movember, and Prostate Cancer UK. VK is funded by Prostate Cancer UK and The John Black Charitable Foundation. He receives speaker fees from the European Association of Urology, Singapore Urology Association, The Clinical Comms Group and Got IT consulting SL. All authors declare that there are no conflicts of interest. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care.
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49	500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants from MRC, CRUK, Movember, and Prostate Cancer UK. VK is funded by Prostate Cancer UK and The John Black Charitable Foundation. He receives speaker fees from the European Association of Urology, Singapore Urology Association, The Clinical Comms Group and Got IT consulting SL. All authors declare that there are no conflicts of interest. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care.
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50	500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants from MRC, CRUK, Movember, and Prostate Cancer UK. VK is funded by Prostate Cancer UK and The John Black Charitable Foundation. He receives speaker fees from the European Association of Urology, Singapore Urology Association, The Clinical Comms Group and Got IT consulting SL. All authors declare that there are no conflicts of interest. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care.
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51	500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants from MRC, CRUK, Movember, and Prostate Cancer UK. VK is funded by Prostate Cancer UK and The John Black Charitable Foundation. He receives speaker fees from the European Association of Urology, Singapore Urology Association, The Clinical Comms Group and Got IT consulting SL. All authors declare that there are no conflicts of interest. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care. WHO Trial Registration Dataset Please see Table 3 for the WHO trial registration dataset.
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52	500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants from MRC, CRUK, Movember, and Prostate Cancer UK. VK is funded by Prostate Cancer UK and The John Black Charitable Foundation. He receives speaker fees from the European Association of Urology, Singapore Urology Association, The Clinical Comms Group and Got IT consulting SL. All authors declare that there are no conflicts of interest. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care. WHO Trial Registration Dataset Please see Table 3 for the WHO trial registration dataset.
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53	500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants from MRC, CRUK, Movember, and Prostate Cancer UK. VK is funded by Prostate Cancer UK and The John Black Charitable Foundation. He receives speaker fees from the European Association of Urology, Singapore Urology Association, The Clinical Comms Group and Got IT consulting SL. All authors declare that there are no conflicts of interest. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care. WHO Trial Registration Dataset Please see Table 3 for the WHO trial registration dataset.
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants from MRC, CRUK, Movember, and Prostate Cancer UK. VK is funded by Prostate Cancer UK and The John Black Charitable Foundation. He receives speaker fees from the European Association of Urology, Singapore Urology Association, The Clinical Comms Group and Got IT consulting SL. All authors declare that there are no conflicts of interest. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care. WHO Trial Registration Dataset Please see Table 3 for the WHO trial registration dataset.
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 55	500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants from MRC, CRUK, Movember, and Prostate Cancer UK. VK is funded by Prostate Cancer UK and The John Black Charitable Foundation. He receives speaker fees from the European Association of Urology, Singapore Urology Association, The Clinical Comms Group and Got IT consulting SL. All authors declare that there are no conflicts of interest. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care. WHO Trial Registration Dataset Please see Table 3 for the WHO trial registration dataset. Current Protocol Version The current protocol is V.2.0, issued 27 April 2021. The current protocol amendment number is 01. For full amendment history, please see Table 4.
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57	500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants from MRC, CRUK, Movember, and Prostate Cancer UK. VK is funded by Prostate Cancer UK and The John Black Charitable Foundation. He receives speaker fees from the European Association of Urology, Singapore Urology Association, The Clinical Comms Group and Got IT consulting SL. All authors declare that there are no conflicts of interest. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care. WHO Trial Registration Dataset Please see Table 3 for the WHO trial registration dataset. Current protocol Version The current protocol is V.2.0, issued 27 April 2021. The current protocol amendment number is 01. For full amendment history, please see Table 4.
32 33 34 35 36 37 38 39 40 41 42 43 44 546 47 48 49 50 51 52 53 54 55 56 57 58	500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants from MRC, CRUK, Movember, and Prostate Cancer UK. VK is funded by Prostate Cancer UK and The John Black Charitable Foundation. He receives speaker fees from the European Association of Urology, Singapore Urology Association, The Clinical Comms Group and Got IT consulting SL. All authors declare that there are no conflicts of interest. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care. WHO Trial Registration Dataset Please see Table 3 for the WHO trial registration dataset. Current protocol Version The current protocol is V.2.0, issued 27 April 2021. The current protocol amendment number is 01. For full amendment history, please see Table 4.
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59	500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants from MRC, CRUK, Movember, and Prostate Cancer UK. VK is funded by Prostate Cancer UK and The John Black Charitable Foundation. He receives speaker fees from the European Association of Urology, Singapore Urology Association, The Clinical Comms Group and Got IT consulting SL. All authors declare that there are no conflicts of interest. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care. WHO Trial Registration Dataset Please see Table 3 for the WHO trial registration dataset. Current Protocol Version The current protocol is V.2.0, issued 27 April 2021. The current protocol amendment number is 01. For full amendment history, please see Table 4.
32 33 34 35 36 37 38 39 40 41 42 43 44 54 47 48 49 50 51 52 54 55 56 57 58 59 60	500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525	AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants from MRC, CRUK, Movember, and Prostate Cancer UK. VK is funded by Prostate Cancer UK and The John Black Charitable Foundation. He receives speaker fees from the European Association of Urology, Singapore Urology Association, The Clinical Comms Group and Got IT consulting SL. All authors declare that there are no conflicts of interest. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care. WHO Trial Registration Dataset Please see Table 3 for the WHO trial registration dataset. Current Protocol Version The current protocol is V.2.0, issued 27 April 2021. The current protocol amendment number is 01. For full amendment history, please see Table 4.

3 526 Funding 4

1 2

5

6

7

8

9

10

11

527 The PRIME is primarily funded by Prostate Cancer UK (grant number: TLD-PF19-004) and The John 528 Black Charitable Trust Travelling Prize Grant (grant number: TLD-PF19-004). The EAU Research 529 Foundation (EAU RF) and The Dieckmann Foundation also supported costs for international sites. 530

531 **Roles and Responsibilities**

Please see **Table 5** for roles and responsibilities of the trial sponsor and involved committees. 532

12 534 Acknowledgements

13 535 We would like to thank our patients and funders, without whom we wouldn't be able to carry out this 14 536 important study: Prostate Cancer UK & The John Black Charitable Trust, European Association of 15 537 Urology Research Foundation and the Dieckmann Foundation. We thank all the international centres 16 538 taking part in PRIME. We are grateful to EAU Research Foundation and the XClinical team for their 17 539 support with the MARVIN database; and Sydney Lindner, Steven Lelie, Jessica Sternisa, Tyler Edwards, 18 19 540 Adam Kulp, Jon Piper from the MIM Software Inc team. We are thankful for the trial oversight provided 20 541 by our sponsor, University College London and the National Cancer Imaging Translational Accelerator 21 542 trials unit.

22 543 23

549

556

557

558

559

560

561

562

563

567

568

569

570

571

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47 48

49

50

51

52

53

533

544 **Author Contributions**

24 545 Study concept and design: ANg, AA, AN, VC, PK, FG, CA, AF, SP, PL, CSC, CBG, NM, ME, RA, YT, JD, CMM, 25 VK. Drafting of manuscript: AA, AN, CSC, CBG, RA, YT, VK. Critical revision of the manuscript for 546 26 important intellectual content: all authors. Supervision: CA, VK. All authors read and approved the 547 27 548 final manuscript. 28 29

550 REFERENCES

- 1. A-W. Chan, JM. Tetzlaff, PC. Gøtzsche, et al. SPIRIT 2013 explanation and elaboration: 551 552 Guidance for protocols of clinical trials. BMJ, 346 (2013), e7586, 10.1136/bmj.e7586.
- 553 2. N. Mottet, P. Cornford, R. Van Den Bergh, et al. EAU guidelines: prostate cancer. European 554 Association of The Netherlands Urology, Arnhem, (2021). 555 https://uroweb.org/guideline/prostate-cancer/
 - 3. V. Kasivisvanathan, A.S. Rannikko, M. Borghi, et al. MRI-targeted or standard biopsy for N Engl Med, 378 (2018), pp. 1767-1777, prostate-cancer diagnosis. J 10.1056/NEJMoa1801993.
 - 4. N. Mottet, P. Cornford, R. Van Den Bergh, et al. EAU guidelines: prostate cancer. European Association of Urology, Arnhem, The Netherlands (2021). https://uroweb.org/guideline/prostate-cancer/
 - 5. National Prostate Cancer Audit Annual Report 2019. https://www.npca.org.uk/reports/npca-annual-report-2019/
- 6. S. Verma, B. Turkbey, N. Muradyan, A. Rajesh, et al. Overview of dynamic contrast-enhanced 564 565 MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol, 198 (2012), pp. 566 1277-1288. 10.2214/AJR.12.8510
 - 7. R. Berman, A. Brown, S. Chang, et al. DCE MRI of prostate cancer. Abdom Radiol (NY), 41 (2016), pp. 844-853. 10.1007/s00261-015-0589-3
 - 8. M. Engelbrecht, H. Huisman, R. Laheij, et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology. 229 (2003), pp. 248-254. 10.1148/radiol.2291020200
- 54 572 9. M. van der Leest, E. Cornel, B. Israël, et al. Head-to-head comparison of transrectal ultrasound-55 guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent 573 56 magnetic resonance-guided biopsy in biopsy-naïve men with elevated prostate-specific 57 574 58 575 antigen: a large prospective multicenter clinical study. Eur Urol, 75 (2019), pp. 570-578, 59 576 10.1016/j.eururo.2018.11.023 60

10. L. Boesen, N. Nørgaard, V. Løgager, et al. biparametric magnetic resonance imaging for Biparametric MRI for Detection of Prostate Cano n e180219 10 1001/jamanetworkopen 2018 0	Assessment of the diagnostic accuracy of prostate cancer in biopsy-naive men: the cer (BIDOC) study. <i>JAMA Netw Open</i> , 1 (2018), 219
 Z. Kang, X. Min, J. Weinreb, Q. Li, Z. Feng, L. Wai multiparametric MRI for diagnosis of prostate ca <i>Am Roengenol</i>, 212 (2018), pp. 357-365, 10.22 	ng. Abbreviated biparametric versus standard ancer: a systematic review and meta-analysis.
 12. M. Alabousi, J.P. Salameh, K. Gusenbauer, et a magnetic resonance imaging for the detection o a diagnostic test accuracy systematic review an 220, 10, 1111 (1): 11750. 	al. Biparametric vs multiparametric prostate f prostate cancer in treatment-naïve patients: d meta-analysis. <i>BJU Int</i> , 124 (2019), pp. 209-
 13. A. Ng, P. Khetrapal, V. Kasivisvanathan. Is It PRIM Imaging in Prostate Cancer Diagnosis? <i>Eur</i> 10 1016/i eururo 2022 02 021 	1E Time for Biparametric Magnetic Resonance r <i>Urol,</i> S0302-2838 (2022), pp. 01663-3,
 14. F. Giganti, C. Allen, M. Emberton, C.M. Moore, (PI-QUAL): a new quality control scoring syste imaging of the prostate from the PRECISION 1 10 1016/j euo 2020 06 007 	V. Kasivisvanathan. Prostate Imaging Quality em for multiparametric magnetic resonance trial. <i>Eur Urol Oncol,</i> 3 (2020), pp. 615-619,
15. J.C. Weinreb, J.O. Barentsz, P.L. Choyke, et al. Pl System: 2015, Version 2. <i>Eur Urol</i> , 69 (2016), pp	I-RADS Prostate Imaging - Reporting and Data 1. 16-40, 10.1016/j.eururo.2015.08.052.
//RI = biparametric MRI, DCE = dynamic contrast enhance ffusion-weighted sequence, mpMRI = multiparametric / ghted sequence.)	d sequence, DRE = digital rectal examination, DWI MRI, PSA = prostate specific antigen, T2W = T2-
ble 1 Secondary outcomes in PRIME	
	Time frame for assessment
oportion of men with clinically insignificant cancer leason grade 3+3 / Gleason grade group 1)	When biopsy results available, at an expected average of 30 days post-biopsy
reement between bpMRI and mpMRI for score of spicion	When MRI results available, at an expected average of 30 days post-MRI
oportion of bp-MRI scans and mpMRI whose quality as deemed adequate for reporting	When MRI results available, at an expected average of 30 days post-MRI
reement between bpMRI and mpMRI for	
reement between bnMRI and mnMRI for	When MRI results available, at an expected average of 30 days post-MRI
eatment eligibility	When MRI results available, at an expected average of 30 days post-MRI When treatment eligibility is discussed in a multidisciplinary meeting, at an expected average of 30 days post biopsy.

Am J Roengenol, 212 (2018), pp. 357-365, 10.22	214/ajr.18.20103
12. M. Alabousi, J.P. Salameh, K. Gusenbauer, et	al. Biparametric vs multiparametric prostate
magnetic resonance imaging for the detection of	of prostate cancer in treatment-naïve patients:
a diagnostic test accuracy systematic review ar	d meta-analysis. BJU Int, 124 (2019), pp. 209-
220, 10.1111/bju.14759	
13. A. Ng. P. Khetrapal. V. Kasivisvanathan. Is It PRI	ME Time for Biparametric Magnetic Resonance
Imaging in Prostate Cancer Diagnosis? Eu	r Urol. \$0302-2838 (2022), pp. 01663-3.
10.1016/i.eururo.2022.02.021.	· ···, ···· ··· (-·,, pp. ···· ·,
14 E Giganti C Allen M Emberton CM Moore	V Kasivisyanathan Prostate Imaging Quality
(PI-OUAL): a new quality control scoring syst	em for multiparametric magnetic resonance
imaging of the prostate from the PRECISION	trial Fur Urol Oncol 3 (2020) np 615-619
10 1016/i euo 2020 06 007	
15 LC Weinreh LO Barentsz PL Chovke et al E	LRADS Prostate Imaging - Reporting and Data
System: 2015 Version 2 Eur Urol 60 (2016) p	16.40, 10.1016/i oururo 2015.09.052
System. 2015, version 2. Eur Oror, 09 (2010), pj	J. 10-40, 10.1010/J.eurur0.2013.08.032.
igure 1 The DRIME trial scheme the approach prior t	
here internivie und scheind – the approach prior to	u villi.
= diffusion-weighted sequence mnMRI = multingrametric	MRI PSA = prostate specific antigen T2W - T2
veighted sequence.)	$\sqrt{1}$
5 , ,	
TABLES	
TABLES	
TABLES Table 1 Secondary outcomes in PRIME	
Table 1 Secondary outcomes in PRIME Outcome	Time frame for assessment
TABLES Table 1 Secondary outcomes in PRIME Outcome Proportion of men with clinically insignificant cancer	Time frame for assessment When biopsy results available, at an expected
Table 1 Secondary outcomes in PRIME Outcome Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1)	Time frame for assessment When biopsy results available, at an expected average of 30 days post-biopsy
TABLES Table 1 Secondary outcomes in PRIME Outcome Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) Agreement between bpMRI and mpMRI for score of	Time frame for assessment When biopsy results available, at an expected average of 30 days post-biopsy When MBL results available, at an expected
Table 1 Secondary outcomes in PRIME Outcome Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) Agreement between bpMRI and mpMRI for score of suspicion	Time frame for assessment When biopsy results available, at an expected average of 30 days post-biopsy When MRI results available, at an expected average of 30 days post-MRI
TABLES Table 1 Secondary outcomes in PRIME Outcome Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) Agreement between bpMRI and mpMRI for score of suspicion Proportion of bp-MRI scans and mpMRI whose quality	Time frame for assessment When biopsy results available, at an expected average of 30 days post-biopsy When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected
TABLES Table 1 Secondary outcomes in PRIME Outcome Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) Agreement between bpMRI and mpMRI for score of suspicion Proportion of bp-MRI scans and mpMRI whose quality was deemed adequate for reporting	Time frame for assessment When biopsy results available, at an expected average of 30 days post-biopsy When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI
Table 1 Secondary outcomes in PRIME Outcome Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) Agreement between bpMRI and mpMRI for score of suspicion Proportion of bp-MRI scans and mpMRI whose quality was deemed adequate for reporting	Time frame for assessment When biopsy results available, at an expected average of 30 days post-biopsy When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI
TABLES Table 1 Secondary outcomes in PRIME Outcome Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) Agreement between bpMRI and mpMRI for score of suspicion Proportion of bp-MRI scans and mpMRI whose quality was deemed adequate for reporting	Time frame for assessment When biopsy results available, at an expected average of 30 days post-biopsy When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI
Table 1 Secondary outcomes in PRIME Outcome Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) Agreement between bpMRI and mpMRI for score of suspicion Proportion of bp-MRI scans and mpMRI whose quality was deemed adequate for reporting Agreement between bpMRI and mpMRI for score of suspicion	Time frame for assessmentWhen biopsy results available, at an expected average of 30 days post-biopsyWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRI
TABLES Table 1 Secondary outcomes in PRIME Outcome Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) Agreement between bpMRI and mpMRI for score of suspicion Proportion of bp-MRI scans and mpMRI whose quality was deemed adequate for reporting Agreement between bpMRI and mpMRI for radiological staging decision	Time frame for assessment When biopsy results available, at an expected average of 30 days post-biopsy When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI
ABLES Table 1 Secondary outcomes in PRIME Outcome Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) Agreement between bpMRI and mpMRI for score of suspicion Proportion of bp-MRI scans and mpMRI whose quality was deemed adequate for reporting Agreement between bpMRI and mpMRI for radiological staging decision Agreement between bpMRI and mpMRI for	Time frame for assessment When biopsy results available, at an expected average of 30 days post-biopsy When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When treatment eligibility is discussed in a
TABLES Table 1 Secondary outcomes in PRIME Outcome Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) Agreement between bpMRI and mpMRI for score of suspicion Proportion of bp-MRI scans and mpMRI whose quality was deemed adequate for reporting Agreement between bpMRI and mpMRI for radiological staging decision Agreement between bpMRI and mpMRI for radiological staging decision	Time frame for assessment When biopsy results available, at an expected average of 30 days post-biopsy When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When treatment eligibility is discussed in a multidisciplinary meeting, at an expected
TABLES Table 1 Secondary outcomes in PRIME Outcome Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) Agreement between bpMRI and mpMRI for score of suspicion Proportion of bp-MRI scans and mpMRI whose quality was deemed adequate for reporting Agreement between bpMRI and mpMRI for radiological staging decision Agreement between bpMRI and mpMRI for treatment eligibility	Time frame for assessmentWhen biopsy results available, at an expected average of 30 days post-biopsyWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen treatment eligibility is discussed in a multidisciplinary meeting, at an expected average of 30 days post biopsy
TABLES Table 1 Secondary outcomes in PRIME Outcome Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) Agreement between bpMRI and mpMRI for score of suspicion Proportion of bp-MRI scans and mpMRI whose quality was deemed adequate for reporting Agreement between bpMRI and mpMRI for radiological staging decision Agreement between bpMRI and mpMRI for treatment eligibility Test_performance_characteristics_for_bpMRI_and	Time frame for assessmentWhen biopsy results available, at an expected average of 30 days post-biopsyWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen treatment eligibility is discussed in a multidisciplinary meeting, at an expected average of 30 days post biopsy.When biopsy results available, at an expected average of 30 days post biopsy.
TABLES Table 1 Secondary outcomes in PRIME Outcome Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) Agreement between bpMRI and mpMRI for score of suspicion Proportion of bp-MRI scans and mpMRI whose quality was deemed adequate for reporting Agreement between bpMRI and mpMRI for radiological staging decision Agreement between bpMRI and mpMRI for treatment eligibility Test performance characteristics for bpMRI and mpMRI and mpMRI when using the likert scoring system in	Time frame for assessment When biopsy results available, at an expected average of 30 days post-biopsy When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When treatment eligibility is discussed in a multidisciplinary meeting, at an expected average of 30 days post biopsy. When biopsy results available, at an expected average of 30 days post-MRI
TABLES Table 1 Secondary outcomes in PRIME Outcome Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) Agreement between bpMRI and mpMRI for score of suspicion Proportion of bp-MRI scans and mpMRI whose quality was deemed adequate for reporting Agreement between bpMRI and mpMRI for radiological staging decision Agreement between bpMRI and mpMRI for treatment eligibility Test performance characteristics for bpMRI and mpMRI when using the Likert scoring system in comparison to the PL PADS scoring system in	Time frame for assessmentWhen biopsy results available, at an expected average of 30 days post-biopsyWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen treatment eligibility is discussed in a multidisciplinary meeting, at an expected average of 30 days post biopsy.When biopsy results available, at an expected average of 30 days post-MRI
TABLES Table 1 Secondary outcomes in PRIME Outcome Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) Agreement between bpMRI and mpMRI for score of suspicion Proportion of bp-MRI scans and mpMRI whose quality was deemed adequate for reporting Agreement between bpMRI and mpMRI for radiological staging decision Agreement between bpMRI and mpMRI for treatment eligibility Test performance characteristics for bpMRI and mpMRI when using the Likert scoring system in comparison to the PI-RADS scoring system	Time frame for assessment When biopsy results available, at an expected average of 30 days post-biopsy When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When MRI results available, at an expected average of 30 days post-MRI When treatment eligibility is discussed in a multidisciplinary meeting, at an expected average of 30 days post biopsy. When biopsy results available, at an expected average of 30 days post-MRI
TABLES Table 1 Secondary outcomes in PRIME Outcome Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) Agreement between bpMRI and mpMRI for score of suspicion Proportion of bp-MRI scans and mpMRI whose quality was deemed adequate for reporting Agreement between bpMRI and mpMRI for radiological staging decision Agreement between bpMRI and mpMRI for treatment eligibility Test performance characteristics for bpMRI and mpMRI when using the Likert scoring system in comparison to the PI-RADS scoring system Proportion of men with clinically significant cancer	Time frame for assessmentWhen biopsy results available, at an expected average of 30 days post-biopsyWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen treatment eligibility is discussed in a multidisciplinary meeting, at an expected average of 30 days post biopsy.When biopsy results available, at an expected average of 30 days post-MRIWhen biopsy results available, at an expected average of 30 days post-MRI
TABLES Table 1 Secondary outcomes in PRIME Outcome Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) Agreement between bpMRI and mpMRI for score of suspicion Proportion of bp-MRI scans and mpMRI whose quality was deemed adequate for reporting Agreement between bpMRI and mpMRI for radiological staging decision Agreement between bpMRI and mpMRI for treatment eligibility Test performance characteristics for bpMRI and mpMRI when using the Likert scoring system in comparison to the PI-RADS scoring system Proportion of men with clinically significant cancer missed by bpMRI and mpMRI-targeted biopsies and	Time frame for assessmentWhen biopsy results available, at an expected average of 30 days post-biopsyWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen MRI results available, at an expected average of 30 days post-MRIWhen treatment eligibility is discussed in a multidisciplinary meeting, at an expected average of 30 days post biopsy.When biopsy results available, at an expected average of 30 days post-MRIWhen biopsy results available, at an expected average of 30 days post-MRIWhen biopsy results available, at an expected average of 30 days post-MRI

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2	
3	
4	
5	
6	
7	
, 0	
ð	
9	
10	
11	
12	
13	
14	
15	
16	
10	
17	
18	
19	
20	
21	
22	
 วว	
23	
24	
25	
26	
27	
28	
29	
30	
21	
21	
32	
33	
34	
35	
36	
37	
20	
20	
39	
40	
41	
42	
43	
44	
45	
16	
40	
4/	
48	
49	
50	
51	
52	
53	
55	
54	
55	
56	
57	
58	

59 60

(bpMRI = biparametric MRI; mpMRI = multiparametric M	RI.)				
Table 2A Participant timeline in the trial: the t undergoing MPL	imeline fo	or men e	nrolled to	the trial	prior
	Contact	with pation	ent		
	Visit 0*	Visit 1	Visit 2	Visit 3	Visit
Screening	Х	Х			
PIS given	Х	Х			
Consent	Х	Х			
IIFE-5 and IPSS questionnaires	Х	X			
Multiparametric MRI			X		
Radiologists reports bnMRI (T2W and DWI only)			X		
Radiologists reports mpMRI (T2W and DWI only)			X		
MRL-targeted bionsy and systematic bionsy				X	
Test results given and treatment decision				Λ	X
Follow-up for further investigations from					X
treatment decision					
Serious adverse event	Complet	e as requ	uired at a	any time	follow
	registrat	ion		,	
(*Visit 0 is an optional teleconsult, depending on local pro take place on the same day, depending on local practice (day as subsequent biopsies).	registrat actice. Not e.g. in cent	e as req ion e: where a tres where	uired at a pplicable, n an MRI is p	any time nore than o performed o	follow one visi on the s
(*Visit 0 is an optional teleconsult, depending on local pro take place on the same day, depending on local practice (day as subsequent biopsies). IIEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic contr Table 2B Participant timeline in the trial: the	registrat actice. Nota e.g. in cent = Internat multiparc ast-enhan timeline	e as req ion e: where a tres where ional Prost metric Mi ced sequer for mer	uired at a pplicable, n an MRI is p rate Sympto RI, T2W = 1 ace.)	any time nore than o performed o om Score, P 72-weighted after un	follow me visi on the s IS = pa d seque
(*Visit 0 is an optional teleconsult, depending on local pro take place on the same day, depending on local practice (day as subsequent biopsies). IIEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic contr Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care	registrat actice. Nota e.g. in cent = Internat multiparc ast-enhand timeline	e as req ion e: where a tres where ional Prost ional Prost ional Prost ional Prost ional Prost ional Prost ional Prost ional Prost ional Prost ional Prost	uired at a pplicable, m an MRI is p rate Sympto RI, T2W = T ace.) n enrolled ient	any time nore than o performed o om Score, P T2-weighted after un	follow one visi on the s IS = pa d seque
(*Visit 0 is an optional teleconsult, depending on local pro take place on the same day, depending on local practice (day as subsequent biopsies). IIEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic contr Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care	registrat actice. Nota e.g. in cent = Internat multiparc ast-enhand timeline Contact Visit 0	e as req ion e: where a tres where ional Prost metric Mi ced sequer for mer t with pat	uired at a pplicable, m an MRI is p rate Sympto RI, T2W = 1 face.) n enrolled ient Visit 2	any time nore than o performed o om Score, P "2-weighted after un Visit 3	follow one visi on the s IS = pa d seque idergo
(*Visit 0 is an optional teleconsult, depending on local pro take place on the same day, depending on local practice (day as subsequent biopsies). IIEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic contr Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening	registrat actice. Nota e.g. in cent = Internat multiparc ast-enhan timeline Contact Visit 0	e as requion ion e: where a tres where ional Prost metric Mi ced sequer for mer t with pat Visit 1 X	uired at a pplicable, m an MRI is p rate Sympto RI, T2W = 7 ace.) n enrolled ient Visit 2	any time nore than a performed a om Score, P 72-weighted after un Visit 3	follow one visi on the s IS = pa d seque idergo
(*Visit 0 is an optional teleconsult, depending on local pro take place on the same day, depending on local practice (day as subsequent biopsies). IIEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic contr Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given	registrat actice. Nota e.g. in cent = Internata multiparc ast-enhand timeline Contact Visit 0	e as require as require as requires where a stress	uired at a pplicable, m an MRI is p rate Sympto RI, T2W = T face.) n enrolled ient Visit 2	any time nore than a performed a om Score, P 2-weighted after un Visit 3	follow me visi on the s IS = pa d seque dergo
(*Visit 0 is an optional teleconsult, depending on local pro take place on the same day, depending on local practice (day as subsequent biopsies). IIEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic contr Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given Consent	registrat actice. Nota e.g. in cent = Internata multiparc ast-enhan timeline Contact Visit 0	e as requion ion e: where a tres where ional Prost metric MI ced sequer for mer t with pat Visit 1 X X X X	uired at a pplicable, m an MRI is p rate Sympto RI, T2W = 1 nce.) n enrolled ient Visit 2	any time nore than a performed a om Score, P 2-weighted after un Visit 3	follow me visi on the s IS = pa d seque d seque dergo
(*Visit 0 is an optional teleconsult, depending on local pro take place on the same day, depending on local practice (day as subsequent biopsies). IIEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic contr Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given Consent	registrat actice. Notice.g. in cent = Internat. multiparciast-enhand timeline Contact Visit 0	e as requion ion e: where a tres where ional Prost metric Mi ced sequer for mer t with pat Visit 1 X X X X	uired at a pplicable, m an MRI is p rate Sympto RI, T2W = 7 face.) n enrolled ient Visit 2	any time nore than a performed a om Score, P 72-weighted after un Visit 3	follow one visi on the s IS = pa d seque idergo
(*Visit 0 is an optional teleconsult, depending on local protake place on the same day, depending on local practice (day as subsequent biopsies). IIEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic contr Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given Consent IIEF-5 and IPSS questionnaires	registrat actice. Nota e.g. in cent = Internata multiparc ast-enhand timeline Contact Visit 0	e as requion ion e: where a tres where ional Prost metric Mi ced sequer for mer t with pat Visit 1 X X X X	uired at a pplicable, m an MRI is p rate Sympto RI, T2W = 1 face.) n enrolled ient Visit 2	any time nore than a performed a om Score, P "2-weighted after un Visit 3	follow one visi on the s IS = pa d seque dergo Visi t
(*Visit 0 is an optional teleconsult, depending on local protake place on the same day, depending on local practice (day as subsequent biopsies). IIEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic contr Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given Consent IIEF-5 and IPSS questionnaires Multiparametric MRI	registrat actice. Notice.g. in centration = Internation ast-enhant timeline Contact Visit 0	e as requion ion e: where a tres where ional Prost metric Mi ced sequer for mer t with pat Visit 1 X X X X X	uired at a pplicable, m an MRI is p rate Sympto RI, T2W = 7 face.) n enrolled ient Visit 2	any time nore than a performed a om Score, P "2-weighted after un Visit 3	follow one visi on the s IS = pa d seque idergo Visit
(*Visit 0 is an optional teleconsult, depending on local protake place on the same day, depending on local practice (day as subsequent biopsies). IIEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic contr Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given Consent IIEF-5 and IPSS questionnaires Multiparametric MRI Radiologists reports bpMRI (T2W and DWI only)	registrat actice. Nota e.g. in cent = Internata multiparca ast-enhand timeline Contact Visit 0	e as requion ion e: where a tres where a tres where a tres where ional Prost metric MI ced sequer for mer t with pat Visit 1 X X X X X X	uired at a pplicable, m an MRI is p rate Sympto RI, T2W = 7 ince.) n enrolled ient Visit 2	any time nore than a performed a om Score, P 2-weighted after un Visit 3	follow me visi on the s IS = pa d seque idergo Visi t
(*Visit 0 is an optional teleconsult, depending on local protake place on the same day, depending on local practice (day as subsequent biopsies). IIEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic contr Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given Consent IIEF-5 and IPSS questionnaires Multiparametric MRI Radiologists reports bpMRI (T2W and DWI only) Radiologists reports mpMRI (T2W, DWI and DCE)	registrat actice. Nota e.g. in cent = Internata multiparc ast-enhand timeline Contact Visit 0	e as requion ion e: where a tres where a tres where ional Prost metric MI ced sequer for mer t with pat X X X X X X X X	uired at a pplicable, m an MRI is p rate Sympto RI, T2W = 1 face.) n enrolled ient Visit 2	any time nore than o performed o om Score, P "2-weighted after un Visit 3	follow one visi on the s IS = pa d seque adergo Visi
(*Visit 0 is an optional teleconsult, depending on local protocol take place on the same day, depending on local practice (day as subsequent biopsies). IIEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic contr Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given Consent IIEF-5 and IPSS questionnaires Multiparametric MRI Radiologists reports bpMRI (T2W and DWI only) Radiologists reports mpMRI (T2W, DWI and DCE) MRI-targeted biopsy and systematic biopsy	registrat actice. Notice.g. in cent e.g. in cent multiparciast-enhand timeline Contact Visit 0	e as requion ion e: where a tres where ional Prost metric Mi ced sequer for mer t with pat Visit 1 X X X X X X X X	uired at a pplicable, m an MRI is prate Symptor RI, T2W = 7 nce.) n enrolled ient Visit 2 X	any time nore than a performed a om Score, P "2-weighted after un Visit 3	follow one visi on the s IS = pa d seque dergo Visi t
(*Visit 0 is an optional teleconsult, depending on local protocol take place on the same day, depending on local practice (day as subsequent biopsies). IIEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic contr Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given Consent IIEF-5 and IPSS questionnaires Multiparametric MRI Radiologists reports bpMRI (T2W and DWI only) Radiologists reports mpMRI (T2W, DWI and DCE) MRI-targeted biopsy and systematic biopsy Test results given and treatment decision	registrat actice. Nota e.g. in cent = Internata multiparca ast-enhand timeline Contact Visit 0	e as requion ion e: where a tres where a tres where a tres where ional Prost metric MI ced sequer for mer t with pat X X X X X X X X X X X X X X X X X X X	uired at a pplicable, m an MRI is p rate Sympto RI, T2W = 7 ace.) a enrolled ient Visit 2	any time nore than o performed o om Score, P C2-weighted after un Visit 3	follow one vision the single follow IS = pad d sequent oderga Vision

1 2 3 4 5 6	
3 4 5 6 7 8 9 10 11 23 4 5 6 7 8 9 10 11 21 23 24 25 26 27 28 20 31 22 33 4 35 36 37 38 9 40 41 42	61 619 620
44 45 46 47 48	
49 50 51 52 53 54 55 56 57	
58 59 60	

Serious adverse eve	nt	Complete as required at any time following
Withdrawal form		Complete as required at any time following
		registration
IEF-5 = The Internation formation sheet, bpN WI = diffusion-weight	nal Index of Erectile Function, IPSS /IRI = biparametric MRI, mpMRI = ed sequence, DCE = dynamic contro	= International Prostate Symptom Score, PIS = patien multiparametric MRI, T2W = T2-weighted sequence ast-enhanced sequence.)
Table 3 WHO trial re	egistration dataset	
Data category	Information	
Primary registry and trial identifying number	ClinicalTrials.gov: NCT045718	40
Date of	October 1, 2020	
registration in the primary registry		
Sources of	Prostate Cancer UK	
monetary or	The John Black Charita	able Foundation
material support	European Association	of Urology Research Foundation
	The Dieckmann Found	dation
Primary sponsor	University College London	
Secondary	N/A	
sponsor(s)	Mr.)/aaru Kasiyisyanathan yas	
contact for public	Div of Surgery & Intervention	
queries	University College London	
	3 rd Floor, Charles Bell House,	
	43-45 Foley Street, London, W	V1W 7TS
Contact for	Mr Veeru Kasivisvanathan vee	eru.kasi@ucl.ac.uk
scientific queries	Div of Surgery & Interventiona	al Sci,
	University College London,	
	3 rd Floor, Charles Bell House,	
	43-45 Foley Street, London, W	V1W 7TS
title	Prostate imaging Using MRI +,	/- Contrast Enhancement (PRIME)
Acronym	PRIME	
Scientific title	A trial assessing whether bipa MRI in the diagnosis of clinica	arametric MRI is non-inferior to multiparametric Ily significant prostate cancer
Countries of	Argentina	
recruitment	Australia	
	Belgium	
	Brazil	
	Canada	
	Denmark	
	France	
	Finianu	
	Italy	
	The Netherlands	
	Singanore	

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1	
2	
3	
4	
5	
6	
7	
, 8	
٥	
10	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
32	
34	
35	
36	
30 27	
3/	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
50	

	Spain
	UK
	USA
Health	Prostate neoplasm
condition(s) or	
problem(s)	
studied	
Intervention(s)	Device: Miki
	Diagnostic Test: Multiparametric MRI +/- prostate biopsy
Intonuontion	1 Active comparator: Multiparametric MPI (mpMPI)
description	1. Active comparator: Multiparametric MRI (mpiviRi)
description	sequences followed by prostate bionsy if indicated on MPI and clinical findings
	Diagnostic Test: Multiparametric MRI $\pm/-$ prostate biopsy
	1 Experimental: Biparametric MRI (bpMRI)
	MRI with T2-weighted and diffusion weighted sequences followed by prostate
	biopsy if indicated on MRI and clinical findings
	Diagnostic Test: Biparametric MRI +/- prostate biopsy
Key inclusion and	Inclusion Criteria:
exclusion criteria	1. Men at least 18 years of age referred with clinical suspicion of prostate
	cancer 💦
	2. Serum PSA ≤ 20ng/mL
	3. Fit to undergo all procedures listed in protocol
	Able to provide written informed consent
	Exclusion Criteria:
	1. Prior prostate biopsy
	2. Prior treatment for prostate cancer
	3. Prior prostate MRI on a previous encounter
	4. Contraindication to MRI
	5. Contraindication to prostate biopsy
Study type	Interventional
Study type	Allocation: Non-Randomized
	Intervention Model: Single Group Assignment
	Intervention Model Description: Within-person controlled, paired cohort,
	diagnostic evaluation study. Participants undergo two index tests and a
	reference test.
	Masking: Single (Care Provider)
	Masking Description: Radiologist assessing MRI for suspicion of prostate
	cancer is blinded to the contrast sequence when reporting the biparametric
	MRI. After this report, they are unblinded to the contrast sequence and report
	the multiparametric MRI. All biopsies conducted as a result of MRI findings will
	be labelled as bpMRI and mpMRI, and diagnostic accuracy will be assessed
	against histology findings.
Date of first	05 April 2022
enrolment	
larget sample size	500
Recruitment	Recruiting
status	

Primary	Proportion of men with clinically significant cancer
Key second outcomes	 Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) Agreement between bpMRI and mpMRI for score of suspicion Proportion of bp-MRI scans and mpMRI whose quality was deemed adequate for reporting Agreement between bpMRI and mpMRI for radiological staging decision Agreement between bpMRI and mpMRI for treatment eligibility Test performance characteristics for bpMRI and mpMRI when using the Likert scoring system in comparison to the PI-RADS scoring system Proportion of men with clinically significant cancer missed by bpMRI and mpMRI-targeted biopsies and detected by systematic biopsy Cost-effectiveness of bpMRI compared to mpMRI (cost per diagnosis of prostate cancer)
Table 4 Revisior	chronology for amendments to protocol
Protocol version to date	Reasons for amendments
V.1.0, issued 24	Original protocol
10gu3t 2020	
V.2.0, issued 27 April 2021	 Main reasons for amendment: minor changes to make existing trial docume clearer. Main changes: 1. Updated Section 18 Record Keeping and Archiving. Added the sente "Identifiable data will be kept by the site for 10 years, and non-identifia data will be kept for a minimum of 20 years." 2. Version number and date added to all pages.
V.2.0, issued 27 April 2021	 Main reasons for amendment: minor changes to make existing trial docume clearer. Main changes: 1. Updated Section 18 Record Keeping and Archiving. Added the sente "Identifiable data will be kept by the site for 10 years, and non-identifia data will be kept for a minimum of 20 years." 2. Version number and date added to all pages.
V.2.0, issued 27 April 2021 Table 5 Roles ar	 Main reasons for amendment: minor changes to make existing trial docume clearer. Main changes: Updated Section 18 Record Keeping and Archiving. Added the senter "Identifiable data will be kept by the site for 10 years, and non-identifiadata will be kept for a minimum of 20 years." Version number and date added to all pages.
Table 5 Roles ar Role Trial sponsor	 Main reasons for amendment: minor changes to make existing trial docum clearer. Main changes: Updated Section 18 Record Keeping and Archiving. Added the sente "Identifiable data will be kept by the site for 10 years, and non-identific data will be kept for a minimum of 20 years." Version number and date added to all pages. d responsibilities in the PRIME Trial Details and responsibilities University College London (UCL) Sponsor's Edge reference: 135819 Email: Rand.D@uclh.nhs.uk The trial sponsor did not provide any funding for the study. University College London has the role of research governance sponsor of PRIME. UCL adopted the study as sponsor after the UCL CCTU carried out a trial adoption process which involved the UCL CCTU reviewing the protocol to ensure it conformed to high standards of trial conduct and met the governance requirements of UCL. The UCL CCTU is responsible for oversight of the trial. The sponsor plays no role in data collection, management, analysis and interpretation of data, writing of the report or the decision to submit the report for publication.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2
2
2
4
5
6
7
/
8
9
10
10
11
12
13
14
14
15
16
17
10
١ð
19
20
21
21
22
23
24
25
25
26
27
28
20
29
30
31
27
32
33
34
25
55
36
37
38
20
39
40
41
12
⊤∠ 4⊃
43
44
45
16
40
47
48
<u>4</u> 0
50
51
52
52
22
54
55
56
50
5/
FO

625

59 60

	 Assistance with international review board/independent ethics committee applications Preparation of investigators brochure and CRFs Organisation of steering committee meetings Provide annual progress reports to the ethics committee Reporting serious adverse events to the sponsor and ethics committee when necessary Responsible for trial master file Budget administration and contractual issues with individual centres Advice for PIs Site initiation visits Data verification and management Central monitoring and resolving data queries with clinicians and nurses at the trial sites Maintenance of the trial Information Technology (IT) system Publication of study reports
Principal Investigator	At each participating site, the PI is responsible for the conduct of the clinical trial to ensure the safety of participants and the reliability and robustness of the data generated. They will be responsible for identification, recruitment, data collection and completion of CRFs, along with follow-up of trial patients and adherence to trial protocol. The PI as leader of the research team may delegate their duties to members of their team.
Global Trial Steering Committee	The NCITA global prostate trial steering committee (TSC) is responsible for the governance of the PRIME Study, and they have delegated safety to a data monitoring subcommittee (DMSC). Roles and responsibilities: To act as the oversight body for up to five prostate cancer studies on behalf of the Sponsor and Funders. In addition, the independent members will form a sub-committee to review safety. The role of the TSC is to provide oversight for the studies and provide advice through its Chair to the Chief Investigators (CI), work in tandem with the Data Monitoring Sub-Committee (DMSC), Sponsor, Funders and host institution on all aspects of the studies. The rights, safety and well-being of the study participants are the most important consideration and should prevail over the interests of science and society.



VISIT 4: Test results given & treatment decision (as per local standard of care) Follow-up for further investigations from treatment decision

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

EZ-LTA





In the case of diffuse changes on **both sides** of the prostate scoring ≥3 (Likert), the diffuse changes on each side of the prostate can be arbitrarily treated as **separate targets.** "Diffuse change" is defined as an intermediate or low T2 signal that occupies the majority of at least one side of the peripheral zone, without a defined border

58 59

TRIAL IDENTIFIER:

PARTICIPANT INITIALS:

1 2 3 1. Radiologists should **first** annotate, draw and label the diagram on the first page with **up to 3** suspicious areas 4 5 scoring \geq 3 on the Likert scale (L) of suspicion (1–5). Clinical information is permitted to be used to influence 6 the score. 7 2. Radiologists should then score suspicious areas **strictly** using the PI-RADS v2.1 (P) criteria, **without** allowing 8 9 clinical information to influence the score. 10 3. If an additional area of suspicion is identified when scoring with PI-RADS v2.1 that was not present on Likert, 11 please draw on this 4th suspicious area. 12 13 14 15 A maximum of **4 targets** can be drawn on this report. 16 17 18 1. Every lesion **must have both** a Likert and PI-RADS v2.1 score marked on. 19 2. Mark the **most suspicious** area, "Target 1". 20 a. Mark the **next most suspicious area**, "Target 2". 21 22 b. Mark the **subsequent most suspicious area**, "Target 3" and so on. 23 3. On the diagram above, every lesion drawn must have the following marked and labelled: 24 a. Target number 25 b. Likert score 26 c. PI-RADS v2.1 score 27 28 4. Please then insert these into **Table 1** and fill out the rest of the proforma. 29 30 31 e.g. Target 1. Likert 3. PI-RADS 1. 32 33 34 **MRI Scanner and Clinical Information** 35 36 PSA 37 Patient age (years): 38 (ng/ml): 39 40 **PSA Density** MRI volume of prostate 41 (ml): (ng/ml/ml): 42 43 Field Strength of Magnet □ 1.5T □ 3T 44 45 46 47 **Confirmation of blinding** 48 49 50 51 Confirmation by another individual / system that

Which MRI scanner was used?

1.

SCANNER ONE

2. □ SCANNER TWO

3. □ SCANNER THREE



the radiologist is **blinded** to DCE images

(mandatory)

52

53

□ Yes



PARTICIPANT INITIALS:

Table 1. Please only enter Targets below if the Likert or PI-RADS v2.1 score is \geq 3.

TARGET SPECIFIC INFORMATION	TARGET 1	TARGET 2	TARGET 3	TARGET 4
	🗆 Right	Right	🗆 Right	🗆 Right
Location of suspicious area(s) (select one	🗆 Left	🗆 Left	🗆 Left	🗆 Left
	🗆 Bilateral	🗆 Bilateral	🗆 Bilateral	🗆 Bilateral
	□ Base	□ Base	□ Base	□ Base
Location in prostate according to PI-RADS	🗆 Mid	🗆 Mid	🗆 Mid	🗆 Mid
v2.1 41-sector diagram (select the one	🗆 Apex		□ Apex	□ Apex
main location which contains the target):	□ Seminal Vesicle	□ Seminal Vesicle	□ Seminal Vesicle	SeminalVesicle
Main sector which contains the lesion according to PI-RADS v2.1 41-sector diagram (write one , <i>e.g.</i> "PZpI"):	0			
Likert score of suspicion (1–5):	Í.			
PI-RADS v2.1 score of suspicion (1–5):	1			
Target appearance (select one):	Focal	Focal	🗆 Focal	Focal
The default is focal, unless there is diffuse change in the peripheral zone	Diffuse		Diffuse	Diffuse
Biaxial diameter on sequence where it was largest, in axial plane (mm x mm):		?		
	□ T2	□ T2	□ T2	□ T2
Sequence used to measure biaxial diameter (select one):	🗆 High b	🗆 High b	🗆 High b	🗆 High b

Overall patient Likert score	Overall patient PIRADS v2.1 score
Enter the highest Likert score	Enter the highest PI-RADS v2.1 score

If there are no Targets scoring \geq 3 on either scoring system, then the overall Likert and PI-RADS v2.1 score will be 1 or 2.

PARTICIPANT INITIALS:

TRIAL IDENTIFIER:

Table 2. Staging information. Complete **only if** a Target has been identified above:

Radiological stage:	🗆 T2a	□ T2b	□ T2c	🗆 T3a 🛛 T3b	□ T4
	Radiological	T3a = unequiv	ocal extracapsul	ar disease	
Likelihood of right -sided extracapsular spread*: 1 = highly unlikely , 3 = equivocal, 5 = highly likely	□ 1	□ 2	□ 3	□ 4	□ 5
Likelihood of left -sided extracapsular spread*:		□ 2	□ 3	□ 4	□ 5
Likelihood of right seminal vesicle involvement:		□ 2	□ 3	□ 4	□ 5
Likelihood of left seminal vesicle involvement:		□ 2	□ 3	□ 4	□ 5
Likelihood of urethral sphincter involvement:		□ 2	□ 3	□ 4	□ 5
Likelihood of bladder neck involvement:		□ 2	□ 3	□ 4	□ 5
Likelihood of rectal involvement:	□ 1	□ 2	□ 3	□ 4	□ 5

*See PI-RADS v2.1 guidelines for examples of features suggestive of extracapsular spread.

MRI Quality: Please **complete** this for **all** MRIs <u>regardless</u> of whether a Target was identified:

Was there a problem with the quality of the	of the T2W sequence?		□ No		
Was there a problem with the quality of the	e DWI sequence?		□ Yes		□ No
If there were problems, please describe these (tick all that apply):		2	7		
For T2W:	Rectal air		vement artefact	Prosthesis	□ Other
For DWI:	Rectal air		vement artefact	Prosthesis	\Box Other
If other, please describe:			2		
Was the quality of the scan sufficient for you to make a diagnostic assessment?	🗆 Yes 🔅 No				
Hypothetically, if this patient only had this biparametric MRI scan:					
• Would you typically have recommended a repeat bpMRI?	□ Yes □ No				
• Would you typically have recommended a contrast sequence to be done?	□ Yes] No	
Radiologist			Date of MRI:		
(Forename, Surname):			Date of Repo	rt:	

TRIAL IDENTIFIER:	PA	RTICIPANT INITIALS:
	Reporting Proforma (mpMRI):	
Report	2 – Multiparametric MRI (mpMRI)	Report
he same radiologist should annotate vill be used by the biopsy operator to	the diagrams below after they are unblind p perform targeted biopsy .	ed to the DCE sequence. This repor
a total of maximum 8 suspicious a eport.	areas scoring \geq 3 on either Likert or PI	-RADS v2.1 can be annotated in this
	PART ONE: TARGETS SEEN ON BPMRI	
1. First, copy any targets drawn	on Report 1 (bpMRI) onto this report (Re	eport 2 – mpMRI).
a. Draw them on the di	agram.	
b. Specify their biparam	netric MRI status (bpMRI +ve or bpMRI -ve)	when you label each lesion.
2 Upon viewing the DCE find	ings for each of these lesions please spe	cify their multi-parametric MRI statu
(mpMRI +ve or mpMRI -ve)	on the diagram then specify updated Like	rt (L) and PI-RADS v2.1 (P) scores of
mpMRI.		
	` `	
No targets seen on bpMRI or mpMRI	Target identified on bpMRI <i>but</i> Target is no longer scoring \ge 3 on Likert or PI-RADS v2 1 on mpMRI	Target identified on bpMRI and remains scoring \geq 3 on Likert or PI-RADS v2 1 on mpMRI
bpMRI -ve, mpMRI -ve	Label Target on diagram as bpMRI +ve, mpMRI -ve	Label Target on diagram as bpMRI +ve, mpMRI +ve
Leave Table 1, 2 & 3 blank	Label Target on diagram with Likert	and PI-RADS v2.1 scores on mpMRI
Complete overall Likert and PI-RADS v2.1 score, MRI quality	Complete Table 1 and	l rest of the proforma
information and biopsy plan		



TRIAL IDENTIFIER:



In the case of diffuse changes on **both sides** of the prostate scoring ≥3 (Likert), the diffuse changes on each side of the prostate can be arbitrarily treated as **separate Targets.** "Diffuse change" is defined as an intermediate or low T2 signal that occupies the majority of at least one side of the peripheral zone, without a defined border.



Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

PARTICIPANT INITIALS:

Patient age (years)	PSA (ng/ml):			
MRI volume of prostate (ml):	PSA Density (ne	g/ml/ml):		
able 1. Information from Targets origina	Illy identified on	the biparametr	ric MRI (if appli	cable):
TARGET SPECIFIC INFORMATION	TARGET 1	TARGET 2	TARGET 3	TARGET 4
СОРУ І	FROM REPORT	1 (BPMRI):	1	1
Location of suspicious area(s) (select one option):	□ Right □ Left □ Bilateral	□ Right □ Left □ Bilateral	□ Right □ Left □ Bilateral	RightLeftBilateral
Location in prostate according to PI-RADS v2.1 41-sector diagram (select the one main location which contains the target):	 Base Mid Apex Seminal Vesicle 			
Main sector which contains the lesion according to PI-RADS v2.1 41-sector diagram (write one sector, <i>e.g.</i> "PZpI"):	2	•		
Biparametric MRI Likert score (1–5):		4		
Biparametric MRI PI-RADS v2.1 score (1–5):		0,		
RE-ASSESS, TAKING INTO ACCOU		FION FROM DC	CE SEQUENCE ((MPMRI):
Multiparametric MRI Likert score (1–5):		3		
Multiparametric MRI PI-RADS v2.1 score (1–5):				
Target appearance (select one):	Focal Diffuse	Focal Diffuse	Focal Diffuse	□ Focal □ Diffuse
Biaxial diameter on sequence where it was largest, in axial plane (mm x mm):				
Sequence used to measure biaxial diameter	□ T2 □ High b	🗆 T2 🛛 High b	🗆 T2 🗆 High b	🗆 T2 🗆 Hiç

 \Box ADC \Box DCE



 \Box ADC \Box DCE

 \Box ADC \Box DCE

(select one):

TRIAL IDENTIFIER:

PARTICIPANT INITIALS:

PART TWO: NEW DCE-TARGETS ON DYNAMIC CONTRAST ENHANCED SEQUENCE New **parts** of previously identified New Target on DCE? lesion larger on DCE?* Draw and annotate as a new Target on diagram and label as a DCE-Target Label Target on diagram as bpMRI -ve, mpMRI +ve Label Target on diagram with Likert and PI-RADS v2.1 scores on mpMRI Complete Table 2 and the rest of the proforma * Please note: this is a subjective decision by the radiologist as to whether new parts of an existing lesion on bpMRI would need to be declared as a new target in order not to be missed on biopsy. A clear example of when to declare a new DCE-Target would be if the non-overlapping part of the lesion on DCE crosses into a new sector on the PI-RADSv2.1 sector diagram 5. Any new targets should be labelled **DCE-Target-x.** a. The first new, most suspicious, target should be DCE-Target-1. The second if applicable, DCE-Target-2 and so on. 6. A maximum of **4 new targets** can be drawn on this report (**Report 2**). a. Thus, a maximum of 8 targets can be drawn in total (4 carried over from Report 1 and 4 new DCE targets). 7. On the diagram on Page 2, every lesion drawn must have the following marked and labelled: a. Target number b. bpMRI status (positive or negative) c. mpMRI status (positive or negative) d. Likert score for mpMRI e. PI-RADS v2.1 score for mpMRI e.g. DCE-Target-1. bpMRI negative. mpMRI positive. Likert 4. PI-RADS 2. 8. Then complete **Table 2** and the rest of the MRI proforma.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

TRIAL IDENTIFIER:

PARTICIPANT INITIALS:

Table 2. Information from Targets identified **ONLY** by DCE, which were <u>not</u> identified on the **biparametric MRI** (if applicable). If there are no DCE-Targets then leave Table 2 blank & move onto overall patient Likert & PI-RADs scores):

TARGET SPECIFIC INFORMATION	DCE-TARGET 1	DCE-TARGET 2	DCE-TARGET 3	DCE-TARGET 4	
DCE-Target (select if new lesion or part of	□ New	□ New	□ New	□ New	
existing lesion bigger on DCE):	Existing	Existing	Existing	Existing	Prot
	🗆 Right	🗆 Right	🗆 Right	🗆 Right	ectec
Location of suspicious area(s) (select one):	🗆 Left	🗆 Left	🗆 Left	🗆 Left	
O,	Bilateral	Bilateral	Bilateral	Bilateral	pyri
	□ Base	□ Base	□ Base	□ Base	gnt, I
Location in prostate according to PI-RADS v2.1	🗆 Mid	🗆 Mid	🗆 Mid	🗆 Mid	nciuc
41-sector diagram (select the one main	□ Apex	□ Apex	□ Apex	□ Apex	r Burk
location which contains the target).	Seminal Vesicle	Seminal Vesicle	SeminalVesicle	Seminal Vesicle	or uses
Main sector which contains the lesion according to PI-RADS v2.1 41-sector diagram (write one , <i>e.g.</i> "PZpI"):	(C)	•			related to tex
Multiparametric MRI Likert score (1–5):	C	24			t and data n
Multiparametric MRI PI-RADS v2.1 score (1–5):		0			nining, Al tr
-	Focal	Focal	Focal	Focal	ainin
l'arget appearance (select one):	□ Diffuse	🗆 Diffuse	Diffuse	Diffuse	g, anc
Biaxial diameter on dominant sequence in axial plane (mm x mm):					i similar tec
Looking back again at the T2W and DWI only ,	□ No	🗆 No	🗆 No	□ No	nnolo
is the DCE-target identified here actually visible on the bpMRI?	□ Yes	□ Yes	□ Yes	□ Yes	gies.
If you answered Yes , please specify whether the lesion was missed on 1 st look <i>or</i> whether	\Box Missed on 1^{st} look	\Box Missed on 1^{st} look	□ Missed on 1 st look	\Box Missed on 1^{st} look	
it was seen but scored a 1 or 2 on PI-RADS v2.1 and Likert	 Seen on 1st look but scored a 1 or 2 	 Seen on 1st look but scored a 1 or 2 	 Seen on 1st look but scored a 1 or 2 	 Seen on 1st look but scored a 1 or 2 	

TRIAL IDENTIFIER:

PARTICIPANT INITIALS:

Please complete the **overall scores** <u>regardless</u> of whether there are any Targets identified above:

Overall patient Likert score	Overall patient PI-RADS v2.1 score
Enter the highest Likert score on either biparametric MRI or multiparametric MRI	Enter the highest PI-RADS v2.1 score on either biparametric MRI or multiparametric MRI

Please note: if a lesion was suspicious on biparametric MRI but **not** suspicious on mpMRI (*i.e.* bpMRI +ve, mpMRI -ve), it should still be biopsied if either the Likert or PI-RADS v2.1 score on bpMRI is \geq 3. This highest score on either bpMRI or mpMRI should be entered above.

Table 3. Staging information. Complete only if a Target has been identified above. Select one option each time:

Radiological stage:	□ T2a Radiolo	□ T2b □ ogical T3a = unequ	∃ T2c uivocal ext	□ T3a □ T3b racapsular disease	□ T4
Likelihood of right -sided extracapsular spread*: 1 = highly unlikely , 3 = equivocal, 5 = highly likely		□ 2	□ 3	□ 4	□ 5
Likelihood of left -sided extracapsular spread*:		□ 2	□ 3	□ 4	□ 5
Capsular involvement on DCE :	🗆 No	□Yes, on right	□Yes, o	n left 🗆 Yes, on bo	oth sides
Likelihood of right seminal vesicle involvement:		□ 2	□ 3	□ 4	□ 5
Likelihood of left seminal vesicle involvement:		□ 2	□ 3	□ 4	□ 5
Seminal vesicle involvement on DCE:	🗆 No	□Yes, on right	□Yes, o	n left	oth sides
Likelihood of urethral sphincter involvement:		🗆 2 🕻	□ 3	□ 4	□ 5
Urethral sphincter involvement on DCE:	🗆 No	□Yes, on right	□Yes, o	n left	oth sides
Likelihood of bladder neck involvement:		□ 2	□ 3	□ 4	□ 5
Bladder neck involvement on DCE:	🗆 No		□ Yes	5	
Likelihood of rectal involvement:		□ 2	□ 3	□ 4	□ 5
Rectal wall involvement on DCE:	🗆 No		□ Yes	5	

*See PI-RADS v2.1 guidelines for examples of features suggestive of extracapsular spread.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

TRIAL IDENTIFIER:

PARTICIPANT INITIALS:

MRI Quality. Please complete this for all MRIs regardless of whether a Target was identified:

Was there a problem with the quality o	the DCE sequence?		□ No		
If problems with DCE, please specify: Tick all that apply	Rectal air		ement artefact	Prosthesis	□ Other
If other, please describe:					
Was the quality of the scan sufficient for you to make a diagnostic assessment?	□ Yes		□ No	0	
Based on the quality of the mpMRI scan and your typical practice, would you recommend a repeat multiparametric MRI be performed?	□ Yes		□ No	0	

Biopsy protocol guidelines

It is **mandatory** to follow these recommendations below:

Number of MRI targets	Location of MRI targets in prostate	Number of MRI- targeted biopsy cores	Number of contralateral systematic cores	Total number of biopsy cores
0	If PSA De	nsity is < 0.15ng/ml/ml		0
0	If PSA Density is \geq 0.15ng/ml/r (6	If PSA Density is \geq 0.15ng/ml/ml, then 12 systematic biopsy cores are taken (6 from each side)		
1	Unilateral	4	6	10
2	Unilateral	8	6	14
3	Unilateral	12	6	18
4-8	Unilateral	16–32	6	22–38
1	Bilateral (<i>e.g.</i> crossing midline)	4	0	4
2	Bilateral	8	0	8
3	Bilateral	12	0	12
4-8	Bilateral	16–32	0	16–32

Note: For 4–8 MRI targets, determine the number of MRI-targeted cores by using the principle of 4 cores per MRI target.



Recommended Biopsy Plan for biopsy operator to follow

The radiologist should now complete this biopsy plan which should be passed directly to the person performing biopsy (if one is required) along with the labelled diagram on Page 2:

Even if radiologists do not typically write biopsy plans, we request they do this here following the protocol in the table above, in order to reduce errors between linking the MRI information to the protocol biopsy plan.

	with MRI-targeted biopsy:		
(<i>Note:</i> Targets which are only susp targets for biopsy therefore include	icious on bpMRI should still be biopsied. T s MRI targets identified only on bpMRI, on	ne number of MRI- ly on mpMRI or on	
both bpMRI and mpMRI and on eith	er the Likert scoring system or the PIRADsv	2.1 scoring system)	
Total number of MRI-targeted b	opsy cores to be taken:		
(<i>Note:</i> 4 biopsy cores should be tak	en per lesion)		
Total number of systematic biop	sy cores to be taken:		
(Note: Systematic cores should be p	eripheral zone-focused cores)		
Number of systematic cores to t	e taken from right side of prostate:		
(Note: do not take systematic cores	from the same side as an MRI target)		
Number of systematic cores to b (<i>Note:</i> do not take systematic cores	e taken from left side of prostate: from the same side as an MRI target)		
Number of systematic cores to b (<i>Note:</i> do not take systematic cores Total number of systematic and	e taken from left side of prostate: from the same side as an MRI target) targeted cores to be taken	0,	
Number of systematic cores to b (<i>Note:</i> do not take systematic cores Total number of systematic and	e taken from left side of prostate: from the same side as an MRI target) targeted cores to be taken	0,5	
Number of systematic cores to t (<i>Note:</i> do not take systematic cores Total number of systematic and	e taken from left side of prostate: from the same side as an MRI target) targeted cores to be taken	0,52	
Number of systematic cores to t (<i>Note:</i> do not take systematic cores Total number of systematic and	e taken from left side of prostate: from the same side as an MRI target) targeted cores to be taken	0,52	



Supplementary Appendix 2: Detailed PRIME Biopsy Plans

To be pragmatic and allow results to be generalisable to biopsy practice around the world, biopsies can be performed transperineally (**Figures 1** and **2**) or transrectally (**Figures 3 and 4**) as per local practice. We split this Appendix into these sections, respectively.

If there is an MRI lesion (scores 3, 4 or 5 on *either* Likert or PI-RADS v2.1 scoring systems), then MRI-targeted biopsy and some limited contralateral systematic biopsy should be performed. MRI-targeted biopsy should be performed **first**, with 4 cores per suspicious area. Then the systematic biopsy cores should be taken but avoid taking biopsies from the same side of the prostate that targeted biopsies were taken from.

Table of Contents

Systematic Transperineal Biopsy Schema2
Non-suspicious MRI but a PSA Density of \geq 0.15ng/mL/mL scenario2
Suspicious MRI lesion scenarios4
Single lesion scenario
Bilateral lesions scenario4
Lesion crossing midline scenario5
Bilateral diffuse change on Likert scoring scenario5
New lesion is revealed on DCE sequence scenario6
New part of existing lesion is revealed on DCE sequence scenario
Systematic Transrectal Biopsy Schema7
Non-suspicious MRI but a PSA Density of \geq 0.15ng/mL/mL scenario7
Suspicious MRI lesion scenarios9
Single lesion scenario9
Bilateral lesions scenario10
Lesion crossing midline scenario11
Bilateral diffuse change on Likert scoring scenario12
New lesion is revealed on DCE sequence scenario13
New part of existing lesion is revealed on DCE sequence scenario
Summary Biopsy Guidelines16



Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.
Systematic Transperineal Biopsy Schema

Figures 1 and **2A-F** depict examples of how to perform the systematic biopsy in the **absence** of an MRI lesion and in the **presence** of MRI lesions, respectively.

Non-suspicious MRI but a PSA Density of \geq 0.15ng/mL/mL scenario

In patients with a **non-suspicious MRI but a PSA Density of** \geq **0.15ng/mL/mL**, 12-core systematic biopsy should be performed (Figure 1).

The number of systematic cores that should be taken per patient is **12**.

Systematic biopsy cores are taken from:

- Right anterior zone (2 cores)
- Right mid zone (2 cores)
- Right posterior zone (2 cores)
- Left anterior zone (2 cores)
- Left mid zone (2 cores)
- Left posterior zone (2 cores)

Systematic biopsy cores should be stored and labelled in a way that their **location** can be identified when the pathologist reports the result.

Figure 1. The transperineal biopsy schema for men with a **non-suspicious MRI** (scores 1 or 2 on both Likert and PI-RADS v2.1 scoring systems) *but* a PSA Density of \geq 0.15ng/mL/mL, undergoing 12-core systematic biopsy.







For each pair of biopsies - one core is more lateral, one core is more medial. From anteriorposterior, there are 3 planned rows of biopsies - anterior, mid zone, posterior. Avoid biopsy around the urethra.



Suspicious MRI lesion scenarios

Figure 2. Examples of how to perform transperineal biopsies in patients with an MRI Target (scores 3, 4 or 5 on *either* Likert or PI-RADS v2.1 scoring systems).

2A. Single lesion example.



This is a single lesion in the right mid-gland peripheral zone posteromedially (PZ pm) and posterolaterally (PZ pl).

- Take 4 targeted biopsies from the Target.
- Then take 6 peripheral zone focused biopsies from the contralateral side.
- Do not resample the targeted biopsy side.

2B. Bilateral peripheral zone lesions example.



There are **two lesions**: one in right mid-gland, peripheral zone posteromedially and posterolaterally (PZ pm and PZ pI); one in left mid-gland, peripheral zone posteromedially and posterolaterally (PZ pm and PZ pI).

- Take 4 targeted biopsies from *each* Target *i.e.* 8 targeted biopsies in total.
- **Do not take any systematic biopsies** as targeted biopsies are taken from both sides of the prostate.



2C. Lesion crossing midline example.



This is one lesion crossing the midline in the mid-gland, anterior fibromuscular stroma.

- Take 4 targeted biopsies from the Target. •
- Do not take any systematic biopsies as targeted biopsies are taken from both sides • of the prostate.

2D. Bilateral diffuse change on Likert scoring example.



ιple. In the circumstance where on Likert scoring, the peripheral zone gives diffuse change, scoring 3 out of 5, arbitrarily treat each peripheral zone as a different Target.

- Take 4 targeted biopsies from each half of the peripheral zone i.e. 8 biopsies in • total.
- Do not take any systematic biopsies as targeted biopsies are taken from both sides • of the prostate.



2E. A new lesion is revealed on DCE sequence example.



This is one lesion in the right mid-gland, peripheral zone posterolaterally. This **new Target** was specifically *not* suspicious (scored 1 or 2 on both Likert and PI-RADS v2.1) on bpMRI sequences (T2W and DWI). However, when the contrast sequence is revealed, the lesion appears to be suspicious (scored 3, 4 or 5 on Likert) on the dynamic contrast-enhanced (DCE) sequence than on the bpMRI.

- Thus, label the new lesion as a DCE-Target.
- Take 4 targeted biopsies from DCE-Target-1.
- Then take **6 peripheral zone focused biopsies** from the **contralateral** side of the prostate.
- Do **not** resample the targeted biopsy side.

2F. A new **part** of an *existing* lesion is revealed on DCE sequence example.



There are two lesions in this example. **Target 1** (**red**) was suspicious on **both** bpMRI and mpMRI. It is in the right mid-gland, peripheral zone, posterolaterally (PZ pl). It scores Likert 4 and PI-RADS v2.1 4.

However, when the contrast sequence is revealed, this lesion appears to be larger on the DCE sequence than on bpMRI. The part of the lesion that is **non-overlapping** would **not** have been



target biopsied if bpMRI <u>alone</u> was used. Thus, the second lesion (the non-overlapping part, **purple**) is called **DCE Target 1**. It is in the right mid-gland, peripheral zone, posteromedially (PZ pm).

Thus, the instructions are as follows in this instance:

- Take 4 targeted biopsies from Target 1.
- Take 4 targeted biopsies from DCE Target 1.
- Take 6 peripheral zone focused biopsies from the contralateral side of the prostate.
- Do **not** resample the targeted biopsy side.

Systematic Transrectal Biopsy Schema

Figures 3 and **4** depict examples of how to perform the systematic biopsy in the **absence** of an MRI lesion and in the **presence** of MRI lesions, respectively.

Non-suspicious MRI but a PSA Density of \geq 0.15ng/mL/mL scenario

In patients with a **non-suspicious MRI but a PSA Density of** \geq **0.15ng/mL/mL**, 12-core systematic biopsy should be performed (Figure 3).

If performing biopsies transrectally, systematic biopsy cores should be taken from:

- Right base (2 cores)
- Right mid gland (2 cores)
- Right apex (2 cores)
- Left base (2 cores)
- Left mid gland (2 cores)
- Left apex (2 cores)

Systematic biopsy cores should be stored and labelled in a way that their location can be identified when the pathologist reports the result.

The 12 systematic biopsies **should be focused on the peripheral zone.** The urethra should be avoided.



Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Figure 3. The transrectal biopsy schema for men with a **non-suspicious MRI** (scores 1 or 2 on both Likert and PI-RADS v2.1 scoring systems) *but* a PSA Density of \geq 0.15ng/mL/mL, undergoing 12-core systematic biopsy.





Suspicious MRI lesion scenarios

Figure 4. Examples of how to perform transrectal biopsies in patients with an MRI Target (scores 3, 4 or 5 on *either* Likert or PI-RADS v2.1 scoring systems).

4A. Single lesion example.



This is a single lesion in the right mid-gland peripheral zone posteromedially (PZ pm) and posterolaterally (PZ pl).

- Take **4 targeted biopsies** from the Target.
- Then take 6 peripheral zone focused biopsies from the contralateral side.





4B. Bilateral peripheral zone lesions example.



There are **two lesions**: one in right mid-gland, peripheral zone posteromedially and posterolaterally (PZ pm and PZ pl); one in left mid-gland, peripheral zone posteromedially and posterolaterally (PZ pm and PZ pl).

• Take 4 targeted biopsies from *each* Target – *i.e.* 8 targeted biopsies in total.



• **Do not take any systematic biopsies** as targeted biopsies are taken from both sides of the prostate.

4C. Lesion crossing midline example.



This is one lesion crossing the midline in the mid-gland, anterior fibromuscular stroma.

• Take **4 targeted biopsies** from the Target.



- **Do not take any systematic biopsies** as targeted biopsies are taken from both sides of the prostate.
- 4D. Bilateral diffuse change on Likert scoring example.



In the circumstance where on Likert scoring, the peripheral zone gives diffuse change, scoring 3 out of 5, arbitrarily **treat each peripheral zone** as a **different Target**.



- Take **4 targeted biopsies** from *each half* of the peripheral zone *i.e.* **8 biopsies** in total.
- **Do not take any systematic biopsies** as targeted biopsies are taken from both sides of the prostate.

4E. A new lesion is revealed on DCE sequence example.



This is one lesion in the right mid-gland, peripheral zone posterolaterally. This **new Target** was specifically *not* suspicious (scored 1 or 2 on both Likert and PI-RADS v2.1) on bpMRI sequences (T2W and DWI). However, when the contrast sequence is revealed, the lesion



Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

appears to be suspicious (scored 3, 4 or 5 on Likert) on the dynamic contrast-enhanced (DCE) sequence than on the bpMRI.

- Thus, label the **new lesion** as a **DCE-Target**.
- Take 4 targeted biopsies from DCE-Target-1.
- Then take **6 peripheral zone focused biopsies** from the **contralateral** side of the prostate.
- Do **not** resample the targeted biopsy side.

4F. A new **part** of an *existing* lesion is revealed on DCE sequence example.

There are two lesions in this example. **Target 1** (**red**) was suspicious on **both** bpMRI and mpMRI. It is in the right mid-gland, peripheral zone, posterolaterally (PZ pl). It scores Likert 4 and PI-RADS v2.1 4.

However, when the contrast sequence is revealed, this lesion appears to be larger on the DCE sequence than on bpMRI. The part of the lesion that is **non-overlapping** would **not** have been target biopsied if bpMRI <u>alone</u> was used. Thus, the second lesion (the non-overlapping part, **purple**) is called **DCE Target 1**. It is in the right mid-gland, peripheral zone, posteromedially (PZ pm).

Thus, the instructions are as follows in this instance:

- Take 4 targeted biopsies from Target 1.
- Take 4 targeted biopsies from DCE Target 1.
- Take 6 peripheral zone focused biopsies from the contralateral side of the prostate.
- Do **not** resample the targeted biopsy side.





Summary	Biopsy	Guide	lines
Sammary	Diopsy	ourac	mics

Number of MRI targets	Location of MRI targets in prostate	Number of MRI- targeted biopsy cores	Number of contralateral systematic cores	Total number of biopsy cores				
0	If P	0						
0	If PSA Density is ≥ (f PSA Density is ≥ 0.15ng/ml/ml, then 12 systematic biopsy cores are taken (6 from each side)						
1	Unilateral	4	6	10				
2	Unilateral	8	6	14				
3	Unilateral	12	6	18				
4–8	Unilateral	16–32	6	22–38				
1	Bilateral (<i>e.g</i> . crossing midline)	4	0	4				
2	Bilateral	8	0	8				
3	Bilateral	12	0	12				
4–8	Bilateral	16–32	0	16–32				



1

Please present on local headed paper

REC Number: IRAS Number: 282789

Subject Identification: _____ Study Number ;_____

CONSENT FORM

Title of Project: PRostate Imaging using MRI +/- contrast Enhancement (PRIME)

Name of Researcher:

Please initial box

1. I confirm that I have read and understand the information sheet dated...... (version.....) for the above study. I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.

I understand that my participation is voluntary and that I am free to withdraw at any time without giving any reason, without my medical care or legal rights being affected.

3. I understand that relevant sections of my medical notes and data collected during the study, may be looked at by individuals from the sponsor of the trial (University College London), responsible persons authorised by the sponsor, from regulatory authorities, from the NHS Trust and from PRIME study researchers who may be outside of my local centre, where it is relevant to my taking part in this research. I give permission for these individuals to have access to my records.

4. I agree to my GP being informed of my participation in the study.

5. I give my permission for the PRIME research team at my local centre to hold identifiable information such as my name, address, date of birth, email address, mobile phone number, NHS number or other applicable hospital identifier. I understand this may be used to collect longer term healthcare information on me from national records, such as the Office for National Statistics, NHS Digital, Public Health England, and other applicable NHS information systems, or other relevant national databases. This data may be linked to my data from the PRIME study in future research.

IRAS Reference Number 282789 PRIME Consent Form Version 2.0 Dated 27APR2021











BMJ Open

6. I give permission to be contacted for further information in the future. This may include requests to complete quality of life questionnaires or for ascertaining future health status, if required. 7. I give permission for my samples to be sent to UCL by courier for quality control assessments. 8. I give permission for my anonymized data to be used for teaching and educational purposes for healthcare professionals. 9. I give my permission for my anonymized data to be shared with affiliated researchers and commercial partners who are approved by the PRIME study team for future research if deemed suitable by the PRIME Chief Investigator 10. I give my permission to be approached for other studies in the future that may be relevant to me, and for my study data collected in PRIME to be used for this purpose. 11. I agree to take part in the above study and to complete study procedures outlined in the patient information sheet provided. All boxes above must be initialed for consent to be valid

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Name of Participant	Date	Signature	-
Name of Person	Date	Signature	-

When completed: 1 for participant; 1 (original) for researcher site file; 1 to be kept in medical notes.

IRAS Reference Number 282789 PRIME Consent Form Version 2.0 Dated 27APR2021

taking consent

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

PLACE HOSPITAL LETTER HEAD ON FIRST PAGE ONLY.

Affix patient sticker / details here

Version 3.0 8 June 2021

This is the Patient Information Sheet for a Health Research Study called PRIME

Study Short Title: Prostate Imaging using MRI +/- contrast Enhancement

Study acronym: PRIME

Chief Investigator: Mr Veeru Kasivisvanathan

UCL Reference number: 135819

REC Reference number: 21/WM/0091

IRAS Number: 282789

We would like to invite you to take part in our research study. Before you decide we would like you to understand why you are being invited, why the research is being done and what it would involve for you. One of our team will go through the information sheet with you and answer any questions you have. Talk to others about the study if you wish.

Part 1 tells you the purpose of this study and what will happen to you if you take part. Part 2 gives you more detailed information about the conduct of the study.

Ask us if there is anything that is not clear. Please take as much time as you need to consider the study.

Part 1

1. Why have I been invited?

You are being invited because you may require further investigation of your prostate with an MRI scan and / or a prostate biopsy. You have not been diagnosed with cancer but an MRI and / or a biopsy may be required to establish whether you do or do not have cancer. The clinical Urology team that you have been referred to has informed us that you may be eligible for this study.

2. What is the purpose of the study?

The standard way of diagnosing prostate cancer is to carry out a multiparametric prostate MRI scan and prostate biopsy. This type of MRI scan normally involves an injection of contrast into one of your veins.

Another type of MRI scan (biparametric) can be performed that does not require contrast, and therefore does not require the insertion of a cannula. We currently do not know for certain whether using this type of MRI will allow us to detect the same, more or less prostate cancer than if we use the standard (multiparametric) type of MRI. Current evidence supports the idea that using biparametric MRI may detect a similar amount of cancer to when it is not used but one advantage is it may allow a man to have a scan without contrast.

The main purpose of this study is to assess if biparametric MRI can provide similar information to multiparametric MRI. You will undergo a multiparametric MRI with a contrast injection, which is the typical method used for investigating the prostate for the presence of cancer. The doctor reviewing your scan will be asked to review the MRI scan in a particular order so that they can tell whether the additional information given by the contrast injection helps identifies prostate cancer.

If there is a suspicious area in the prostate on the MRI, a few biopsies can be directed at where the suspicious area is thought to be, also using an ultrasound probe in the back passage. If there is no suspicious area on the MRI and if you at low risk of harbouring cancer, which occurs in about 30% of men, then no biopsy will be taken at all.

3. Do I have to take part?

It is up to you to decide to join the study. We will describe the study and go through this information sheet. If you agree to take part, we will then ask you to sign a consent form. You are free to withdraw at any time without giving a reason. This will not affect the standard of care you receive.

4. What are the benefits to me of taking part in this study?

The healthcare team carrying out the tests in the study are experienced in carrying out and interpreting these tests. The research team will ensure your tests are carried out as quickly as possible and will be a point of contact for you should you have any concerns or questions.

The information we get from this study will help improve the diagnosis of prostate cancer for men in the future.

5. What type of study is this?

This is a study evaluating the accuracy of diagnostic tests. In this trial, you will have the same investigation (multiparametric MRI) as your hospital normally does to investigate the prostate, but the doctor interpreting your scan will be asked to report this in a particular order. The full information will be available to the doctors as it would normally be available if you were not taking part in the study.

You will be required to attend a screening visit with a member of the research team who will spend around 40 minutes explaining what is involved in the study and making sure you are

eligible for the study. Where possible, all study visits that do not require a journey to the hospital will be performed remotely (e.g. over the phone or video call).

6. What will happen to me if I take part?

After you have attended the screening visit, if you are eligible to take part in the study, you will asked to visit the hospital 2-3 times in total, which is the same as if you were not taking part in the study. After you consent to participating in the study, you will be asked to complete two short questionnaires which will ask about any symptoms related to your prostate that you may be having. These are questionnaires that are typically used as part of routine care. You would only undergo tests that you would normally have as part of routine care if you were not taking part in the study.

If you have not already had a prostate MRI, you will have one within a few weeks after the screening visit. The MRI takes about 40 minutes. Alternatively, it is possible that you are approached for the study after you have had your prostate MRI.

If you have an MRI with a high enough suspicion (MRI Score 3, 4 or 5) you will be booked for a biopsy following the MRI. If the MRI is non-suspicious but you are at high risk of having cancer because of a blood test result, (called your prostate specific antigen density) you will also undergo a prostate biopsy. If you do not need a biopsy (if your MRI is non-suspicious and your prostate specific antigen density is low) then you do not need to undergo a biopsy and we will explain this to you once your MRI results is available.

The biopsy procedure itself takes about 40 minutes and is typically carried out under local or general anaesthetic. Prostate biopsies, which take very small samples of prostate tissue, are taken from the prostate gland and sent to the lab to determine whether there is cancer there or not. If there is a suspicious area on the MRI scan, the MRI information will be used to influence where the biopsies are taken from. Software may be used to transfer additional information from the original MRI onto the screen when the biopsies are taken. In some centres, this would be exactly what you would normally get, and there would be no difference to standard of care. In other centres, their usual practice may be slightly different to this, and you may be required to have a few extra or fewer biopsies than what is typical in your usual centre. After the procedure, we then wait for the results and discuss treatment options with you in clinic at approximately 2-3 weeks after the biopsies.

Please note that the above time frames are suggested time frames and depending on clinical workload within the hospital, the time frame may be shorter or longer. This would be no different than if you were not part of the study.

Being involved in the study does not limit subsequent tests or treatment you may receive. If you do undergo further tests or treatment after the study is complete we may check the results of these on your records. We use the research data we have gathered from your involvement in the study to help us determine how good the diagnostic tests you have had are. We will work with other research teams to do this. We also ask your permission to use research data for teaching and education of other healthcare professionals. After completing the study, we also ask your permission to check your health through national databases. We may also contact you for further information in the future. This may include requests to complete quality of life questionnaires or for ascertaining future health status. All information which is collected about you during the course of the research will be kept strictly confidential, and any information about you which leaves the hospital will have your name and address removed so that you cannot be recognised. Please see Part 2 for further information on this.

7. What data will be collected and use of data

We will need to use information from your medical records for this research project. Your hospital will hold personal identifiable data on you. This information will include information such as age, PSA level, family history of medical conditions such as prostate cancer and examination findings. We allow the PRIME research team at your local site to hold

identifiable data on you, which will be for 10 years. Longer term data that may be requested from you include information on whether or not you have had further investigations or treatment for prostate problems and what the outcomes of those were as well as quality of life assessments. Non-identifiable data will be stored in the MARVIN database and the database will be transferred and stored at UCL within UCL's data safe haven. You will be given a subject number and a subject identifier, and this will be used on all your study records. The code for this number will be known to the investigators at your site so that the link between your name and the data we hold on the study database is not completely broken. Any paperwork for the study will be kept in locked cupboards, staff access to these cupboards is strictly controlled.

In general, UCL, as a university and a study sponsor, uses personally-identifiable information to conduct research to improve health, care and services. As a publicly-funded organisation, we have to ensure that it is in the public interest when we use personally-identifiable information from people who have agreed to take part in research. This means that when you agree to take part in a research study, we will use your data in the ways needed to conduct and analyse the research study. Your rights to access, change or move your information are limited, as we need to manage your information in specific ways in order for the research to be reliable and accurate. If you withdraw from the study, we will use the minimum personally-identifiable information possible.

Health and care research should serve the public interest, which means that we have to demonstrate that our research serves the interests of society as a whole. We do this by following the UK Policy Framework for Health and Social Care Research.

All data is managed in line with the Data Protection Act (2018) & General Data Protection Regulations (GDPR).

If you wish to raise a complaint on how we have handled your personal data, you can contact our Data Protection Officer who will investigate the matter. If you are not satisfied with our response or believe we are processing your personal data in a way that is not lawful you can complain to the Information Commissioner's Office (ICO).

UCL Data Protection Officer can be contacted on data-protection@ucl.ac.uk

8. What will I have to do?

You should attend your screening visit and if eligible for the study, await contact from the hospital for further dates of investigations. Unless otherwise advised by a doctor you should carry on with your normal activities and medication. Sometimes before a biopsy your doctor will prescribe you antibiotics and may ask you to stop blood-thinning medications.

You should undergo the necessary tests and biopsy procedures that you are advised to have by your doctor.

You should attend your follow up clinic appointment where we discuss your results. Treatment options will be discussed with you at the results clinic. In total you will typically be required to attend the hospital 2-3 times.

9. What are the alternatives for diagnosis?

An MRI scan and biopsies of the prostate if required are the standard ways in which prostate cancer is diagnosed.

10. What are the possible disadvantages and risks of taking part?

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Being involved in the study is unlikely to expose you to additional risk than if you were not involved in the study but underwent the normal procedures for men referred for further investigation of prostate disease.

Risks of prostate biopsy include:

- Temporary discomfort in the back passage (most men)
- Blood in the urine up to 2 weeks (most men)
- Blood in the semen up to 3 months (most men)
- Blood in the back passage up to 1 week (most men)
- Infection in the blood stream 1-4 out of 100 men
- Urinary tract infection 4 out of 100 men
- Urinary retention 1 out of 100 men
- Adverse reaction to antibiotics less than 1 in 100 men

Risks of MRI include:

- Discomfort from cannulation
- Allergic reaction:
 - o Mild reaction e.g. rash, itching less than 1 in 250 men
 - Moderate reaction e.g. nausea, omitting less than 1 in 2000 men
 - Severe reaction e.g. breathing problems less than 1 in 10000 men

In some centres, you would receive exactly what you would normally get outside of the study. In other centres, their usual practice may be slightly different to this, and you may be required to have a few extra or fewer biopsies than what is typical in your usual centre. However, there is no evidence that a few extra or fewer biopsies within the proposed study would result in additional adverse effects for you.

Before participating you should consider if this will affect any insurance you have and seek advice if necessary.

11. What should you do if you experience any problems during the study?

Though the risk is very low, if you do experience any possible signs of infection after biopsies (fevers and feeling generally unwell) then you should urgently go to your nearest accident and emergency department which is open 24 hours a day. If you are not able to pass urine you should urgently go to your nearest accident and emergency. If you are unsure about what to do or have any questions please call 0207 679 9092 between 9am and 5pm and a member of our team may be able to offer you advice or direct you to someone who can offer you advice.

If you experience any other untoward complication or need to see a doctor we would like to know about this so please let us know on the above number as soon as possible after the complication. For any emergencies at any time or if you are unable to contact a member of the research team, please attend your local accident and emergency for an assessment.

12. What happens when the research study stops?

Once the results of the MRI and, if required, biopsy are available you will be called to clinic to discuss them. Once a treatment decision is made, most men in the study will complete the study and your normal clinical team will continue to look after your care. Being part of the study does not prevent you from undergoing any further diagnostic test or treatment that your clinician would normally recommend.

13. What if there is a problem?

Any complaint about the way you have been dealt with during the clinical study or any possible harm you might suffer will be addressed. The detailed information concerning this is given in Part 2 of this information sheet. If you have any concerns or complaints you should contact a member of the research team in the first instance.

14. Will my taking part in the study be kept confidential?

Yes. We will follow ethical and legal practice and all information about you will be handled in confidence. The details are included in Part 2.

15. Will any costs I incur in travelling to study visits be reimbursed to me?

Reasonable transport costs that you incur to get to additional study visits (if any further visits are necessary) that are above what you would normally need if you were not part of the study may be reimbursed. Please contact your local study nurse or doctor or the Study Coordinator (details below) for further information on claiming.

16. Contact Details

If you have any further questions or need any further information please do no hesitate to contact the research team.

or the Chief Investigator:

Mr Veeru Kasivisvanathan MBBS BSc FRCS MSc PGCert PhD Division of Surgery and Interventional Science, University College London 3rd floor Charles Bell House, 43-45 Foley Street London W1W 7TS T: 0207 679 9092 F: 0207 679 9511 E: veeru.kasi@ucl.ac.uk

This completes Part 1 of the Information Sheet.

If the information in Part 1 has interested you and you are considering participation, please read the additional information in Part 2 before making any decision.

review only

Part 2

17. What if relevant new information becomes available?

Sometimes we get new information about the procedures being studied. If this happens and we feel it is important to your participation in the study, we will tell you about it and discuss whether you want to or should continue in the study. If you decide not to carry on, we will make arrangements for your care to continue. If you decide to continue in the study, we may ask you to sign an updated consent form. You can also find out if there is any new relevant information by visiting www.ncita.org.uk.

18. What will happen if I don't want to carry on with the study?

You can withdraw from the study at any point and it will not affect the care that you are given. We will use information collected about you up until your withdrawal. Kindly keep in contact with us to let us know your progress.

19. What if there is a problem?

If you have a concern about any aspect of this study, you should ask to speak to your research team who will do their best to answer your questions, please see point number 24. You can also contact the Chief Investigators on the number or address given earlier in this document. If you wish to complain by other means or have any concerns about any aspect of the way you have been approached or treated by members of staff or about any side effects (adverse events) you may have experienced due to your participation in the clinical study, the normal National Health Service complaints mechanisms are available to you. You can contact the hospital Patient Advice and Liaison Service (PALS). Your local PALS team can be contacted at the following number:

Local team to insert contact details of local PALS office here:

You can also contact NHS helpline at 111 which will be able to give you the number of your local PALS office if you are concerned.

Every care will be taken in the course of this clinical study. However in the unlikely event that you are injured by taking part, compensation may be available.

If you suspect that the injury is the result of the Sponsor's (University College London) or the hospital's negligence, then you may be able to claim compensation. After discussing with your study doctor, please make the claim in writing to Mr Veeru Kasivisvanathan who is the Chief Investigator for the clinical study and is based at University College London. The Chief Investigator will then pass the claim to the Sponsor's Insurers, via the Sponsor's office. You may have to bear the costs of the legal action initially, and you should consult a lawyer about this.

20. Will my taking part in this study be kept confidential?

If you consent to take part in this study, the records obtained while you are in this study as well as related health records will remain strictly confidential at all times. The information will be held securely on paper and electronically at your treating hospital under the provisions of the Data Protection Act 2018 and the General Data Protection Regulations 2018. The information will be made available to persons in the clinical and research teams treating you. Your name and personal details will not be passed to anyone else outside the clinical team, research team or the Sponsor, who is not involved in the study. No additional samples will be taken specially for research in this study. All The research team may verify results of tests carried out at your local hospital (for example MRI results or prostate biopsy results) by transferring and analysing a small number of samples collected to UCL. samples and information collected will be de-identified to you prior to transfer to UCL, so only non-identifiable data will be transferred to UCL. This includes some pathology glass slides, which will be reviewed at Dr Alex Freeman's laboratory at University College London (UCL), for quality control. Slides sent to UCL will be

 not have your name assigned. Samples will be sent using one of UCL's preferred couriers, for both pick up and return.

Any data stored by the research team outside of your treating hospital will be kept at a secure location and will not contain information that can directly identify you. You will be allocated a study number, which will be used as a code to identify you on all study forms and data. The information will be linked to you so that if we did need to identify you for your safety or to clarify some information we would be able to by using a unique key, which will be known only to your local hospital team.

Your records will be available to people authorised to work on the study but may also need to be made available to people authorised by the Sponsor, which is the organisation responsible for ensuring that the study is carried out correctly. By signing the consent form, you agree to this access for the current study and any further research that may be conducted in relation to it, even if you withdraw from the current study. All will have a duty of confidentiality to you as a research participant.

If you withdraw consent from further study treatment, your data and samples will remain on file and will be included in the final study analysis.

In line with the regulations, at the end of the study your data will be securely archived for 20 years. Arrangements for confidential destruction will then be made.

Anonymised data collected during the study may be transferred for the purpose of processing or analysis to approved associated researchers and commercial partners within/outside the European Economic Area. The Sponsor of the study will take all reasonable steps to protect your privacy.

In the future we may publish our findings from the study in scientific journals, but you will not be identifiable in any publications.

21. Will my GP be informed of my involvement?

Because this study is not being carried out by your GP, we would like to inform them of your participation. If you agree to take part and agree to us contacting your GP, we will give him or her details of the study and inform them that you have chosen to participate in it. You will not be able to participate in this study if you do not give us this permission to inform your GP.

22. What will happen to the results of the research study?

The results of the study will be available after it finishes and will usually be published online in a medical journal and presented at a scientific conference, they will also be posted to. The data will be anonymous and it will not be possible to identify you in any report or publication. Sometimes the data may be used to teach other healthcare professionals how to treat patients in a similar position to you.

Should you wish to see the results, or the publication, please ask your study doctor or see the trial website on <u>https://www.ucl.ac.uk/surgery/research/research-department-targeted-intervention/prime-trial-information</u>, or the clinical trials units website www.ncita.org.uk.

23. Who is organising and funding the research?

The governance sponsor is University College London. The study is funded by Prostate Cancer UK, the European Association of Urology Research Foundation, the UK National Institute for Health Research via an Academic Clinical Lectureship to Dr Veeru Kasivisvanathan and the UK National Cancer Imaging Translational Accelerator.

24. Who has reviewed the study?

All research in the NHS is looked at by an independent group of people, called a Research Ethics Committee, to protect your interests. This study has been reviewed and given favorable opinion by National Research Ethics Service Committee _West Midlands - Black Country Research Ethics Committee. Patients and members of the public have also reviewed the study documents to ensure they are appropriate and well written.

25. Further information

You are encouraged to ask any questions you wish, before, during or after your investigations. If you have any questions about the study, please speak to your study nurse or doctor on the numbers specified below, who will be able to provide you with up to date information about the procedures involved. If you wish to read the research on which this study is based, please ask your study nurse or doctor.

Site Study staff contact details:

Principal Investigator (site) details:

Alternatively, if you or your relatives have any questions about this study you may wish to contact one of the following organisations that are independent of the hospital at which you are being treated:

Prostate Cancer UK - 0800 082 1616 - http://prostatecanceruk.org

Macmillan Cancer Support - 0808 808 0000 - http://www.macmillan.org.uk

If you decide you would like to take part then please read and sign the consent form. You will be given a copy of this information sheet and the consent form to keep. A copy of the consent form will be filed in your patient notes, one will be filed with the study records and one may be sent to the Research Sponsor.

You can have more time to think this over if you are at all unsure.

Thank you for taking the time to read this information sheet and to consider this study.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and

provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRITreporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A,

Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D, SPIRIT 2013 Explanation and

Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586

m as: text and data mining, Al training, and similar technologies. Reporting Item Administrative information

- Descriptive title identifying the study design, Title #1 population, interventions, and, if applicable, trial acronym
- Trial registration #2a Trial identifier and registry name. If not yet

BMJ Open		

1 2			registered, name of intended registry	
3 4	Trial registration:	<u>#2b</u>	All items from the World Health Organization Trial	Table 3
5 6 7	data set		Registration Data Set	
8 9 10 11	Protocol version	<u>#3</u>	Date and version identifier	Table 4
12 13	Funding	<u>#4</u>	Sources and types of financial, material, and other	#13ted
14 15			support	by сор
16 17 18	Roles and	<u>#5a</u>	Names, affiliations, and roles of protocol	vright #13t
19 20	responsibilities:		contributors	includ
21 22 23	contributorship			ling for us
24 25 26	Roles and	<u>#5b</u>	Name and contact information for the trial sponsor	Table 5
27 28	responsibilities:			ited to
29 30	sponsor contact			text ar
32 33	information			nd data r
34 35 36	Roles and	<u>#5c</u>	Role of study sponsor and funders, if any, in study	Table 5
37 38	responsibilities:		design; collection, management, analysis, and	Al trai
39 40	sponsor and funder		interpretation of data; writing of the report; and the	ning, a
41 42 43			decision to submit the report for publication,	and sin
44 45			including whether they will have ultimate authority	nilar te
46 47 48			over any of these activities	chnolog
49 50	Roles and	<u>#5d</u>	Composition, roles, and responsibilities of the	Table 5 [.]
51 52	responsibilities:		coordinating centre, steering committee, endpoint	
55 55	committees		adjudication committee, data management team,	
56 57 58			and other individuals or groups overseeing the trial,	
59 60		For peer	review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

		if applicable (see Item 21a for data monitoring committee)
Introduction		
Background and	<u>#6a</u>	Description of research question and justification for
rationale		undertaking the trial, including summary of relevant
		studies (published and unpublished) examining
		benefits and harms for each intervention
Background and	<u>#6b</u>	Explanation for choice of comparators
rationale: choice of		
comparators		
Objectives	<u>#7</u>	Specific objectives or hypotheses
Trial design	<u>#8</u>	Description of trial design including type of trial (eg,
		parallel group, crossover, factorial, single group),
		allocation ratio, and framework (eg, superiority,
		equivalence, non-inferiority, exploratory)
Methods:		
Participants,		
interventions, and		
outcomes		
Study setting	<u>#9</u>	Description of study settings (eg, community clinic,
		academic hospital) and list of countries where data
		will be collected. Reference to where list of study
		sites can be obtained
	For peer	review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2022-070280 on 5 April 2023. Downloaded from http://bmjopen.bmj.com/ on May 20, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1 2	Eligibility criteria	<u>#10</u>	Inclusion and exclusion criteria for participants. If
3 4			applicable, eligibility criteria for study centres and
5 6 7			individuals who will perform the interventions (eg,
7 8 9			surgeons, psychotherapists)
10 11 12	Interventions:	<u>#11a</u>	Interventions for each group with sufficient detail to
13 14	description		allow replication, including how and when they will
15 16 17			be administered
18 19 20	Interventions:	<u>#11b</u>	Criteria for discontinuing or modifying allocated
20 21 22	modifications		interventions for a given trial participant (eg, drug
23 24			dose change in response to harms, participant
25 26 27			request, or improving / worsening disease)
28 29	Interventions:	<u>#11c</u>	Strategies to improve adherence to intervention
30 31 32	adherance		protocols, and any procedures for monitoring
33 34 35			adherence (eg, drug tablet return; laboratory tests)
36 37	Interventions:	<u>#11d</u>	Relevant concomitant care and interventions that
38 39 40	concomitant care		are permitted or prohibited during the trial
41 42	Outcomes	<u>#12</u>	Primary, secondary, and other outcomes, including
43 44 45			the specific measurement variable (eg, systolic
46 47			blood pressure), analysis metric (eg, change from
48 49			baseline, final value, time to event), method of
50 51			aggregation (eg, median, proportion), and time point
52 53			for each outcome. Explanation of the clinical
55 56			relevance of chosen efficacy and harm outcomes is
57 58			strongly recommended
59 60		For peer r	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2	Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions	Table 2 and	BMU
3 4			(including any run-ins and washouts), assessments,	Figure 1	Open
5 6 7			and visits for participants. A schematic diagram is		: first
7 8 9			highly recommended (see Figure)		publish
10 11 12	Sample size	<u>#14</u>	Estimated number of participants needed to achieve	Protec #9tec	ied as 1
13 14			study objectives and how it was determined,	ted by	0.1136
15 16			including clinical and statistical assumptions	соруг	i/bmjop
17 18 19			supporting any sample size calculations	ight, incl	en-2022-
20 21 22	Recruitment	<u>#15</u>	Strategies for achieving adequate participant	uding f #9g f	-07028(
23 24 25			enrolment to reach target sample size	or uses r) on 5 Ap
26 27	Methods:			elated	ril 2023 Erasm
28 29 30	Assignment of			to text	3. Dowr
31 32	interventions (for			and di	nloade Iescho
33 34 35	controlled trials)			ata minir	d from h
36 37	Allocation:	<u>#16a</u>	Method of generating the allocation sequence (eg,	ng, N/A ⊨	ttp://br
38 39 40	sequence		computer-generated random numbers), and list of	raining	njopen
40 41 42	generation		any factors for stratification. To reduce predictability	, and s	.bmj.c
43 44			of a random sequence, details of any planned	similar	om/ or
45 46			restriction (eg, blocking) should be provided in a	techn	ר May
47 48			separate document that is unavailable to those who	ologie	20, 20:
49 50 51			enrol participants or assign interventions	Ň	25 at Dep
52 53 54	Allocation	<u>#16b</u>	Mechanism of implementing the allocation	N/A	bartmen
55 56	concealment		sequence (eg, central telephone; sequentially		t GEZ-
57 58 50	mechanism		numbered, opaque, sealed envelopes), describing		·LTA
60 59		For peer r	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml		

1			any steps to conceal the sequence until	
2 3 4			interventions are assigned	
5 6 7	Allocation:	<u>#16c</u>	Who will generate the allocation sequence, who will	N/A
, B 9	implementation		enrol participants, and who will assign participants	
10 11			to interventions	Protec
2 3 4	Blinding (masking)	<u>#17a</u>	Who will be blinded after assignment to	N/Ay
5 5			interventions (eg, trial participants, care providers,	copyri
/ 8 9			outcome assessors, data analysts), and how	ght, incl
) <u>2</u>	Blinding (masking):	<u>#17b</u>	If blinded, circumstances under which unblinding is	N/Ag
3 1	emergency		permissible, and procedure for revealing a	or use
5	unblinding		participant's allocated intervention during the trial	s relate
;	Methods: Data			d to text
))	collection,			and c
2 3 4	management, and			lata mi
5	analysis			ning, Al
3	Data collection plan	<u>#18a</u>	Plans for assessment and collection of outcome,	#9 and
•			baseline, and other trial data, including any related	Supplementary
			processes to promote data quality (eg, duplicate	Appendix 1
			measurements, training of assessors) and a	r techr
,			description of study instruments (eg,	nologie
)			questionnaires, laboratory tests) along with their	Ň
2 3			reliability and validity, if known. Reference to where	
4 5			data collection forms can be found, if not in the	
6 7 8			protocol	
9 0		For peer r	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Data collection plan:	<u>#18b</u>	Plans to promote participant retention and complete	#9
3 4	retention		follow-up, including list of any outcome data to be	
5 6 7			collected for participants who discontinue or deviate	
, 8 9			from intervention protocols	
10 11 12	Data management	<u>#19</u>	Plans for data entry, coding, security, and storage,	#9
13 14			including any related processes to promote data	
15 16 17			quality (eg, double data entry; range checks for data	
17 18 19			values). Reference to where details of data	
20 21			management procedures can be found, if not in the	
22 23 24			protocol	
25 26	Statistics: outcomes	<u>#20a</u>	Statistical methods for analysing primary and	#1(
27 28 29			secondary outcomes. Reference to where other	
30 31			details of the statistical analysis plan can be found,	
32 33			if not in the protocol	
35 36	Statistics: additional	<u>#20b</u>	Methods for any additional analyses (eg, subgroup	#10
37 38 39	analyses		and adjusted analyses)	
40 41	Statistics: analysis	<u>#20c</u>	Definition of analysis population relating to protocol	#10
42 43 44	population and		non-adherence (eg, as randomised analysis), and	
45 46	missing data		any statistical methods to handle missing data (eg,	
47 48 49			multiple imputation)	
49 50 51 52	Methods: Monitoring			
53 54 55	Data monitoring:	<u>#21a</u>	Composition of data monitoring committee (DMC);	#1 ⁻
56 57	formal committee		summary of its role and reporting structure;	
58 59 60	1	For peer r	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

		statement of whether it is independent from the	
		sponsor and competing interests; and reference to	
		where further details about its charter can be found,	
		if not in the protocol. Alternatively, an explanation of	
		why a DMC is not needed	Ţ
Data manitarina:	#216	Description of any interim analyses and stanning	otecte
	<u>#210</u>		#11ă 94 04
interim analysis		guidelines, including who will have access to these	соруги
		interim results and make the final decision to	gnt, In
		terminate the trial	
Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and	ق #119 ل
		managing solicited and spontaneously reported	ises re
		adverse events and other unintended effects of trial	lated t
		interventions or trial conduct	o text a
Auditing	<u>#23</u>	Frequency and procedures for auditing trial	Table 5
		conduct, if any, and whether the process will be	
		independent from investigators and the sponsor	9, Al t
			rainin
Ethics and			g, ano
dissemination			SIMI
Research ethics	<u>#24</u>	Plans for seeking research ethics committee /	#111 #11
approval		institutional review board (REC / IRB) approval	loop
Protocol	<u>#25</u>	Plans for communicating important protocol	Table 4
amendments		modifications (eg, changes to eligibility criteria,	
		outcomes, analyses) to relevant parties (eg,	
		investigators, REC / IRBs, trial participants, trial	
	For peer r	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1			registries, journals, regulators)	B
3	Consent or assent	<u>#26a</u>	Who will obtain informed consent or assent from	#12 pp
5 6 7			potential trial participants or authorised surrogates,	: first
7 8 9			and how (see Item 32)	publish
10 11 12	Consent or assent:	<u>#26b</u>	Additional consent provisions for collection and use	Supplementarytect 10.
13 14 15	ancillary studies		of participant data and biological specimens in	Appendix 3
15 16 17			ancillary studies, if applicable	:opyrig
18 19 20	Confidentiality	<u>#27</u>	How personal information about potential and	10-2022-0 #12inclu #12lu
21 22			enrolled participants will be collected, shared, and	ding f
23 24			maintained in order to protect confidentiality before,	or use
25 26 27			during, and after the trial	April 202 Eras s relatec
28 29 30	Declaration of	<u>#28</u>	Financial and other competing interests for principal	1 to tshog #12 text #12 text
31 32	interests		investigators for the overall trial and each study site	and dat
33 34 35	Data access	<u>#29</u>	Statement of who will have access to the final trial	a - from #12mi - m
36 37			dataset, and disclosure of contractual agreements	ng, Al t
38 39 40			that limit such access for investigators	mjopen.t
41 42 42	Ancillary and post	<u>#30</u>	Provisions, if any, for ancillary and post-trial care,	#111 sir
43 44 45	trial care		and for compensation to those who suffer harm	n/ on l nilar te
46 47			from trial participation	schnolog
48 49 50	Dissemination	<u>#31a</u>	Plans for investigators and sponsor to communicate	gies: #12 [:] at
51 52	policy: trial results		trial results to participants, healthcare professionals,	Depari
53 54 55			the public, and other relevant groups (eg, via	tment
56 57 58			publication, reporting in results databases, or other	GEZ-LTA
59 60		For peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

		data sharing arrangements), including any	
		publication restrictions	
Dissemination	<u>#31b</u>	Authorship eligibility guidelines and any intended	#12
policy: authorship		use of professional writers	
Dissemination	<u>#31c</u>	Plans, if any, for granting public access to the full	Protect #12ect
policy: reproducible		protocol, participant-level dataset, and statistical	ed by
research		code	copyri
Appendices			ght, includi
Informed consent	<u>#32</u>	Model consent form and other related	ی Supplementary
materials		documentation given to participants and authorised	Appendix 3
		surrogates	elated to
Biological	<u>#33</u>	Plans for collection, laboratory evaluation, and	Supplementary
specimens		storage of biological specimens for genetic or	ط Appendix 1 and 2
		molecular analysis in the current trial and for future	minir
		use in ancillary studies, if applicable	ηg, Al t
Notes:			raining,
18a: #11 and Supplementary Appendix 1			
26b: Supplementary Appendix 3			
• 32: Supplementary Appendix 3			
33: Supplementary Appendix 1 and 2			
• The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative			
Commons Attribution License CC-BY-NC. This checklist was completed on 16. November 2022			
BMJ Open

1 2 3 4 5	using https://www.goodreports.org/ , a tool made by the EQUATOR Network in collaboration with Penelope.ai
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	Procepting and and a constrained of a co
56 57 58 59 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

Comparing biparametric to multiparametric MRI in the diagnosis of clinically significant prostate cancer in biopsynaive men (PRIME): a prospective, international, multicentre, non-inferiority, within-patient, diagnostic yield trial protocol

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-070280.R1
Article Type:	Protocol
Date Submitted by the Author:	08-Feb-2023
Complete List of Authors:	Asif, Aqua; University College London, Division of Surgery and Interventional Science Nathan, Arjun; University College London, Division of Surgery and Interventional Science; Royal College of Surgeons of England, Clinical Effectiveness Unit Ng, Alexander; University College London, Division of Surgery and Interventional Science Khetrapal, Pramit; University College London, Division of Surgery and Interventional Science; Whipps Cross University Hospital, Department of Urology Chan, Vinson Wai-Shun; University College London, Division of Surgery and Interventional Science; University College London, Division of Surgery and Interventional Science; University College London, Division of Surgery and Interventional Science; University College London Hospitals NHS Foundation Trust, Department of Radiology Allen, Clare; University College London Hospitals NHS Foundation Trust, Department of Radiology Freeman, Alex; University College London Hospitals NHS Foundation Trust, Department of Radiology Punwani, Shonit; University College London Hospitals NHS Foundation Trust, Department of Histopathology Punwani, Shonit; University College London Hospitals NHS Foundation Trust, Department of Radiology; University College London, Centre for Medical Imaging Lorgelly, Paula; University College London, Institute of Epidemiology and Health Care; The University College London, Research Department of Primary Care and Population Health Brew-Graves, Chris; University College London, National Cancer Imaging Translational Accelerator Muirhead, Nicola; University College London, National Cancer Imaging Translational Accelerator Emberton, Mark; University College London, Division of Surgery and Interventional Science; University College London Hospitals NHS Foundation Trust, Department of Urology Agarwal, Ridhi; University of Birmingham, Test Evaluation Research Group, Institute of Applied Health Research; University Hospitals Birmingham NHS Foundation Trust, NIHR Birmingham Biomedical

	Research Centre Takwoingi, Yemisi; University of Birmingham, Test Evaluation Research Group, Institute of Applied Health Research; University Hospitals Birmingham NHS Foundation Trust, NIHR Birmingham Biomedical Research Centre Deeks, Jonathan; University of Birmingham, Test Evaluation Research Group, Institute of Applied Health Research; University Hospitals Birmingham NHS Foundation Trust, NIHR Birmingham Biomedical Research Centre Moore, Caroline; University College London, Division of Surgery and Interventional Science; University College London Hospitals NHS Foundation Trust, Department of Urology Kasivisvanathan, Veeru; University College London, Division of Surgery and Interventional Science; University College London Hospitals NHS Foundation Trust, Department of Urology Trial Group, PRIME; University College London
Primary Subject Heading :	Urology
Secondary Subject Heading:	Radiology and imaging, Surgery
Keywords:	Prostate disease < UROLOGY, Magnetic resonance imaging < RADIOLOGY & IMAGING, RADIOLOGY & IMAGING, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Urological tumours < ONCOLOGY

SCHOLARONE[™] Manuscripts

BMJ Open: first published as 10.1136/bmjopen-2022-070280 on 5 April 2023. Downloaded from http://bmjopen.bmj.com/ on May 20, 2025 at Department GEZ-LTA Erasmushogeschool

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2						
3	1	Comparing biparametric to multiparametric MRI in the diagnosis of clinically significant prostate				
4	2	cancer in biopsy-naive men (PRIME): a prospective, international, multicentre, non-inferiority				
5	3	within-patient, diagnostic vield trial protocol				
6	4					
/	5	Authors:				
0 0	6	Aqua Asif ^{1†}				
10	7	Ariun Nathan ^{1,2†}				
11	, 8	Alexander Ng ¹				
12	0	Dramit Khatranal ^{1,3}				
13	9 10	Vincon Wai Shun Chanl				
14	10	Francesco Cigantil ¹⁴				
15	11					
16	12					
17	13	Alex Freeman ³				
18	14	Shohit Puhwani ^{*,0}				
19	15	Paula Lorgelly ^{7,8}				
20	16	Caroline S Clarke ⁹				
21	17	Chris Brew-Graves ¹⁰				
22	18	Nicola Muirhead ¹⁰				
23	19	Mark Emberton ^{1,11}				
25	20	Ridhi Agarwal ^{12,13}				
26	21	Yemisi Takwoingi ^{12,13}				
27	22	Jon Deeks ^{12,13}				
28	23	Caroline M Moore ^{1,11}				
29	24	Veeru Kasivisvanathan ^{1,11}				
30	25	On behalf of the PRIME Trial Group*				
31	26					
32	27	⁺ Joint-first authors have made equal contribution to this study				
33	28					
24 25	29	*PubMed Indexed Collaborators (PRIME Trial Group)				
36	30	John Wilkinson, Marimo Rossiter, Réka Novotta, Philip Ryan, Alex Kirkham, Louise Dickinson, Tushar				
37	31	Narain, Hazel McBain, Antonette Andrews, Daniel Margolis, Valeria Panebianco, Antti Ranniko, Peter				
38	32	Albertsen, Lance Mynderse, Adam Froemming, Naoki Takahasi, Tristan Barrett, Raphaele Renard				
39	33	Penna, Vibeke Løgager, Lars Boesen, Sangeet Ghai, Lars Budäus, Valeria Panebianco, Enrique Gómez				
40	34	Gómez, Jeremy Grummet, Tho Pham, Aiman Haider, Jing Yi Jessica Weng, Anders Biartell, Wim Wities,				
41	35	Christien Caris, Joke Van Egmond.				
42	36					
43	37	Affiliations:				
44	38	1 Division of Surgery and Interventional Science University College London London United				
45 46	39	Kingdom				
40 47	40	2 Clinical Effectiveness Unit The Royal College of Surgeons of England United Kingdom				
47	40 //1	 Connect Effectiveness only, the Royal Conege of Surgeons of England, Onliced Kingdom Department of Urology, Whinps Cross Hospital, Barts Health NHS Trust, London, United Kingdom 				
49	41 // 2	A Department of Radiology University College London Hospital NHS Foundation Trust London				
50	42	4. Department of Radiology, oniversity conege condon hospital who roundation must, condon,				
51	45 //	5 Department of Pathology University College London Hospitals NHS Equipartient Truct London				
52	44 15	J. Department of Fathology, oniversity conege condon nospitals NRS Foundations must, condon,				
53	45 46	Contro for Madical Imaging University College London London United Vincedor				
54	40	 centre for iviencel imaging, university college London, London, United Kingdom Institute of Enidemiology and Lookh Core. University College London, London, United Kingdom 				
55	4/	7. Institute of Epidemiology and Health Care, University College London, London, United Kingdom				
56	48	8. School of Population Health, The University of Auckland, Auckland, 1023, New Zealand				
5/	49	9. Research Department of Primary Care and Population Health, University College London, London,				
20 50	50	United Kingdom				
60						
00						

1		
2		
4	51	10. National Cancer Imaging Translational Accelerator, Division of Medicine, University College
5	52	London, London, United Kingdom
6	53	11. Department of Urology, University College London Hospital NHS Foundation Trust, London, United
7	54	Kingdom 12. Test Evolution December Crown, Institute of Applied Health December Huivensity of Directorhead
8	55	12. Test Evaluation Research Group, Institute of Applied Health Research, University of Birmingham,
9	50	Birmingham, United Kingdom
10	57	13. NIAR Birmingham Biomedical Research Centre, University Hospitals Birmingham NAS Foundation
12	58	Trust, University of Birmingham, Birmingham, United Kingdom
13	59	Corresponding Authory
14	60 61	Corresponding Author:
15	62	
16	62	Weel ukasi Division of Surgery and Interventional Science, University College London, London, United Kingdom
17	03 64	Division of Surgery and Interventional Science, University Conege London, London, Onited Kingdom
18	04 65	Konverde
19 20	05 66	Reywords:
20	67	prostate cancer, diagnostic, MRI, prostate, biopsy
22	69	Current word count: 2600
23	60	Figure limit: No limits on figures or tables
24	70	Figure count: 1
25	70	Box count: 2
26	71	Table count: 5
2/	72	Sunnlementary annendix count: 3
20 29	73	Supplementary appendix count. S
30	75	
31	75	
32	70	STRENGTHS AND LINITATIONS Strength: DPIME is a progratic prospective international multicentre trial being carried out
33	79	• Strength. Prime is a plagmatic, prospective, international, multicentre that being carried out
34	70	 Strength: Its within-patient design allows nations to act as their own control improving the
35	80	• Strength. its within-patient design allows patients to act as their own control, improving the
30 27	80 81	• Strength: Its within-nations design allows the impact of the dynamic contrast enhanced
38	82	sequences on staging decisions and treatment eligibility to be made at an individual nations
39	83	
40	84	• Strength: PRIME will be one of the first trials to quality control the performance of sites'
41	85	dynamic contrast enhanced sequences prior to their involvement in the trial
42	86	Limitation: as both biparametric and multiparametric targeted biopsies are carried out in the
43	87	same patient it is possible for the performance of one technique to influence the other
44	88	sume patient it is possible for the performance of one testinique to inducted the other
45 46	89	
47	05	
48		
49		
50		
51		
52 52		
55 54		
55		
56		
57		
58		
59		
60		

ABSTRACT

Introduction

Prostate MRI is a well-established tool for the diagnostic work-up for men with suspected prostate cancer. Current recommendations advocate the use of multiparametric MRI (mpMRI), which is comprised of three sequences: T2-weighted (T2W), diffusion-weighted (DWI), and dynamic contrast enhanced (DCE). Prior studies suggest that a biparametric MRI approach (bpMRI), omitting the DCE sequences, may not compromise clinically significant cancer detection, though there are limitations to these studies, and it is not known how this may affect treatment eligibility. A bpMRI approach will reduce scanning time, may be more cost effective and at a population level, allow more men to gain access to an MRI than a mpMRI approach.

Methods

PRIME is a prospective, international, multicentre within-patient diagnostic yield trial, assessing whether bpMRI is non-inferior to mpMRI in the diagnosis of clinically significant prostate cancer. Patients will undergo the full mpMRI scan. Radiologists will be blinded to the dynamic contrast enhanced sequence (DCE) and will initially report the MRI using only the bpMRI (T2W and DWI) sequences. They will then be unblinded to the DCE sequence and will then re-report the MRI using the mpMRI sequences (T2W, DWI and DCE). Men with suspicious lesion(s) on either bpMRI or mpMRI will undergo prostate biopsy. The main inclusion criteria are men with suspected prostate cancer, with a serum PSA of \leq 20 ng/mL and no prior prostate biopsy. The primary outcome is the proportion of men with clinically significant prostate cancer detected (Gleason \geq 3+4 or Gleason Grade Group \geq 2). A sample size of at least 500 patients is required. Key secondary outcomes include the proportion of clinically insignificant prostate cancer detected and treatment decision.

- Ethics and Dissemination Ethical approval was obtained from the National Research Ethics Committee West Midlands, Nottingham 21/WM/0091. Results of this trial will be disseminated through peer-reviewed publications. Participants and relevant patient support groups will be informed about the results of the trial.
- **Registration details NCT04571840**

STUDY TITLE

Long Title: A trial assessing whether biparametric MRI is non-inferior to multiparametric MRI in the diagnosis of clinically significant prostate cancer

Short Title: Prostate Imaging Using MRI +/- Contrast Enhancement

Trial Acronym: PRIME

INTRODUCTION

This protocol was written according to SPIRIT guidelines [1]. Magnetic Resonance Imaging (MRI) is widely established as the gold standard diagnostic imaging modality for detecting clinically significant prostate cancer (PCa) [2]. The landmark PRECISION study established the benefit of detecting clinically significant prostate cancer using MRI and targeting biopsies based on MRI findings [3]. The National Prostate Cancer Audit data from England showed that only 62% of patients receive prostate MRI before biopsy, despite the level 1 evidence to support the use of MRI [2] [3] [4].

Current recommendations for the use of MRI for detection of PCa focus on the use of multiparametric MRI (mpMRI) [2] [3]. mpMRI consists of three sequences: T2-weighted (T2W), diffusion-weighted (DWI) and dynamic contrast enhanced (DCE) sequences. On the DCE sequences, cancer-suspicious areas can demonstrate early wash-in, enhancement and rapid wash-out of contrast [5] [6] [7] [8]. The DCE sequences involve administering gadolinium contrast via an intravenous cannula. Therefore, it increases scanning time and healthcare costs compared to a bpMRI approach where only T2W and DWI are used. Whilst gadolinium is in widespread use, literature suggests it may accumulate in the basal ganglia, though its clinical relevance is not fully understood [9] [10]. In patients who are likely to get repeated scans over their lifetime – there may be no advantage of using the additional contrast if the bpMRI option is as good as the mpMRI option.

Removing the DCE sequences from the MRI protocol has been suggested as a potential avenue to improve the cost-effectiveness of using MRI in the diagnostic pathway for PCa [11] [12] and the reduced scanning time required may improve the number of men with suspected prostate cancer accessing an MRI scan. Using bpMRI has demonstrated similar detection rates of PCa as mpMRI but current evidence is limited primarily to retrospective, single-centre studies [12] [13]. The few prospective studies have not been typically robustly designed to evaluate the role of DCE in prostate cancer detection [13] [14].

The PRIME trial aims to assess whether bp-MRI is non-inferior to mpMRI in the detection of clinically significant prostate cancer. PRIME may redefine the standard of care diagnostic test for men with suspicion of PCa and allow many more patients who need access to an MRI to get one.

Objectives

The primary objective is to compare the detection of clinically significant PCa (Gleason \geq 3+4 or Gleason Grade Group \geq 2) using bpMRI ± targeted biopsy with mpMRI ± targeted biopsy.

Key secondary objectives include:

- To compare the proportion of men who have clinically insignificant PCa (Gleason 3+3 or Gleason Grade Group 1) detected for bpMRI versus mpMRI
- To compare the proportion of men with non-suspicious MRIs for bpMRI versus mpMRI •
- To compare the proportion of men with indeterminately-scored MRI as reported by bpMRI and mpMRI
- To compare the proportion of men with MRIs of adequate standard for reporting for bpMRI • versus mpMRI
 - To compare the diagnostic test performance for bpMRI versus mpMRI •
 - To compare radiological staging for bpMRI versus mpMRI
 - To compare treatment eligibility decisions for bpMRI when compared with mpMRI •
- To compare diagnostic performance of bpMRI and mpMRI when using the Likert scoring • system in comparison to the PI-RADS v2.1 scoring system
- To compare the cost effectiveness of bpMRI when compared to mpMRI •

³ 177 Trial Design

The PRIME trial is designed as a prospective, multicentre, within-patient, diagnostic yield trial, assessing whether bpMRI is non-inferior to mpMRI for the diagnosis of clinically significant PCa in biopsy-naive men. A paired cohort design was chosen rather than a randomised trial design for the following reasons:

- More efficient design (sevenfold lower sample size required) with equivalent quality of evidence in the setting of a diagnostic study
- Patients act as their own control due to the within-patient design, thus allowing us to draw
 conclusions regarding the value of DCE sequences on a per patient level
 - Allows for the evaluation of the impact of contrast on staging decisions and treatment eligibility decisions at an individual patient level
 - Patients get the benefit of having targeted biopsies based on the information from both bpMRI and mpMRI information, whereas with a randomised study, patients randomised to one technique will be denied of potential benefit of the other

192 METHODS AND ANALYSIS

21 193 Trial Setting

We expect centres who perform prostate cancer diagnostics and management from the following countries to take part: Argentina, Australia, Belgium, Brazil, Canada, Denmark, France, Finland, Germany, Italy, Netherlands, Singapore, Spain, UK and USA. Sites will be required to undergo a period of quality control prior to including patients to ensure minimum acceptable standards for the conduct of mpMRI, reporting and targeted biopsy.

200 Eligibility Criteria

Patients will be considered eligible for registration into this trial if they fulfil all of the inclusion criteria
 and none of the exclusion criteria (**Box 1**).

203			
	Box 1	Eligibility criteria	
	on criteria		
	1.	Men at least 18 years of age referred with clinical suspicion of prostate cancer	
	2.	Serum PSA ≤ 20 ng/mL	
	3.	Fit to undergo all procedures listed in protocol	
	4.	Able to provide written informed consent	
	Exclus	ion criteria	
	1.	Prior prostate biopsy	
	2.	Prior treatment for prostate cancer	
	3.	Prior prostate MRI on a previous encounter	
	4.	Contraindication to MRI (e.g. claustrophobia, some pacemakers)	
	5.	Contraindication to prostate biopsy	
	6.	Unfit to undergo any procedures listed in protocol	
204			
205	Interver	itions	
206	MRI Con	duct	
207	MRI will	be conducted with 1.5T or 3.0T with pelvic-phased array coils, with or without endorectal	
208	coils. Th	e PRECISION study quality control highlighted that the image quality of the DCE sequences	
209	was the most variable sequence across sites [3]. Therefore, to give DCE a reasonable chance of demonstrating whether it has value, MRI scanner approval for use in the study will be made on the basis of central review of MRI images, utilising the Prostate Imaging Quality (PI-QUAL) scoring system		
210			
211			
212	[15]. In brief, PI-QUAL is a 5-point Likert scoring system, where 1 indicates no sequences are of diagnostic quality and 5 implies that each sequence individually is of optimal diagnostic quality. The		
213			
214	objective criteria used to determine PI-QUAL scores are derived from internationally published		

 minimum standards for MRI conduct [16]. If necessary, sites will be given recommendations to improve image quality and will be re-evaluated after optimisation for participation in the study. <i>Reporting of MRI</i> Patients will undergo (or will have undergone) standard of care mpMRI as per their local protocol. The radiologits participating in this trial will be blinded to the DCE sequences and will report the MRI using only the biparametric (T2W and DWI) sequences in Report 1. After reporting the bpMRI, the same radiologits will be unblinded to the DCE sequences and will re-port the MRI using the mpMRI sequences (T2W, DWI and DCE) in Report 2 (Figure 1). The MRIs and lesions are scored on a 1–5 scale of suspicion for the likelihood that clinically significant sequences (T2W, DWI and DCE) in Report 2 (Figure 1). The MRIs and lesions are scored on a 1–5 scale of suspicion. Both the traditional Likert and PL RADS v2.1 scoring systems will be used to identify any suspicious lesions in the prostate. Suspicious areas (Likert or PLRADS v2.1. 23) on either bpMRI or mpMRI will undergo targeted biopsy of the prostate, with cores from contrast-enhanced suspicious areas stored separately. A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2. Please see Supplementary Appendix 1 for our model reporting proformas, which radiologists participating in the PRIME trial will use to label lesions. Mon-suspicious bp/MRI and mpMRI Men whose MRIs do not show suspicious areas on bpMRI and mpMRI (i.e. scored 1 or 2 on Likert and PLRADS v2.1) will be stratified by PSA density. Men with PSA density <-0.15ng/mL/mL/mL will undergo biopsy and men with PSA density. 20.15ng/mL/mL will undergo systematic biopsy. Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious a	1			
215 minimum standards for Wirk Conduct [16]. If necessary, sites will be given recommendations to 216 improve image quality and will be re-evaluated after optimisation for participation in the study. 217 Reporting of MRI 218 Reporting of MRI 219 Patients will undergo (or will have undergone) standard of care mpMRI as per their local protocol. The 211 radiologists participating in this trial will be binded to the DCE sequences and will re-prove the MRI using the mpMRI sequences (T2W, DWI and DCE) in Report 1. After report the MRI using the mpMRI sequences (T2W, DWI and DCE) in Report 2 (Figure 1). 212 The MRIs and lesions are scored on a 1–5 scale of suspicion. Both the traditional Likert and PL red is present, with 5 representing the greatest score of suspicion. Both the traditional Likert and PL red is present, with cores from contrast-enhanced suspicious areas stored separately. 213 A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2. Please see 214 A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2. Please see 215 Non-suspicious bpMRI and mpMRI 216 Men whose MRIs do not show suspicious areas on bpMRI will undergo systematic biopsy. 217 PraNos V.11 will be stratified by PSA density. Men with PSA density <0.15 mg/m/m. will not undergo systematic biopsy.	2 3 245	naining standards for MDI and st [40]. If an anomaly sites will be since a second stime to		
216 Improve Image quality and will be re-evaluated after optimisation for participation in the study. 217 Reporting of MRI 218 Reporting of MRI 219 Patients will undergo (or will have undergone) standard of care mpMRI as per their local protocol. The 210 radiologists participating in this trial will be blinded to the DCE sequences and will report the MRI using 211 radiologist participating in this trial will be sequences and will re-report the MRI using the mpMRI 212 radiologist will be unshinded to the DCE sequences and will re-report the MRI using the mpMRI 212 radiologist will be unshinded to the DCE sequences and will re-report the MRI using the mpMRI 212 The MRIs and lesions are scored on a 1–5 scale of suspicion. Botons in the prostate. Suspicious areas tore of suspicion. Botons in the prostate. Suspicious areas (Likert or PI-RADS v2.1 23) on either bgMRI or mpMRI will undergo targeted biopsy of the 218 prostate, with cores from contrast-enhanced suspicious areas stored separately. 210 A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2 . Please see 211 A summary of not show suspicious serves on bgMRI and mpMRI 212 Non-suspicious bpMRI and mpMRI 213 Non-suspicious bands and the porting rules 214 Men whose MRIs do not show suspicious sereas on bgMRI and mpMRI (i	³ 215 4 216	minimum standards for MRI conduct [16]. If necessary, sites will be given recommendations to		
6 217 7 218 Reporting of MRI 8 219 Patients will undergo (or will have undergone) standard of care mpMRI as per their local protocol. The 8 219 radiologists participating in this trial will be blinded to the DCE sequences and will report the MRI using 9 220 only the biparametric (TZW and DVI) sequences in Report 1. After reporting the bpMRI, the same 112 221 sequences (TZW, DWI and DCE) in Report 2 (Figure 1). 12 223 The MRIs and lesions are scored on a 1–5 scale of suspicion. Both the traditional Likert and PI- 12 224 The MRIs and lesions are scored on a 1–5 scale of suspicion. Both the traditional Likert and PI- 12 226 The MRIs and lesions are scored on a 1–5 scale of suspicion. Both the traditional Likert and PI- 12 227 RADS V2.1 scoring systems will be used to identify any suspicious lesions in the prostate. Suspicious 128 areas (Liker or PI-RADS V2.1 23) on either bpMRI or mpMRI will undergo targeted biopsy of the 129 prostate, with cores from contrast-enhanced suspicious areas stored separately. 1231 A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2. Please see 232 Supplementary Appendix 1 for our model reporting mSI and mpMRI (i.e. scored 1 or 2 on Likert and PI-RADS V2.1 sc	5 216	improve image quality and will be re-evaluated after optimisation for participation in the study.		
7 218 Reporting of MRI 219 Patients will undergo (or will have undergone) standard of care mpMRI as per their local protocol. The 210 radiologists participating in this trial will be blinded to the DCE sequences and will report the MRI using 211 radiologist will be unblinded to the DCE sequences and will report the MRI using the mpMRI 212 radiologist will be unblinded to the DCE sequences and will report the MRI using the mpMRI 212 The MRIs and lesions are scored on a 1–5 scale of suspicion. Both the traditional Likert and PH 212 The MRIs and lesions are scored on a 1–5 scale of suspicion. Both the traditional Likert and PH 212 The MRIs and lesions are scored on a 1–5 scale of suspicion. Both the traditional Likert and PH 213 The MRIs and lesions are scored on a 1–5 scale of suspicion. Both the traditional Likert and PH 219 prostate, with cores from contrast-enhanced suspicious areas stored separately. 210 areas (Likert or PI-RADS v2.1 ≥3) on either bpMRI or mpMRI will undergo targeted biopsy of the 213 A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2 . Please see 224 Supplementary Appendix 1 for our model reporting proformas, which radiologists participating in the 213 Non-suspicious bpMRI and mpMRI 224 Non-suspicious byMRI and mpMRI	6 217			
9 Patients will undergo (or will have undergone) standard of care mpMRI as per their local protocol. The radiologist sparticipating in this trial will be binded to the DCE sequences and will report the MRI using the mpMRI sequences in Report 1. After reporting the bpMRI, the same radiologist will be unblinded to the DCE sequences and will re-report the MRI using the mpMRI sequences (T2W, DWI and DCE) in Report 2 (Figure 1). 12 The MRIs and lesions are scored on a 1–5 scale of suspicion for the likelihood that clinically significant PCa is present, with 5 representing the greatest score of suspicion. Both the traditional Likert and PI-RADS V2.1 scoring systems will be used to identify any suspicious lesions in the prostate. Suspicious areas (Liker to PI-RADS V2.1 ±3) on either bpMRI or mpMRI will undergo targeted biopsy of the prostate, with cores from contrast-enhanced suspicious areas stored separately. 230 A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2 . Please see Supplementary Appendix 1 for our model reporting proformas, which radiologists participating in the PRIME trial will use to label lesions. 233 Non-suspicious BpMRI and mpMRI 234 Men whose MRIs do not show suspicious areas on bpMRI and mpMRI (i.e. scored 1 or 2 on Likert and PI-RADS v2.1 scoring system) to 1. The radiologist reporting this will be binded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc.) 235 Non-suspicious BpMRI and mpMRI 236 Report 1 (biparametric MRI: T2W and DVI) 337 I. The radiologist should then interpret the bpMRI sequences blinded to DCE	7 218	Reporting of MRI		
9 220 radiologists participating in this trial will be bilneded to the DCE sequences and will re-reporting the byMRI, the same radiologist will be unblinded to the DCE sequences and will re-report the MRI using the mpMRI 221 1222 radiologist will be unblinded to the DCE sequences and will re-report the MRI using the mpMRI 222 1224 The MRIs and lesions are scored on a 1–5 scale of suspicion for the likelihood that clinically significant PCa is present, with 5 representing the greatest score of suspicion. Both the traditional Likert and PI- 227 1228 The MRIs and lesions are scored on a 1–5 scale of suspicious lesions in the prostate. Suspicious areas (Likert or PI-RADS V2.1 23) on either byMRI or mpMRI will undergo stargeted biopsy of the prostate, with cores from contrast-enhanced suspicious areas stored separately. 229 prostate, with cores from contrast-enhanced suspicious areas stored separately. 231 A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2. Please see 232 234 Supplementary Appendix 1 for our model reporting proformas, which radiologists participating in the PRIME trial will use to label lesions. 235 Non-suspicious bpMRI and mpMRI 236 Non-suspicious bpMRI and mpMRI 237 PI-RADS v.2.1 ywill be stratified by PSA density. Men with PSA density <0.15ng/mL/mL will not undergo biopsy and men with PSA density 20.15ng/mL/mL will undergo system lnc)	8 219	Patients will undergo (or will have undergone) standard of care mpMRI as per their local protocol. The		
10 221 only the biparametric (12W and DWI) sequences in Report 1. After reporting the bpMRI, the same radiologist will be unblinded to the DCE sequences and will re-report the MRI using the mpMRI sequences (12W, DWI and DCE) in Report 2 (Figure 1). 11 223 12 The MRIs and lesions are scored on a 1-5 scale of suspicion. Both the traditional Likert and PI-RADS v2.1 scoring systems will be used to identify any suspicious lesions in the prostate. Suspicious areas (Liker to PI-RADS v2.1 2.3) on either bpMRI or mpMRI will undergo targeted biopsy of the prostate, with cores from contrast-enhanced suspicious areas stored separately. 12 230 12 A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2. Please see Supplementary Appendix 1 for our model reporting proformas, which radiologists participating in the PRIME trial will use to label lesions. 12 233 Non-suspicious bpMRI and mpMRI 234 Non-suspicious bpMRI and mpMRI 235 Non-suspicious bpMRI and mpMRI 236 Non-suspicious bpMRI and mpMRI 237 Non-suspicious sepon or an automated system (MIM by MIM Software Inc) 238 Box 2 Summary of MRI reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) 239 In the radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc)	9 220	radiologists participating in this trial will be blinded to the DCE sequences and will report the MRI using		
11 222 radiologist will be unblinded to the DCE sequences and will re-report the MRI using the mpMRI 13 223 sequences (T2W, DWI and DCE) in Report 2 (Figure 1). 14 224 The MRIs and lesions are scored on a 1–5 scale of suspicion. Both the traditional Likert and PL 16 226 The MRIs and lesions are scored on a 1–5 scale of suspicion. Both the traditional Likert and PL 17 227 The MRIs and lesions are scored on a 1–5 scale of suspicion. Both the traditional Likert and PL 18 228 reservent, with 5 representing the greatest score of suspicion. Both the traditional Likert and PL 18 228 prostate, with cores from contrast-enhanced suspicious areas stored separately. 19 230 A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2 . Please see 233 Supplementary Appendix 1 for our model reporting proformas, which radiologists participating in the 234 PRIME trial will use to label lesions. 235 Non-suspicious bpMRI and mpMRI 236 Nen-suspicious for the SA density Ch.Sng/mL/mL will undergo stored 1 or 2 on Likert and 237 PL-RADS v2.1 will be stratified by PSA density.Me with PSA density ch.Sng/mL/mL will not undergo 238 Box 2 Summary of MRI reporting rules 239	10 221	only the biparametric (T2W and DWI) sequences in Report 1. After reporting the bpMRI, the same		
12 sequences (T2W, DWI and DCE) in Report 2 (Figure 1). 14 224 14 225 15 226 16 227 17 227 18 227 19 227 19 227 19 227 19 227 19 227 19 227 19 227 19 227 19 229 19 220 200 areas (Likert or PI-RADS v2.1 2:3) on either bpMRI or mpMRI will undergo targeted biopsy of the prostate, with cores from contrast-enhanced suspicious areas stored separately. 201 A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2 . Please see 202 200 201 A summary of the rules for reporting MRI scans on bpMRI and mpMRI (i.e. scored 1 or 2 on Likert and PI-RADS v2.1) will be stratified by PSA density. Men with PSA density <-0.15ng/mL/mL will not undergo biopsy and men with PSA density 20.15ng/mL/mL will undergo systematic biopsy.	11 222	radiologist will be unblinded to the DCE sequences and will re-report the MRI using the mpMRI		
13 224 14 225 The MRIs and lesions are scored on a 1–5 scale of suspicion for the likelihood that clinically significant 15 225 The MRIs and lesions are scored on a 1–5 scale of suspicion. Both the traditional Likert and PI 16 226 RADS V2.1 scoring systems will be used to identify any suspicious lesions in the prostate. Suspicious 17 227 RADS V2.1 scoring systems will be used to identify any suspicious lesions in the prostate. Suspicious areas (Likert or PI-RADS V2.1 ±3) on either bpMRI or mpMRI will underge targeted biopsy of the prostate, with cores from contrast-enhanced suspicious areas stored separately. 17 230 A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2. Please see 17 233 Supplementary Appendix 1 for our model reporting proformas, which radiologists participating in the 17 236 Non-suspicious bpMRI and mpMRI 17 236 Non-suspicious bpMRI and mpMRI 18 237 Non-suspicious bpMRI and mpMRI 18 238 Non-suspicious proformas, which radiologists participating in the radiologist spond men with PSA density <0.15ng/mL/mL will not undergo	¹² 223	sequences (T2W, DWI and DCE) in Report 2 (Figure 1).		
14 225 The MRIs and lesions are scored on a 1–5 scale of suspicion for the likelihood that clinically significant 16 226 PCa is present, with 5 representing the greatest score of suspicion. Both the traditional Likert and PL 17 227 RADS V2.1 scoring systems will be used to identify any suspicious lesions in the prostate. Suspicious 18 228 areas (Likert or PI-RADS v2.1 ≥3) on either bpMRI or mpMRI will undergo targeted biopsy of the 19 229 A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2. Please see 223 A summary of the rules for reporting proformas, which radiologists participating in the 238 PRIME trial will use to label lesions. 239 Non-suspicious bpMRI and mpMRI 236 Men whose MRIs do not show suspicious areas on bpMRI and mpMRI (i.e. scored 1 or 2 on Likert and 237 Non-suspicious bpMRI and mpMRI 238 Box 2 Summary of MRI reporting rules 239 Box 2 Summary of MRI reporting rules 239 Box 2 Summary of MRI reporting rules 24 The radiologist should then interpret the bpMRI sequences blinded to DCE 37 In the radiologist should then interpret the bpMRI sequences blinded to DCE 38 Inter radiologist should	¹³ 224			
PCa is present, with 5 representing the greatest score of suspicion. Both the traditional Likert and Pl- RADS V2.1 scoring systems will be used to identify any suspicious lesions in the prostate. Suspicious areas (Likert or Pl-RADS V2.1 23) on either bpMRI or mpMRI will undergo targeted biopsy of the prostate, with cores from contrast-enhanced suspicious areas stored separately. A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2. Please see Supplementary Appendix 1 for our model reporting proformas, which radiologists participating in the PRIME trial will use to label lesions. Manage MRI and mpMRI Men whose MRIs do not show suspicious areas on bpMRI and mpMRI (Lie. scored 1 or 2 on Likert and Pl-RADS v2.1) will be stratified by PSA density. Men with PSA density <0.15ng/mL/mL will not undergo biopsy and men with PSA density 20.15ng/mL/mL will undergo systematic biopsy.	14 225	The MRIs and lesions are scored on a 1–5 scale of suspicion for the likelihood that clinically significant		
RADS v2.1 scoring systems will be used to identify any suspicious lesions in the prostate. Suspicious areas (Likert or PI-RADS v2.1 ≥3) on either bp/RI or mpMRI will undergo targeted biopsy of the prostate, with cores from contrast-enhanced suspicious areas stored separately. 230 A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2 . Please see Supplementary Appendix 1 for our model reporting proformas, which radiologists participating in the PRIME trial will use to label lesions. 231 A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2 . Please see Supplementary Appendix 1 for our model reporting proformas, which radiologists participating in the PRIME trial will use to label lesions. 232 Non-suspicious bp/RI and mp/RI 233 Men whose MRIs do not show suspicious areas on bp/RI and mp/RI (i.e. scored 1 or 2 on Likert and PI-RADS v2.1) will be stratified by PSA density. Men with PSA density <0.15ng/mL/mL will not undergo biopsy and men with PSA density ≥0.15ng/mL/mL will undergo systematic biopsy.	15 226	PCa is present, with 5 representing the greatest score of suspicion. Both the traditional Likert and PI-		
areas (Likert or PI-RADS v2.1 ≥3) on either bpMRI or mpMRI will undergo targeted biopsy of the prostate, with cores from contrast-enhanced suspicious areas stored separately. A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2. Please see supplementary Appendix 1 for our model reporting proformas, which radiologists participating in the PRIME trial will use to label lesions. Non-suspicious bpMRI and mpMRI Men whose MRIs do not show suspicious areas on bpMRI and mpMRI (i.e. scored 1 or 2 on Likert and PI-RADS v2.1) will be stratified by PSA density. Men with PSA density <0.15ng/mL/mL will not undergo	17 227	RADS v2.1 scoring systems will be used to identify any suspicious lesions in the prostate. Suspicious		
19 229 prostate, with cores from contrast-enhanced suspicious areas stored separately. 230 A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2. Please see 231 A summary of the rules for reporting proformas, which radiologists participating in the 232 PRIME trial will use to label lesions. 233 Non-suspicious bpMRI and mpMRI 236 Men whose MRIs do not show suspicious areas on bpMRI and mpMRI (i.e. scored 1 or 2 on Likert and 237 PRIME trial will be stratified by PSA density. Men with PSA density <0.15ng/mL/mL will not undergo	18 228	areas (Likert or PI-RADS v2.1 \geq 3) on either bpMRI or mpMRI will undergo targeted biopsy of the		
 230 231 A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2. Please see 232 Supplementary Appendix 1 for our model reporting proformas, which radiologists participating in the PRIME trial will use to label lesions. 234 235 Non-suspicious bplMI and mpMRI 236 Men whose MRIs do not show suspicious areas on bpMRI and mpMRI (i.e. scored 1 or 2 on Likert and PI-RADS v2.1) will be stratified by PSA density. Men with PSA density <0.15ng/mL/mL will not undergo 238 biopsy and men with PSA density 20.15ng/mL/mL will undergo systematic biopsy. 239 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) 1. The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) 2. The radiologist score 2 a out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on 4. The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram 5. Once Report 1 (biparametric MRI: T2W, DWI and DCE) 1. The same radiologist must report both Report 1 and Report 2 2. They will then be unbinded to the DCE sequence 3. The radiologist should now complete Report 2 4. The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above 5. On Report 2, each of the existing lesions are additionally labelled as one of: 5. DyMRI positive, mpMRI positive This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on <i>either</i> Likert or PI-RADS v2.1 scoring systems 	19 229	prostate, with cores from contrast-enhanced suspicious areas stored separately.		
231 A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2. Please see 232 Supplementary Appendix 1 for our model reporting proformas, which radiologists participating in the 233 PRIME trial will use to label lesions. 234 235 235 Non-suspicious bpMRI and mpMRI 236 Men whose MRIs do not show suspicious areas on bpMRI and mpMRI (i.e. scored 1 or 2 on Likert and 237 PI-RADS v2.1) will be stratified by PSA density. Men with PSA density <0.15ng/mL/mL will not undergo	20 230	·····, · · · · · · · · · · · · · · · ·		
232 Supplementary Appendix 1 for our model reporting proformas, which radiologists participating in the 233 PRIME trial will use to label lesions. 234 235 235 Non-suspicious bp/MRI and mp/MRI 236 Men whose MRIs do not show suspicious areas on bp/MRI and mp/MRI (i.e. scored 1 or 2 on Likert and 237 Pi-RADS v2.1) will be stratified by PSA density. Men with PSA density ×0.15ng/mL/mL will not undergo 238 biopsy and men with PSA density ≥0.15ng/mL/mL will undergo systematic biopsy. 239 Box 2 Summary of MRI reporting rules 240 Report 1 (biparametric MRI: T2W and DWI) 1. The radiologist should then interpret the bp/MRI sequences blinded to DCE 38 Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on 41 4. The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram 35 Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE 42 The same radiologist must report both Report 1 and Report 2 43 5. Once Report 1 (biparametric MRI: T2W, DWI and DCE) 44 after looking at the DCE 5. On Report 2, each of the suspicious area	21 231	A summary of the rules for reporting MRI scans in the PRIME trial is in Box 2. Please see		
233 PRIME trial will use to label lesions. 234 235 236 Mon-suspicious bpMRI and mpMRI 237 PI-RADS v2.1) will be stratified by PSA density. Men with PSA density <0.15ng/mL/mL will not undergo	²² 232	Supplementary Appendix 1 for our model reporting proformas, which radiologists participating in the		
234 235 236 237 238 239 237 238 239 239 239 230 231 232 233 234 235 236 237 238 239 239 239 31 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DVVI) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	²³ 233	PRIME trial will use to label lesions		
Non-suspicious bp/MRI and mp/MRI Men whose MRIs do not show suspicious areas on bp/MRI and mp/MRI (i.e. scored 1 or 2 on Likert and PI-RADS v2.1) will be stratified by PSA density. Men with PSA density <0.15ng/mL/mL will not undergo biopsy and men with PSA density ≥0.15ng/mL/mL will undergo systematic biopsy. Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DVI) 1. The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on Here To I (biparametric MRI: T2W, DWI and DCE) 1. The same radiologist must report both Report 1 and Report 2 Conce Report 1 (biparametric MRI: T2W, DWI and DCE) 1. The same radiologist must report both Report 1 and Report 2 The vill then be unblinded to the DCE sequence 3. The radiologist should now complete Report 2 Her To Ne superior 2, each of the existing lesions are additionally labelled according to the PI-RADS v2.1 41-sector diagram as above Do ne Report 2, each of the existing lesions are additionally labelled as one of: DymRI positive, mpMRI positive This occurs when a lesion scores 3, 4 or 5 on both bp/MRI and mpMRI based on <i>either</i> Likert or PI-RADS v2.1 4.5 scores systems	24 234			
226 Deep suppression by minimum suspicious areas on bpMRI and mpMRI (i.e. scored 1 or 2 on Likert and PI-RADS v2.1) will be stratified by PSA density. Men with PSA density <0.15ng/mL/mL will not undergo biopsy and men with PSA density ≥0.15ng/mL/mL will undergo systematic biopsy.	25 235	Non-suspicious hnMRI and mnMRI		
 Pi-RADS v2.1) will be stratified by PSA density. Men with PSA density v0.15ng/mL/mL will not undergo biopsy and men with PSA density ≥0.15ng/mL/mL will undergo systematic biopsy. Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist reporting this will be blinded to DCE. Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W, DWI and DCE) The same radiologist must report both Report 1 and Report 2 The validogist should now complete Report 2 The radiologist should now complete Report 2 The location of the suspicious areas should be according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W, DWI and DCE) The same radiologist must report both Report 1 and Report 2 They will then be unblinded to the DCE sequence On Report 2, each of the existing lesions are additionally labelled according to the PI-RADS v2.1 41-sector diagram as above On Report 2, each of the existing lesions are additionally labelled as one of: 	26 236	Men whose MRIs do not show suspicious areas on bnMRI and mnMRI (i.e. scored 1 or 2 on Likert and		
 238 biopsy and men with PSA density ≥0.15ng/mL/mL will undergo systematic biopsy. 239 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W, DWI and DCE) The same radiologist must report both Report 1 and Report 2 The radiologist should now complete Report 2 The location of the suspicious areas should be ismilarly labelled according to the PI-RADS v2.1 41-sector diagram as above On Report 2, each of the existing lesions are additionally labelled as one of: 	27 230	PI-RADS v2 1) will be stratified by PSA density. Men with PSA density < 0.15 mg/ml/ml will not undergo		
 Box 2 Summary of MRI reporting rules Report 1 (biparametric MRI: T2W and DWI) The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W, DWI and DCE) The same radiologist must report both Report 1 and Report 2 The radiologist should now complete Report 2 The location of the suspicious areas should be ismilarly labelled according to the PI-RADS v2.1 41-sector diagram as above On Report 2, each of the existing lesions are additionally labelled as one of: 	20 237	hionsy and men with PSA density >0.15ng/ml/ml will undergo systematic hionsy		
Box 2 Summary of MRI reporting rules Box 3 Report 1 (biparametric MRI: T2W and DWI) 1 The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) 2 The radiologist should then interpret the bpMRI sequences blinded to DCE 37 3. Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on 40 4. The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram 43 5. Once Report 1 (biparametric MRI: T2W, DWI and DCE) 44 after looking at the DCE 45 Report 2 (multiparametric MRI: T2W, DWI and DCE) 46 Report 2 (multiparametric MRI: T2W, DWI and DCE) 47 1. The same radiologist must report both Report 1 and Report 2 48 2. They will then be unblinded to the DCE sequence 50 3. The radiologist should now complete Report 2 48 41. The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above 51 42 52 5. On Report 2, each of the existing lesions are additionally labelled as one of: 54 55	30 230	biopsy and men with 15A density 20.15hg/me/me win andergo systematic biopsy.		
 Report 1 (biparametric MRI: T2W and DWI) 1. The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) 2. The radiologist should then interpret the bpMRI sequences blinded to DCE 3. Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on 4. The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram 5. Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE 7. The same radiologist must report both Report 1 and Report 2 2. They will then be unblinded to the DCE sequence 3. The radiologist should now complete Report 2 4. The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above 5. On Report 2, each of the existing lesions are additionally labelled as one of: bpMRI positive, mpMRI positive This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on <i>either</i> Likert or PI-RADS v2.1 scoring systems 	31	Box 2 Summary of MRI reporting rules		
 Report 1 (biparametric WRI: 12W and DWI) 1. The radiologist reporting this will be blinded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) 2. The radiologist should then interpret the bpMRI sequences blinded to DCE 3. Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on 4. The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram 5. Once Report 1 (biparametric MRI: T2W, and DWI) has been done, this cannot be altered after looking at the DCE 7. The same radiologist must report both Report 1 and Report 2 2. The ywill then be unblinded to the DCE sequence 3. The radiologist should now complete Report 2 4. The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above 5. On Report 2, each of the existing lesions are additionally labelled as one of: bpMRI positive, mpMRI positive This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on <i>either</i> Likert or PI-RADS v2.1 scoring systems 	32	Peneut 1 (hippy penetric MDI, T2) () and D) (1)		
 Ineradiologist reporting this will be binded to DCE, with verification of this via an independent person or an automated system (MIM by MIM Software Inc) The radiologist should then interpret the bpMRI sequences blinded to DCE Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE Report 2 (multiparametric MRI: T2W, DWI and DCE) The same radiologist must report both Report 1 and Report 2 The radiologist should now complete Report 2 The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above On Report 2, each of the existing lesions are additionally labelled as one of: 	33	Report I (biparametric Wiki: 12W and DWI)		
 2. The radiologist should then interpret the bpMRI sequences blinded to DCE 3. Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on 4. The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41- sector diagram 5. Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE 78 78 79 70 70 71 71 72 73 74 75 75 75 76 74 74 74 74 74 75 76 7	34 25	1. The radiologist reporting this will be blinded to DCE, with verification of this via an independent generation of this via an		
 37 3. Up to 4 suspicious areas (score ≥ 3 out of 5 on the Likert or PI-RADS v2.1 scoring system) 38 39 39 39 30 30 30 31 32 33 34 35 35 36 36 37 37 38 39 39 39 30 30 31 32 32 33 34 35 35 36 37 37 36 37 37 38 39 39 30 31 32 32 33 34 35 35 36 37 37 37 38 39 39 30 31 32 32 32 33 35 36 37 37 38 38 39 39 30 31 32 34 35 35 35 35 35 36 36 37 37 38 38 39 39 30 31 32 34 35 35 36 37 37 38 38 39 39 39 30 31 32 32 34 35 35 35 36 36 37 37 38 39 39 39 30 31 32 33 34 35 34 35 35 36 37 37 38 39 39 30 31 32 34 34 34 35 35 36 37 37 38 39 39 30 31 32 34 34 34 35 <l< td=""><td>36</td><td>The redicterist of culd then interret the line MD converses blinded to DCF</td></l<>	36	The redicterist of culd then interret the line MD converses blinded to DCF		
 3. Up to 4 suspicious areas (score 2 3 out of 5 on the Likert of PI-RADS V2.1 scoring system) can be marked on Report 1 – if there are more, the four most suspicious should only be marked on 4. The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram 5. Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE Report 2 (multiparametric MRI: T2W, DWI and DCE) 1. The same radiologist must report both Report 1 and Report 2 2. They will then be unblinded to the DCE sequence 3. The radiologist should now complete Report 2 4. The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above 5. On Report 2, each of the existing lesions are additionally labelled as one of: 54 55 bpMRI positive, mpMRI positive This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on <i>either</i> Likert or PI-RADS v2.1 scoring systems 	37	2. The radiologist should then interpret the bplviki sequences blinded to DCE		
 39 Can be marked on Report 1 – If there are more, the four most suspicious should only be marked on 40 41 4. The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-sector diagram 43 5. Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE 46 47 48 48 49 49 40 40 41 42 44 45 46 47 48 49 49 40 40 40 41 41 42 44 45 45 46 47 48 49 40 40 49 40 40 40 40 41 41 42 44 45 45 46 47 48 49 40 40 40 40 40 41 41 42 44 45 46 47 48 49 40 40 40 40 41 44 45 46 47 48 49 40 40 40 41 40 41 41 42 44 44 45 46 47 48 49 49 40 40 40 41 41 41 42 44 45 46 47 47 48 48 49 49 40 40 40 40 41 40 40 40 40 40 40 41 41 41 42 44 45 45 46 46 47 47 48 49 40 <li< td=""><td>38</td><td>3. Up to 4 suspicious areas (score 2 3 out of 5 on the Likert or PI-RADS v2.1 scoring system)</td></li<>	38	3. Up to 4 suspicious areas (score 2 3 out of 5 on the Likert or PI-RADS v2.1 scoring system)		
 40 marked on 41 4. The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41- sector diagram 43 5. Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE 44 after looking at the DCE 45 46 Report 2 (multiparametric MRI: T2W, DWI and DCE) 47 1. The same radiologist must report both Report 1 and Report 2 48 2. They will then be unblinded to the DCE sequence 49 3. The radiologist should now complete Report 2 40 4. The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above 50 5. On Report 2, each of the existing lesions are additionally labelled as one of: 51 5. DpMRI positive, mpMRI positive 56 This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on <i>either</i> Likert or PI- RADS v2.1 scoring systems. 	39	can be marked on Report 1 – If there are more, the four most suspicious should only be		
 4. The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41- sector diagram 5. Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered after looking at the DCE Report 2 (multiparametric MRI: T2W, DWI and DCE) 1. The same radiologist must report both Report 1 and Report 2 2. They will then be unblinded to the DCE sequence 3. The radiologist should now complete Report 2 4. The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above 5. On Report 2, each of the existing lesions are additionally labelled as one of: 55 bpMRI positive, mpMRI positive This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on either Likert or PI- RADS v2.1 scoring systems 	40	marked on		
 42 Sector diagram 43 5. Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered 44 after looking at the DCE 46 Report 2 (multiparametric MRI: T2W, DWI and DCE) 47 1. The same radiologist must report both Report 1 and Report 2 48 2. They will then be unblinded to the DCE sequence 49 3. The radiologist should now complete Report 2 4. The location of the suspicious areas should be similarly labelled according to the PI-RADS 45 v2.1 41-sector diagram as above 53 5. On Report 2, each of the existing lesions are additionally labelled as one of: 54 55 bpMRI positive, mpMRI positive 56 This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on <i>either</i> Likert or PI- 84 8 	41	4. The location of the suspicious areas should be labelled according to the PI-RADS v2.1 41-		
 5. Once Report 1 (biparametric MRI: 12W and DWI) has been done, this cannot be altered after looking at the DCE Report 2 (multiparametric MRI: T2W, DWI and DCE) The same radiologist must report both Report 1 and Report 2 They will then be unblinded to the DCE sequence The radiologist should now complete Report 2 The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above On Report 2, each of the existing lesions are additionally labelled as one of: bpMRI positive, mpMRI positive This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on either Likert or PI-RADS v2.1 scoring systems 	42	sector diagram		
44after looking at the DCE454647471. The same radiologist must report both Report 1 and Report 2482. They will then be unblinded to the DCE sequence503. The radiologist should now complete Report 2514. The location of the suspicious areas should be similarly labelled according to the PI-RADS5253535455 bpMRI positive, mpMRI positive 56578ADS v2.1 scoring systems	43	5. Once Report 1 (biparametric MRI: T2W and DWI) has been done, this cannot be altered		
 Report 2 (multiparametric MRI: T2W, DWI and DCE) The same radiologist must report both Report 1 and Report 2 They will then be unblinded to the DCE sequence The radiologist should now complete Report 2 The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above On Report 2, each of the existing lesions are additionally labelled as one of: bpMRI positive, mpMRI positive This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on <i>either</i> Likert or PI-RADS v2.1 scoring systems 	44 45	after looking at the DCE		
 Report 2 (multiparametric MRI: T2W, DWI and DCE) 1. The same radiologist must report both Report 1 and Report 2 2. They will then be unblinded to the DCE sequence 3. The radiologist should now complete Report 2 4. The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above 5. On Report 2, each of the existing lesions are additionally labelled as one of: 54 55 bpMRI positive, mpMRI positive 56 This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on <i>either</i> Likert or PI-RADS v2.1 scoring systems 	45 46			
 The same radiologist must report both Report 1 and Report 2 They will then be unblinded to the DCE sequence The radiologist should now complete Report 2 The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above On Report 2, each of the existing lesions are additionally labelled as one of: 50 51 54 55 56 57 bpMRI positive, mpMRI positive 57 This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on either Likert or PI-RADS v2.1 scoring systems 	47	Report 2 (multiparametric MRI: T2W, DWI and DCE)		
 They will then be unblinded to the DCE sequence The radiologist should now complete Report 2 The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above On Report 2, each of the existing lesions are additionally labelled as one of: Dom Report 2, each of the existing lesions are additionally labelled as one of: Dom Report 2, each of the existing lesions are additionally labelled as one of: Dom Report 2, each of the existing lesions are additionally labelled as one of: Dom Report 2, each of the existing lesions are additionally labelled as one of: Dom Report 2, each of the existing lesions are additionally labelled as one of: Dom Report 2, each of the existing lesions are additionally labelled as one of: Dom Report 2, each of the existing lesions are additionally labelled as one of: Dom Report 2, each of the existing lesions are additionally labelled as one of: Dom Report 2, each of the existing lesions are additionally labelled as one of: Dom Report 2, each of the existing lesions are additionally labelled as one of: Dom Report 2, each of the existing lesions are additionally labelled as one of: Dom Report 2, each of the existing lesions are additionally labelled as one of: Dom Report 2, each of the existing lesions are additionally labelled as one of: 	48	1. The same radiologist must report both Report 1 and Report 2		
 3. The radiologist should now complete Report 2 4. The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above 5. On Report 2, each of the existing lesions are additionally labelled as one of: 5. bpMRI positive, mpMRI positive 56 This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on <i>either</i> Likert or PI-RADS v2.1 scoring systems 	49	2. They will then be unblinded to the DCE sequence		
 4. The location of the suspicious areas should be similarly labelled according to the PI-RADS v2.1 41-sector diagram as above 5. On Report 2, each of the existing lesions are additionally labelled as one of: 5. bpMRI positive, mpMRI positive 56 This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on <i>either</i> Likert or PI- BADS v2.1 scoring systems 	50	3. The radiologist should now complete Report 2		
 v2.1 41-sector diagram as above On Report 2, each of the existing lesions are additionally labelled as one of: bpMRI positive, mpMRI positive This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on <i>either</i> Likert or PI- BADS v2.1 scoring systems 	51	4. The location of the suspicious areas should be similarly labelled according to the PI-RADS		
 53 5. On Report 2, each of the existing lesions are additionally labelled as one of: 54 55 bpMRI positive, mpMRI positive 56 This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on <i>either</i> Likert or PI- 57 BADS v2.1 scoring systems 	52	v2.1 41-sector diagram as above		
 54 55 bpMRI positive, mpMRI positive 56 This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on <i>either</i> Likert or PI- 57 BADS v2.1 scoring systems 	53	5. On Report 2, each of the existing lesions are additionally labelled as one of:		
 bpMRI positive, mpMRI positive This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on <i>either</i> Likert or PI- RADS v2.1 scoring systems 	54			
This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on <i>either</i> Likert or PI- RADS v2.1 scoring systems	55 56	bpMRI positive, mpMRI positive		
BADS v2.1 scoring systems	00 57	This occurs when a lesion scores 3, 4 or 5 on both bpMRI and mpMRI based on <i>either</i> Likert or PI-		
58	58	RADS v2.1 scoring systems		
59	59			
60 bpMRI positive, mpMRI negative	60	bpMRI positive, mpMRI negative		

This c but a	occurs when a lesion scores 3, 4 or 5 on bpMRI on <i>either</i> Likert or PI-RADS v2.1 scoring systems, Iso scores a 1 or 2 on mpMRI on both Likert and PI-RADS v2.1 scoring systems	
bpMRI negative, mpMRI positive		
	There are two instances in which new targets may be labelled and drawn onto Report 2:	
1	. New lesions scoring 3, 4 or 5, identified by DCE not previously identified on bpMRI should be marked on as new lesions as DCE Targets and bpMRI negative, mpMRI positive	
2	 Lesions that appear larger on DCE should be treated as 2 separate targets One target depicts the completely overlapping segment from Report 1 (bpMRI positive, mpMRI positive) The non-overlapping part which would otherwise not be sampled should be labelled as a new target (bpMRI negative, mpMRI positive). This is a subjective decision by the radiologist. A typical example of when to declare this as a separate target is if the non-overlapping part enters an adjacent sector on the PI-RADS v2.1 sector diagram 	
	A bionsy plan is recommended by the radiologist thereafter for the bionsy operator to	
follow	A biopsy plan is recommended by the radiologist thereafter for the biopsy operator to	
Men w which lesion, separa	rill undergo MRI-targeted biopsy if either their bpMRI or mpMRI identifies a suspicious lesion scores ≥3 on either Likert or PI-RADS v2.1. Four targeted cores will be taken per suspicious and these should be stored and labelled in separate containers to ensure cancer detection from te suspicious areas are ascertained.	
System	natic Bionsy	
System contra are bili	natic biopsies should be performed after targeted biopsies, with 6 cores taken from the lateral side of the MRI lesion, focused on sampling the peripheral zone of the prostate. If there ateral MRI lesions or midline lesions, then no systematic biopsies are necessary.	
Please		
	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted.	
Prosta	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted.	
Both tl	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i>	
cucii li	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> ne Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for ndividual target lesion.	
Pre-Tri	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> he Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for idividual target lesion.	
Pre-Tri For all	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> he Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for idividual target lesion. <i>al Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal	
Pre-Tri For all digital	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> he Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for individual target lesion. <i>al Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal rectal examination). To confirm a patient's eligibility, screening will be undertaken. Patients can	
Pre-Tri For all digital enter t	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> he Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for ndividual target lesion. <i>al Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal rectal examination). To confirm a patient's eligibility, screening will be undertaken. Patients can he trial either before or after they have had their mpMRI scan. If patients are recruited after an	
Pre-Tri For all digital enter t mpMR	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> he Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for ndividual target lesion. <i>al Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal rectal examination). To confirm a patient's eligibility, screening will be undertaken. Patients can he trial either before or after they have had their mpMRI scan. If patients are recruited after an I scan has been carried out, this will only be permitted if the MRI has not been seen by any	
Pre-Tri For all digital enter t mpMR clinicia	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> he Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for ndividual target lesion. <i>al Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal rectal examination). To confirm a patient's eligibility, screening will be undertaken. Patients can he trial either before or after they have had their mpMRI scan. If patients are recruited after an I scan has been carried out, this will only be permitted if the MRI has not been seen by any n.	
Pre-Tri For all digital enter t mpMR clinicia	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> he Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for ndividual target lesion. <i>Cal Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal rectal examination). To confirm a patient's eligibility, screening will be undertaken. Patients can he trial either before or after they have had their mpMRI scan. If patients are recruited after an I scan has been carried out, this will only be permitted if the MRI has not been seen by any n.	
Pre-Tri For all digital enter t mpMR clinicia Registri Follow	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> he Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for ndividual target lesion. <i>Cal Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal rectal examination). To confirm a patient's eligibility, screening will be undertaken. Patients can he trial either before or after they have had their mpMRI scan. If patients are recruited after an I scan has been carried out, this will only be permitted if the MRI has not been seen by any n. <i>ration Procedures</i> ing consent and confirmation of eligibility, trial processes can commence. The patient will be	
Pre-Tri For all digital enter t mpMR clinicia Registi Follow registe	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> the Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for individual target lesion. <i>Tal Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal rectal examination). To confirm a patient's eligibility, screening will be undertaken. Patients can the trial either before or after they have had their mpMRI scan. If patients are recruited after an I scan has been carried out, this will only be permitted if the MRI has not been seen by any n. <i>ration Procedures</i> ing consent and confirmation of eligibility, trial processes can commence. The patient will be red and assigned a trial ID using a central online database (Marvin by XClinical)	
Pre-Tri For all digital enter t mpMR clinicia Registri Follow registe	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> the Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for individual target lesion. <i>Cal Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal rectal examination). To confirm a patient's eligibility, screening will be undertaken. Patients can the trial either before or after they have had their mpMRI scan. If patients are recruited after an I scan has been carried out, this will only be permitted if the MRI has not been seen by any n. <i>ration Procedures</i> ing consent and confirmation of eligibility, trial processes can commence. The patient will be red and assigned a trial ID using a central online database (Marvin by XClinical).	
Pre-Tri For all digital enter t mpMR clinicia Registri Follow registe	see Supplementary Appendix 2 for a detailed overview of how our biopsies will be conducted. <i>te Histopathology</i> the Gleason score and the Gleason Grade Group will be reported for the overall biopsy and for individual target lesion. <i>Cal Assessments</i> patients, patient referral would follow clinical suspicion of PCa (<i>e.g.</i> raised PSA or abnormal rectal examination). To confirm a patient's eligibility, screening will be undertaken. Patients can the trial either before or after they have had their mpMRI scan. If patients are recruited after an I scan has been carried out, this will only be permitted if the MRI has not been seen by any n. <i>ration Procedures</i> ing consent and confirmation of eligibility, trial processes can commence. The patient will be red and assigned a trial ID using a central online database (Marvin by XClinical). <i>ration Procedures</i>	

All patients will undergo a full mpMRI scan. This includes T2W, DWI and DCE sequences. Follow-Up for Results If bpMRI and mpMRI is non-suspicious and PSA density is <0.15 ng/mL/mL, the patient will be counselled for standard of care follow-up – typically consisting of PSA surveillance. If a decision for prostate biopsy or other tests is made, these results will be recorded after which the participant completes the trial. Multidisciplinary Team Decision-Making for Treatment Eligibility Treatment decisions will be per local standard of care, based on pathology results and will be recorded. Subsequently, a virtual multidisciplinary team meeting will be conducted and treatment eligibility decisions blinded to the DCE will be recorded. Once a decision has been recorded, the clinicians will be unblinded to the DCE sequence and the impact that this information makes on treatment eligibility will be evaluated. MRI and Pathology Quality Control Quality control will be carried out at the end of the study by the PRIME chief radiologists reviewing the original MRIs, who will assess the MRI quality and re-report the MRI blinded to the study reports. Anonymised pathology slides from a proportion of patients may also be reviewed by central pathologists. Any slides assessed outside of the originating site will be returned to the original site after quality control. Quality control results will be reported but will not influence patient management or outcomes. Cost-Effectiveness A within-trial incremental cost-effectiveness analysis will be conducted to calculate the difference in mean cost per diagnosis of clinically significant prostate cancer if a strategy of bpMRI were adopted instead of the current mpMRI standard of care, over a time horizon of 30 days. The difference in cost of avoiding each additional case of clinically insignificant prostate cancer diagnosed may also be calculated. Costs of procedures will be estimated by applying standard unit costs to resource use data captured within the trial plus other procedures that would be offered to patients in either pathway. Estimates of the resources used (procedures, tests, radiotherapy, chemotherapy, other therapies, surveillance visits, and other care events) on the two treatment pathways will be obtained for the theoretical bpMRI cohort using decisions made initially by the MDT with information from the bpMRI scan and any biopsies as a result of that scan; and estimates of the treatment pathway resources used in the theoretical mpMRI cohort will be made subsequently by the MDT on viewing additional information from the mpMRI scan and any further biopsies performed as a result of that scan. This thought experiment is required due to the ethical requirement to use all available information, i.e. not just bpMRI and biopsies or just mpMRI and biopsies, when making the actual treatment decision with the patient. The analysis perspective will be that of the NHS and personal social services. Standard unit costs (e.q. NHS Reference Costs) will be supplemented by unit cost data from the participating trial sites. A microcosting study to provide this information will be undertaken in a small number of sites as part of the trial to investigate the resources employed to deliver bpMRI and mpMRI scans. This information will allow us to understand the MRI booking system, consumption of consumables, and staff time as related to delivering bpMRI and mpMRI scans. Depending on the within-trial cost-effectiveness findings, consideration will be given to extending this analysis using decision analytic modelling to estimate quality-adjusted life-years gained (QALYs) over BMJ Open

2		
3	322	a lifetime horizon. Quality of life information will be estimated from anonymised patient-level data by
4	323	the same group from an earlier study in this instance.
5	324	
0 7	325	Outcomes
/ 8	326	Primary Outcome
9	327	The primary outcome will be the proportion of men with clinically significant PCa detected – any
10	328	nattern 4 disease on any core (<i>i.e.</i> Gleason $>3+4$ or Gleason Grade Group >2). The time frame for
11	320	assessment: when bionsy results are available, at an expected average of 30 days nost-bionsy
12	220	assessment. when biopsy results are available, at an expected average of 50 days post biopsy.
13	330	Secondary Outcomes
14	222	Table 1 lists our secondary outcomes
15	332 333	Table I lists our secondary outcomes.
16	333	
17	334	sample size
18	335	The margin of clinical unimportance to allow a conclusion of non-inferiority of bpMRI to mpMRI to be
19	336	made was set at 5 percentage points – i.e. if the lower bound of the 95% confidence intervals (CIs) for
20	337	the difference in detection rates of bpMRI-targeted biopsy compared to mpMRI-targeted biopsy is
21	338	above -5 percentage points, then bpMRI will be deemed as non-inferior.
22	339	Using simulation, an mpMRI underlying probability of detecting clinically significant cancer of 38% (3)
23	340	and the following, two key probabilities were used to determine the sample size:
25	341	
26	342	A. The probability that a patient found to have no suspicious lesions on bpMRI or have no
27	343	clinically significant PCa on bpMRI-targeted biopsy will have clinically significant PCa on mpMRI-
28	344	targeted biopsy
29	345	B. The probability that a patient found to have no suspicious lesions on mpMRI or have no
30	346	clinically significant PCa on mpMRI-targeted biopsy will have clinically significant PCa on bpMRI-
31	347	targeted biopsy
32	348	
33	349	Assuming the probability of A is greater than the probability of B, and applying McNemar's test in each
34	350	of 1.000 simulation runs for each combination of probabilities A and B ranging from 0 to 0.05, a sample
30	351	size of 400 patients gives more than 90% power across these probabilities of A and B. Accounting for
30	352	20% dropout or exclusion after enrolment, at least 500 patients will be required
38	353	
39	354	Recruitment
40	355	At each narticinating site enrolment will occur at outnatient clinics. With at least 25 sites, it is
41	256	estimated that the trial will complete within 24 months of commencement. The trial opened for
42	250	recruitment in April 2022 and the estimated completion date is April 2024
43	220	recruitment in April 2022 and the estimated completion date is April 2024.
44	220	Data Collection Mathada
45	202	The electronic case report form (aCDE) system Marvin by VClinical will be used to callect data
46	300	The electronic case report form (eCRF) system Marvin by Aclinical will be used to collect data.
4/	361	
48	362	Patient-Reported Outcome Measures
49 50	363	The International Index of Erectile Function (IIEF-5) and the International Prostate Symptom Score
51	364	(IPSS) will be utilised to assess baseline erectile function and lower urinary tract symptoms,
52	365	respectively. These questionnaires will aid the multidisciplinary team decision-making for treatment
53	366	eligibility.
54	367	
55	368	Patient Retention
56	369	It is estimated that loss to follow-up will be no more than 20% due to the expected short time interval
57	370	between enrolment and end of study. It is expected that the majority of patients will complete the
58	371	trial within 4 to 6 weeks (Table 2A, Table 2B).
59	372	
60		

3 373 Statistical Methods

A statistical analysis plan will be finalised before our database lock and before any statistical analysis occurs. A consort diagram will be presented. All continuous variables will be described using the mean and standard deviation, or median and interquartile range, as appropriate. Categorical variables will be described using frequencies and percentages. Baseline characteristics will be examined and presented for those with and those without clinically significant PCa. The assumptions underpinning the statistical methods used will be assessed. The use of transformations will be considered to satisfy statistical assumptions.

12 381

13
14382Primary Outcome Analysis

The primary outcome is the difference in the proportion of men with clinically significant PCa, as detected by bpMRI-targeted biopsy compared to mpMRI-targeted biopsy. The proportion of men with clinically significant PCa, Gleason \geq 3+4 or Gleason Grade Group \geq 2, detected by bpMRI-targeted biopsy is defined as the number of men with clinically significant PCa identified on bpMRI-targeted biopsy divided by the number of men undergoing bpMRI. Similarly, the proportion of men with clinically significant PCa detected by mpMRI-targeted biopsy is defined as the number of men with clinically significant PCa identified on mpMRI-targeted biopsy divided by the number of men undergoing mpMRI. Methods that account for the paired nature of the data such as McNemar's test will be used to compare bpMRI and mpMRI.

25 392 26 393 Secondary Outcome Analysis

The proportion of men with clinically insignificant cancer (any cancer core with Gleason 3+3 or Gleason grade group 1 detected by bpMRI-targeted biopsy will be compared to that of mpMRI-targeted biopsy. The proportion of men with clinically insignificant cancer detected by bpMRI-targeted biopsy is defined as the number of men with clinically insignificant prostate cancer identified on bpMRI-targeted biopsy divided by the number of men undergoing bpMRI. Similarly, the proportion of men with clinically insignificant cancer detected by mpMRI-targeted biopsy is defined as the number of men with clinically insignificant prostate cancer identified on mpMRI-targeted biopsy divided by the number of men undergoing mpMRI. The same analytical approach described for clinically significant PCa will be applied.

The number and proportion of men scoring 1 or 2 (non-suspicious) or 3 (indeterminate) on bpMRI and
 mpMRI will be reported. A two-way table will be produced to show the agreement between the two
 MRI results using the Likert scoring system on a scale of 1-5.

407
 42
 408 The number and proportion of men with adequate standard of reporting on bpMRI and mpMRI will
 43
 409 be reported.

A two-way table will be produced to show the number and proportion of patients with each radiological stage of bpMRI and mpMRI. Similarly, we will report the number and proportion of patients eligible for different treatment options following discussion of the bpMRI and mpMRI results in the Multidisciplinary Team meeting.

- Using histopathology as the reference standard, sensitivity, specificity, positive predictive value and negative predictive value with 95% CI of bpMRI and mpMRI will be reported. The following assumptions will be made, where non-suspicious MRI refers to a score of 1 or 2 and suspicious MRI refers to a score of 3, 4 or 5 on the Likert and PI-RADS v2.1 scoring systems and absence of clinically significant cancer refers to a combination of clinical insignificant and no cancer.
- The number and proportion of men with clinically significant cancer detected by systematic biopsy
 and not detected by bpMRI and mpMRI with targeted biopsy will be reported. A two-way table will be

BMJ Open

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

produced to show a comparison between systematic biopsy (no biopsy, clinically significant cancer, clinically insignificant cancer and no cancer) and the two MRI results with targeted biopsy (no biopsy, clinically significant cancer, clinically insignificant cancer and no cancer). Sensitivity and Other Planned Analyses The primary outcome analysis will be repeated with a definition of clinically significant PCa being any primary pattern 4 disease - Gleason 4+3 or Gleason Grade Group 3. Monitoring The NCITA Global Prostate Trial Steering Committee (TSC) is responsible for the governance of the PRIME Study. A sub-group of independent TSC members form the Data Monitoring Sub-Committee (DMSC). Roles and responsibilities of the TSC To act as the oversight body for up to five prostate cancer studies on behalf of the Sponsor and Funders. In addition, the independent members will form a DMSC to review safety. The role of the TSC is to provide oversight for the studies and provide advice through its Chair to the Chief Investigators (CI), whilst working in tandem with the DMSC, Sponsor, Funders and host institution on all aspects of the studies. The rights, safety and well-being of the study participants are the most important consideration and should prevail over the interests of science and society. Harms Adverse events (AEs) will be defined as 'any untoward medical occurrence in a clinical trial subject undergoing any intervention in the trial, which does not necessarily have a causal relationship with this treatment'. Serious adverse events (SAEs) will be defined as 'any untoward medical occurrence as a result of any intervention in the trial that: Results in death, • Is life-threatening Requires hospitalisation or prolongation of existing inpatients' hospitalisation, results in • persistent or significant disability or incapacity' AEs and SAEs will be recorded until 30 days post biopsy. In the event that the patient does not undergo biopsy, AEs and SAEs should be recorded until 30 days post-MRI. Unexpected AEs will be recorded by a member of the research team or clinical team on an AE report form eCRF. All SAEs must be recorded on an SAE report form eCRF which must be sent to the coordinating trials unit within 24 hours of knowledge of the SAE. Both AEs and SAEs should be recorded in the medical notes. Ethics and Approval The UK National REC (West Midlands – Black Country Research Ethics Committee, Nottingham) gave favourable approval for PRIME protocol version 2.0 on 28 June 2021 (Ref:21/WM/0091). All participating centres have gained local and ethical approvals prior to receiving a site initiation visit and approval by the sponsor to open for recruitment. Patient and Public Involvement Patients and public members were involved in defining the research question, evaluation of the research proposal, suggesting modifications to the trial, reviewing the patient information sheet,

es.

3 4	475 476	consent form and GP letter. Patient groups and charities will also be involved in the dissemination of results
5	470	
б	477	Concent
7	470	The clinical teams managing nations, with suspected DCa who are referred to their centre will identify
8	479	The children teams managing patients with suspected PCa who are referred to their centre will dentify
9	480	potential trial participants. Patient information sneets will be provided to patients. Members of staff
10	481	who are trained to take informed consent, as indicated by the PI on the delegation log for that site,
11	482	will take informed consent. A model patient information sheet is shown in Supplementary Appendix
12	483	3.
13	484	
14	485	Confidentiality
16	486	The data of the participants will be recorded into the eCRF system and analysed without any personal
17	487	identifiers, by pseudoanonymised coded information. A site's source documents and identification
18	488	lists will be archived in a secured facility at that centre.
19	489	
20	490	Dissemination
21	/91	Results of this trial will be disseminated through national and international conferences and naners
22	402	Authorship criteria will be based on recommendations of the International Committee of Medical
23	492	Authorship chieffa will be based on recommendations of the international committee of Medical
24	493	journal Editors. The participants and relevant patient support groups will be informed about the
25	494	results of the trial.
26	495	
27	496	Access to Data
28	497	Only authorised individuals within the PRIME Clinical Operations Group have access to the final data
29	498	set. Individual PIs have access to their own data but not that of other sites.
30	499	
31	500	WHO Trial Registration Dataset
32	501	Please see Table 3 for the WHO trial registration dataset.
33	502	
34 25	503	Current Protocol Version
30	504	The current protocol is V.2.0, issued 27 April 2021. The current protocol amendment number is 01.
37	505	For full amendment history, please see Table 4 .
38	506	
39	507	Roles and Responsibilities
40	502	Please see Table 5 for roles and responsibilities of the trial sponsor and involved committees
41	500	Please see Table 5 for foles and responsibilities of the trial sponsor and involved committees.
42	509	
43	510	Acknowledgements
44	511	We would like to thank our patients and funders, without whom we wouldn't be able to carry out this
45	512	important study: Prostate Cancer UK & The John Black Charitable Trust, European Association of
46	513	Urology Research Foundation and the Dieckmann Foundation. We thank all the international centres
47	514	taking part in PRIME. We are grateful to EAU Research Foundation and the XClinical team for their
48	515	support with the MARVIN database; and Sydney Lindner, Steven Lelie, Jessica Sternisa, Tyler Edwards,
49	516	Adam Kulp, Jon Piper from the MIM Software Inc team. We are thankful for the trial oversight provided
50	517	by our sponsor, University College London and the National Cancer Imaging Translational Accelerator
51	518	trials unit.
52	519	
53	520	Author Contributions
54 55	521	Study concept and design: ANg. AA. AN. VC. PK. FG. CA. AF. SP. PL. CSC. CBG. NM. MF. RA. YT. ID. CMM
55 56	522	VK Drafting of manuscript: AA AN CSC CBG RA VT VK Critical revision of the manuscript for
57	522	important intellectual content: all authors Supervision: CA. VK. All authors read and approved the
58	525	final manuscrint
59	524	ווומו וומוועסטוףנ.
60	525	

Funding

The PRIME is primarily funded by Prostate Cancer UK (grant number: TLD-PF19-004) and The John Black Charitable Trust Travelling Prize Grant (grant number: TLD-PF19-004). The EAU Research Foundation (EAU RF) and The Dieckmann Foundation also supported costs for international sites.

Declaration of Interests

AN is an academic clinical fellow funded by the National Institute for Health and Care Research. PK is an academic clinical fellow funded by the National Institute for Health and Care Research and The Urology Foundation. FG is a recipient of the 2020 Young Investigator Award (20YOUN15) funded by the Prostate Cancer Foundation / CRIS Cancer Foundation. SP is supported by the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. ME receives research support from the National Institute of Health and Care Research (NIHR), UCLH and UCL Biomedical Research Centre. YT is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. CMM is an NIHR Research Professor, and receives grants from MRC, CRUK, Movember, and Prostate Cancer UK. VK is funded by Prostate Cancer UK and The John Black Charitable Foundation. He receives speaker fees from the European Association of Urology, Singapore Urology Association, The Clinical Comms Group and Got IT consulting SL. All authors declare that there are no conflicts of interest. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care.

REFERENCES

- 1. A-W. Chan, JM. Tetzlaff, PC. Gøtzsche, et al. SPIRIT 2013 explanation and elaboration: Guidance for protocols of clinical trials. BMJ, 346 (2013), e7586, 10.1136/bmj.e7586.
- 2. N. Mottet, P. Cornford, R. Van Den Bergh, et al. EAU guidelines: prostate cancer. European Association of Urology, Arnhem, The Netherlands (2021). https://uroweb.org/guideline/prostate-cancer/
- 3. V. Kasivisvanathan, A.S. Rannikko, M. Borghi, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med, (2018),pp. 1767-1777, 10.1056/NEJMoa1801993.
- Cancer 4. National Prostate Audit Report -Annual 2019. https://www.npca.org.uk/reports/npca-annual-report-2019/
 - 5. S. Verma, B. Turkbey, N. Muradyan, A. Rajesh, et al. Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol, 198 (2012), pp. 1277-1288. 10.2214/AJR.12.8510
 - 6. R. Berman, A. Brown, S. Chang, et al. DCE MRI of prostate cancer. Abdom Radiol (NY), 41 (2016), pp. 844-853. 10.1007/s00261-015-0589-3
- 7. M. Engelbrecht, H. Huisman, R. Laheij, et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology. 229 (2003), pp. 248-254. 10.1148/radiol.2291020200
- 8. M. van der Leest, E. Cornel, B. Israël, et al. Head-to-head comparison of transrectal ultrasoundguided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naïve men with elevated prostate-specific antigen: a large prospective multicenter clinical study. Eur Urol, 75 (2019), pp. 570-578, 10.1016/j.eururo.2018.11.023
 - 9. T. Fraum, D. Ludwig, M. Bashir, et al. Gadolinium-based contrast agents: A comprehensive risk assessment. J Magn Reson Imaging, 46 (2017), pp. 338-353, 10.1002/jmri.25625.
- 10. M. Ramalho, J. Ramalho, L. Burke, et al. Gadolinium Retention and Toxicity-An Update. Adv Chronic Kidney Dis. 24 (2017), pp. 138-146. 10.1053/j.ackd.2017.03.004.
- 11. L. Boesen, N. Nørgaard, V. Løgager, et al. Assessment of the diagnostic accuracy of biparametric magnetic resonance imaging for prostate cancer in biopsy-naive men: the

2					
3	577	Biparametric MRI for Detection of Prostate Can	cer (BIDOC) study. JAMA Netw Open, 1 (2018),		
4	578	p. e180219, 10.1001/jamanetworkopen.2018.0219			
5	579	12. Z. Kang, X. Min, J. Weinreb, Q. Li, Z. Feng, L. Wang. Abbreviated biparametric versus standard			
7	580	multiparametric MRI for diagnosis of prostate cancer: a systematic review and meta-analysis.			
, 8	581	Am J Roengenol, 212 (2018), pp. 357-365, 10.2214/ajr.18.20103			
9	582	13. M. Alabousi, J.P. Salameh, K. Gusenbauer, et al. Biparametric vs multiparametric prostate			
10	583	magnetic resonance imaging for the detection o	f prostate cancer in treatment-naïve patients:		
11	584	a diagnostic test accuracy systematic review an	d meta-analysis. <i>BJU Int</i> , 124 (2019), pp. 209-		
12	585	220, 10.1111/bju.14759			
13	586	14. A. Ng, P. Khetrapal, V. Kasivisvanathan. Is It PRIN	AE Time for Biparametric Magnetic Resonance		
14	587	Imaging in Prostate Cancer Diagnosis? Eu	r Urol, S0302-2838 (2022), pp. 01663-3,		
15 16	588	10.1016/j.eururo.2022.02.021.			
10	589	15. F. Giganti, C. Allen, M. Emberton, C.M. Moore,	V. Kasivisvanathan. Prostate Imaging Quality		
18	590	(PI-QUAL): a new quality control scoring syste	em for multiparametric magnetic resonance		
19	591	imaging of the prostate from the PRECISION	trial. Eur Urol Oncol, 3 (2020), pp. 615-619,		
20	592	10.1016/j.euo.2020.06.007.			
21	593	16. J.C. Weinreb, J.O. Barentsz, P.L. Choyke, et al. P	I-RADS Prostate Imaging - Reporting and Data		
22	594	System: 2015, Version 2. Eur Urol, 69 (2016), pp	o. 16-40, 10.1016/j.eururo.2015.08.052.		
23	595				
24	596	FIGURE LEGENDS			
25 26	597				
20	598	Figure 1 The PRIME trial schema – the approach prior to	o MRI.		
28	599	(bpMRI = biparametric MRI, DCE = dynamic contrast enhance	d sequence, DRE = digital rectal examination, DWI		
29	600	= diffusion-weighted sequence, mpMRI = multiparametric I	MRI, PSA = prostate specific antigen, T2W = T2-		
30	601	weighted sequence.)			
31	602				
32	603	TABLES			
33	604				
34 35		Table 1 Secondary outcomes in PRIME			
36		Outcome	Time frame for assessment		
37		Proportion of men with clinically insignificant cancer	When biopsy results available, at an expected		
38		(Gleason grade 3+3 / Gleason grade group 1)	average of 30 days post-biopsy		
39		Agreement between bpMRI and mpMRI for score of	When MRI results available, at an expected		
40		suspicion	average of 30 days post-MRI		
41		Proportion of bp-MRI scans and mpMRI whose quality	When MRI results available, at an expected		
42		was deemed adequate for reporting	average of 30 days post-MRI		
45 44					
45					
46		Agreement between bpMRI and mpMRI for	When MRI results available, at an expected		
47		radiological staging decision	average of 30 days post-MRI		
48		Agreement between bpMRI and mpMRI for	When treatment eligibility is discussed in a		
49		treatment eligibility	multidisciplinary meeting, at an expected		
50			average of 30 days post biopsy.		
51		Test performance characteristics for bpMRI and	When biopsy results available, at an expected		
52 52		mpMRI when using the Likert scoring system in	average of 30 days post-MRI		
53 54		comparison to the PI-RADS scoring system			
55		Proportion of men with clinically significant cancer	When biopsy results available, at an expected		
56		missed by bpMRI and mpMRI-targeted biopsies and	average of 30 days post-biopsy		
57		detected by systematic biopsy			
58		Cost-effectiveness of bpMRI compared to mpMRI	At an expected average of 30 days post-		
59		(cost per diagnosis of prostate cancer)	intervention		
60	605	(bpMRI = biparametric MRI; mpMRI = multiparametric MRI.)			
			1/		

BMJ Open

	Contact	Contact with patient			
	Visit 0*	Visit 1	Visit 2	Visit 3	Visit
Screening	Х	Х			
PIS given	Х	Х			
Consent	Х	Х			
IIEF-5 and IPSS questionnaires	X	X			
Multiparametric MRI			Х		
Radiologists reports bpMRI (T2W and DWI only)			Х		
Radiologists reports mpMRI (T2W, DWI and DCE)			Х		
MRI-targeted biopsy and systematic biopsy				Х	
Test results given and treatment decision					Х
Follow-up for further investigations from					Х
treatment decision					
Serious adverse event	Complet	e as requ	ired at a	ny time	follow
\sim	registrat	on			<u> </u>
Withdrawal form	Complet	e as requ	ired at a	iny time	follow
*Visit 0 is an optional teleconsult, depending on local pr	actice. Note	e: where ar	onlicable, n	nore than a	ne vici
ake place on the same day, depending on local practice day as subsequent biopsies). IEF-5 = The International Index of Erectile Function, IPSS nformation sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic conti	(e.g. in cent = Internati = multipara rast-enhand	res where onal Prosto metric MR ced sequen	an MRI is p ate Sympto I, T2W = T ce.)	performed c om Score, P 2-weighted	on the s S = pat d seque
take place on the same day, depending on local practice day as subsequent biopsies). IEF-5 = The International Index of Erectile Function, IPSS nformation sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic contr Table 20. Desticing the sequence of the triple the	(e.g. in cent = Internati = multipara rast-enhand	res where onal Prosto metric MR ced sequen	an MRI is p ate Sympto I, T2W = T ce.)	performed c om Score, P 2-weighted	on the s IS = pa d seque
Take place on the same day, depending on local practice of the same day as subsequent biopsies). IEF-5 = The International Index of Erectile Function, IPSS of the second structure of the second str	(e.g. in cent = Internati = multipara rast-enhand timeline	onal Prosta metric MR ced sequen	an MRI is p ate Sympto 1, T2W = T ce.) enrolled	erformed c om Score, P 2-weighted after un	IS = pa d seque
Take place on the same day, depending on local practice of day as subsequent biopsies). IEF-5 = The International Index of Erectile Function, IPSS Information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic contro Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care	(e.g. in cent = Internati = multipara rast-enhand timeline Contact	onal Prosta metric MR ced sequen for men with pati	an MRI is p ate Sympto 1, T2W = T ce.) enrolled ent	erformed c om Score, P 2-weighted after un	nc visit on the s IS = pa d seque
Take place on the same day, depending on local practice of day as subsequent biopsies). IEF-5 = The International Index of Erectile Function, IPSS Information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic contr Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care	(e.g. in cent = Internati = multipara rast-enhand timeline Contact Visit 0	onal Prosta metric MR ced sequen for men with pati	an MRI is p ate Sympto I, T2W = T ce.) enrolled ent Visit 2	om Score, P 2-weighted after un Visit 3	nt visit nthe s S = pa d seque ndergo Visit
Take place on the same day, depending on local practice of day as subsequent biopsies). IEF-5 = The International Index of Erectile Function, IPSS Information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic control Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening	(e.g. in cent = Internati = multipara rast-enhand timeline Contact Visit 0	onal Prosta metric MR ced sequen for men with pati Visit 1 X	an MRI is p ate Sympto 1, T2W = T ce.) enrolled ent Visit 2	erformed c om Score, P -2-weighted after un Visit 3	IS = pa d seque d seque visit
Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care	(e.g. in cent = Internati = multipara rast-enhand timeline Contact Visit 0	for men with pati X	an MRI is p ate Sympto 1, T2W = T ce.) enrolled ent Visit 2	after un	IS = pa d seque d seque d rgc
 Take place on the same day, depending on local practice of day as subsequent biopsies). IEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic control Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given Consent 	(e.g. in cent = Internati = multipara rast-enhand timeline Contact Visit 0	for men with pati X X X X	an MRI is p ate Sympto II, T2W = T ce.) enrolled ent Visit 2	after un	nt visit on the s d seque ndergo Visi t
 Take place on the same day, depending on local practice of day as subsequent biopsies). IEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic control Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given Consent IIEF-5 and IPSS questionnaires 	(e.g. in cent = Internati = multipara rast-enhand timeline Contact Visit 0	for men with pati X X X X	an MRI is p ate Sympto (1, T2W = T ce.) enrolled ent Visit 2	after un Visit 3	visit on the s on the s of sequence of seq
 Take place on the same day, depending on local practice of day as subsequent biopsies). IEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic control Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given Consent IIEF-5 and IPSS questionnaires Multiparametric MRI 	(e.g. in cent = Internati = multipara rast-enhand timeline Contact Visit 0	res where onal Prosta metric MR ced sequen for men with pati Visit 1 X X X X	an MRI is p ate Sympto (1, T2W = T ce.) enrolled ent Visit 2	after un Visit 3	Visit
 Take place on the same day, depending on local practice of day as subsequent biopsies). IEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic control Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given Consent IIEF-5 and IPSS questionnaires Multiparametric MRI Radiologists reports bpMRI (T2W and DWI only) 	(e.g. in cent = Internati = multipara rast-enhand timeline Contact Visit 0	for men with pati X X X X X	an MRI is p ate Sympto (1, T2W = T ce.) enrolled ent Visit 2	after un Visit 3	vision the solution the solutio
 Take place on the same day, depending on local practice of day as subsequent biopsies). IEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic control Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given Consent IIEF-5 and IPSS questionnaires Multiparametric MRI Radiologists reports bpMRI (T2W and DWI only) Radiologists reports mpMRI (T2W, DWI and DCE) 	(e.g. in cent = Internati = multipara rast-enhand timeline Contact Visit 0	res where onal Prosta metric MR ced sequen for men with pati Visit 1 X X X X X X	an MRI is p ate Sympto (1, T2W = T ce.) enrolled ent Visit 2	after un Visit 3	Visit
 Take place on the same day, depending on local practice of day as subsequent biopsies). IEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic control Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given Consent IIEF-5 and IPSS questionnaires Multiparametric MRI Radiologists reports bpMRI (T2W and DWI only) Radiologists reports mpMRI (T2W, DWI and DCE) MRI-targeted biopsy and systematic biopsy 	(e.g. in cent = Internati = multipara rast-enhand timeline Contact Visit 0	res where onal Proster metric MR ced sequen for men with pati Visit 1 X X X X X X	an MRI is p ate Sympto (1, T2W = T ce.) enrolled ent Visit 2	after un Visit 3	Visit
 Take place on the same day, depending on local practice of day as subsequent biopsies). IEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic control Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given Consent IIEF-5 and IPSS questionnaires Multiparametric MRI Radiologists reports bpMRI (T2W and DWI only) Radiologists reports mpMRI (T2W, DWI and DCE) MRI-targeted biopsy and systematic biopsy Test results given and treatment decision 	(e.g. in cent = Internation = multipara rast-enhance timeline Contact Visit 0 X	for men with pati X X X X X X X	an MRI is p ate Sympto (1, T2W = T ce.) enrolled fent Visit 2	or Score, P T2-weighted after un Visit 3	Visit
 Take place on the same day, depending on local practice of day as subsequent biopsies). IEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic control Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given Consent IIEF-5 and IPSS questionnaires Multiparametric MRI Radiologists reports bpMRI (T2W and DWI only) Radiologists reports mpMRI (T2W, DWI and DCE) MRI-targeted biopsy and systematic biopsy Test results given and treatment decision Follow-up for further investigations from 	(e.g. in cent = Internation = multipara rast-enhance timeline Contact Visit 0 X	res where onal Prosto metric MR ced sequen for men with pati X X X X X X	an MRI is p ate Sympto (1, T2W = T ce.) enrolled ent Visit 2	after un Visit 3	Visit
 Take place on the same day, depending on local practice of day as subsequent biopsies). IEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic control Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given Consent IIEF-5 and IPSS questionnaires Multiparametric MRI Radiologists reports bpMRI (T2W and DWI only) Radiologists reports mpMRI (T2W, DWI and DCE) MRI-targeted biopsy and systematic biopsy Test results given and treatment decision Follow-up for further investigations from treatment decision 	(e.g. in cent = Internation = multipara rast-enhance timeline Contact Visit 0 X	res where onal Proster metric MR ced sequen for men with pati Visit 1 X X X X X X	an MRI is p ate Sympto (1, T2W = T ce.) enrolled ent Visit 2	after un Visit 3	Visit
ake place on the same day, depending on local practice is day as subsequent biopsies). IEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic contri- Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given Consent IIEF-5 and IPSS questionnaires Multiparametric MRI Radiologists reports bpMRI (T2W and DWI only) Radiologists reports mpMRI (T2W, DWI and DCE) MRI-targeted biopsy and systematic biopsy Test results given and treatment decision Follow-up for further investigations from treatment decision Serious adverse event	(e.g. in cent = Internation = multipara rast-enhance timeline Contact Visit 0 X X Comple	for men with pati Visit 1 X X X X X X te as req	an MRI is p ate Sympto (1, T2W = T ce.) enrolled ent Visit 2 X X uired at a	after un Visit 3 Visit 3	NC VISI on the s IS = pa d seque ndergo Visit
ake place on the same day, depending on local practice of day as subsequent biopsies). IEF-5 = The International Index of Erectile Function, IPSS information sheet, bpMRI = biparametric MRI, mpMRI = DWI = diffusion-weighted sequence, DCE = dynamic contri- Table 2B Participant timeline in the trial: the multiparametric MRI as part of routine care Screening PIS given Consent IIEF-5 and IPSS questionnaires Multiparametric MRI Radiologists reports bpMRI (T2W and DWI only) Radiologists reports mpMRI (T2W, DWI and DCE) MRI-targeted biopsy and systematic biopsy Test results given and treatment decision Follow-up for further investigations from treatment decision Serious adverse event	(e.g. in cent = Internation = multipara rast-enhance timeline Contact Visit 0 X X Comple registra	res where onal Prosto metric MR ced sequen for men with pati Visit 1 X X X X X X X X	an MRI is p ate Sympto (I, T2W = T ce.) enrolled ent Visit 2 X uired at a	after un Visit 3 Any time	Visit X X follow

618	DWI = diffusion-weighted sequence, DCE = dynamic contrast-enhanced sequence.)					
	I able 3 WHO trial registration dataset					
	Data category	Information				
	Primary registry and trial identifying number	ClinicalTrials.gov: NCT04571840				
	Date of registration in the primary registry Sources of	• Prostate Cancer UK				
	monetary or material support	 The John Black Charitable Foundation European Association of Urology Research Foundation The Dieckmann Foundation 				
	Primary sponsor	University College London				
	Secondary sponsor(s)	N/A				
	Contact for public queries	Mr Veeru Kasivisvanathan veeru.kasi@ucl.ac.uk Div of Surgery & Interventional Sci, University College London, 3 rd Floor, Charles Bell House, 43-45 Foley Street, London, W1W 7TS				
	Contact for scientific queries	Mr Veeru Kasivisvanathan veeru.kasi@ucl.ac.uk Div of Surgery & Interventional Sci, University College London, 3 rd Floor, Charles Bell House, 43-45 Foley Street, London, W1W 7TS				
	Public title / short title	Prostate Imaging Using MRI +/- Contrast Enhancement (PRIME)				
	Acronym	PRIME				
	Scientific title	A trial assessing whether biparametric MRI is non-inferior to multiparametric MRI in the diagnosis of clinically significant prostate cancer				
	recruitment	Australia Belgium Brazil Canada Denmark France Finland Germany				
		Italy The Netherlands Singapore Spain UK				

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2
2
2
4
5
6
7
8
9
10
10
11
12
13
14
15
16
17
10
18
19
20
21
22
23
24
ב_ד 2⊑
23
26
27
28
29
30
31
37
J∠ 22
33
34
35
36
37
38
39
10
4U
41
42
43
44
45
46
47
-17 ΛΩ
40 40
49
50
51
52
53
54
55
55
20
57
58
59
60

Health condition(s) or problem(s) studied	Prostate neoplasm
Intervention(s)	Device: MRI Diagnostic Test: Multiparametric MRI +/- prostate biopsy Diagnostic Test: Biparametric MRI +/- prostate biopsy
Intervention description	 Active comparator: Multiparametric MRI (mpMRI) MRI with T2-weighted, diffusion weighted and dynamic contrast enhanced sequences followed by prostate biopsy if indicated on MRI and clinical findings Diagnostic Test: Multiparametric MRI +/- prostate biopsy Experimental: Biparametric MRI (bpMRI) MRI with T2-weighted and diffusion weighted sequences followed by prostate biopsy if indicated on MRI and clinical findings Diagnostic Test: Biparametric MRI +/- prostate biopsy
Key inclusion and exclusion criteria	 Inclusion Criteria: Men at least 18 years of age referred with clinical suspicion of prostate cancer Serum PSA ≤ 20ng/mL Fit to undergo all procedures listed in protocol Able to provide written informed consent Exclusion Criteria: Prior prostate biopsy Prior treatment for prostate cancer Prior prostate MRI on a previous encounter Contraindication to MRI Contraindication to prostate biopsy Unfit to undergo any procedures listed in protocol
Study type	Interventional Allocation: Non-Randomized Intervention Model: Single Group Assignment Intervention Model Description: Within-person controlled, paired cohort, diagnostic evaluation study. Participants undergo two index tests and a reference test. Masking: Single (Care Provider) Masking Description: Radiologist assessing MRI for suspicion of prostate cancer is blinded to the contrast sequence when reporting the biparametric MRI. After this report, they are unblinded to the contrast sequence and report the multiparametric MRI. All biopsies conducted as a result of MRI findings will be labelled as bpMRI and mpMRI, and diagnostic accuracy will be assessed against histology findings.
Date of first enrolment	05 April 2022
Target sample size	500
Recruitment status	Recruiting
Primary outcome(s)	Proportion of men with clinically significant cancer

Key secondar outcomes	 Proportion of men with clinically insignificant cancer (Gleason grade 3+3 / Gleason grade group 1) Agreement between bpMRI and mpMRI for score of suspicion Proportion of bp-MRI scans and mpMRI whose quality was deemed adequate for reporting Agreement between bpMRI and mpMRI for radiological staging decision Agreement between bpMRI and mpMRI for treatment eligibility Test performance characteristics for bpMRI and mpMRI when using the Likert scoring system in comparison to the PI-RADS scoring system Proportion of men with clinically significant cancer missed by bpMRI and mpMRI-targeted biopsies and detected by systematic biopsy Cost-effectiveness of bpMRI compared to mpMRI (cost per diagnosis of prostate cancer)
Table 4 Revision	chronology for amendments to protocol
Protocol version to date	Reasons for amendments
V.1.0, issued 24 August 2020	Original protocol
April 2021	 clearer. Main changes: 1. Updated Section 18 Record Keeping and Archiving. Added the sentence "Identifiable data will be kept by the site for 10 years, and non-identifiable data will be kept for a minimum of 20 years." 2. Version number and date added to all pages.
Table 5 Roles and	responsibilities in the PRIME Trial
Role	Details and responsibilities
Trial sponsor	University College London (UCL) Sponsor's Edge reference: 135819 Email: Rand.D@uclh.nhs.uk The trial sponsor did not provide any funding for the study. University College London has the role of research governance sponsor of PRIME. UCL adopted the study as sponsor after the UCL CCTU carried out a trial adoption process which involved the UCL CCTU reviewing the protocol to ensure it conformed to high standards of trial conduct and met the governance requirements of UCL. The UCL CCTU is responsible for oversight of the trial. The sponsor plays no role in data collection, management, analysis and interpretation of data, writing of the report or the decision to submit the report for publication.
PRIME Operations Group	 The PRIME Operations Group consists of the chief investigator, the Clinical Operations Group, National Cancer Imaging Translational Accelerator, the UCL Surgical and Interventional Trials Unit and the eCRF database managers. This group is responsible for: Study planning Preparation of protocol and revisions Assistance with international review board/independent ethics committee applications

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

3	
4	
5	
6	
7	
, 0	
0	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
20 21	
∠ I วา	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
32	
27	
54 2E	
22	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
<u>4</u> 7	
-⊤/ ⊿Ω	
40	
49 50	
50	
51	
52	
53	
54	
55	
56	
57	
58	

59 60 623

	 Preparation of investigators brochure and CRFs Organisation of steering committee meetings Provide annual progress reports to the ethics committee Reporting serious adverse events to the sponsor and ethics committee when necessary Responsible for trial master file Budget administration and contractual issues with individual centres Advice for PIs Site initiation visits Data verification and management Central monitoring and resolving data queries with clinicians and nurses at the trial sites Maintenance of the trial Information Technology (IT) system
Principal Investigator	At each participating site, the PI is responsible for the conduct of the clinical trial to ensure the safety of participants and the reliability and robustness of the data generated. They will be responsible for identification, recruitment, data collection and completion of CRFs, along with follow-up of trial patients and adherence to trial protocol. The PI as leader of the research team may delegate their duties to members of their team.
Global Trial Steering Committee	The NCITA global prostate trial steering committee (TSC) is responsible for the governance of the PRIME Study, and they have delegated safety to a data monitoring subcommittee (DMSC). Roles and responsibilities: To act as the oversight body for up to five prostate cancer studies on behalf of the Sponsor and Funders. In addition, the independent members will form a sub-committee to review safety. The role of the TSC is to provide oversight for the studies and provide advice through its Chair to the Chief Investigators (CI), work in tandem with the Data Monitoring Sub-Committee (DMSC), Sponsor, Funders and host institution on all aspects of the studies. The rights, safety and well-being of the study participants are the most important consideration and should prevail over the interests of science and society.



VISIT 4: Test results given & treatment decision (as per local standard of care) Follow-up for further investigations from treatment decision

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

EZ-LTA





In the case of diffuse changes on **both sides** of the prostate scoring ≥3 (Likert), the diffuse changes on each side of the prostate can be arbitrarily treated as **separate targets.** "Diffuse change" is defined as an intermediate or low T2 signal that occupies the majority of at least one side of the peripheral zone, without a defined border

58 59

TRIAL IDENTIFIER:

PARTICIPANT INITIALS:

1 2 3 1. Radiologists should **first** annotate, draw and label the diagram on the first page with **up to 3** suspicious areas 4 5 scoring \geq 3 on the Likert scale (L) of suspicion (1–5). Clinical information is permitted to be used to influence 6 the score. 7 2. Radiologists should then score suspicious areas **strictly** using the PI-RADS v2.1 (P) criteria, **without** allowing 8 9 clinical information to influence the score. 10 3. If an additional area of suspicion is identified when scoring with PI-RADS v2.1 that was not present on Likert, 11 please draw on this 4th suspicious area. 12 13 14 15 A maximum of **4 targets** can be drawn on this report. 16 17 18 1. Every lesion **must have both** a Likert and PI-RADS v2.1 score marked on. 19 2. Mark the **most suspicious** area, "Target 1". 20 a. Mark the **next most suspicious area**, "Target 2". 21 22 b. Mark the **subsequent most suspicious area**, "Target 3" and so on. 23 3. On the diagram above, every lesion drawn must have the following marked and labelled: 24 a. Target number 25 b. Likert score 26 c. PI-RADS v2.1 score 27 28 4. Please then insert these into **Table 1** and fill out the rest of the proforma. 29 30 31 e.g. Target 1. Likert 3. PI-RADS 1. 32 33 34 **MRI Scanner and Clinical Information** 35 36 PSA 37 Patient age (years): 38 (ng/ml): 39 40 **PSA Density** MRI volume of prostate 41 (ml): (ng/ml/ml): 42 43 Field Strength of Magnet □ 1.5T □ 3T 44 45 46 47 **Confirmation of blinding** 48 49 50 51 Confirmation by another individual / system that

Which MRI scanner was used?

1.

SCANNER ONE

2. □ SCANNER TWO

3. □ SCANNER THREE



the radiologist is **blinded** to DCE images

(mandatory)

52

53

□ Yes



PARTICIPANT INITIALS:

Table 1. Please only enter Targets below if the Likert or PI-RADS v2.1 score is \geq 3.

TARGET SPECIFIC INFORMATION	TARGET 1	TARGET 2	TARGET 3	TARGET 4
	🗆 Right	🗆 Right	🗆 Right	🗆 Right
Location of suspicious area(s) (select one	🗆 Left	🗆 Left	🗆 Left	🗆 Left
	🗆 Bilateral	🗆 Bilateral	🗆 Bilateral	🗆 Bilateral
	□ Base	□ Base	□ Base	□ Base
Location in prostate according to PI-RADS	🗆 Mid	🗆 Mid	🗆 Mid	🗆 Mid
v2.1 41-sector diagram (select the one	🗆 Apex		□ Apex	□ Apex
main location which contains the target):	□ Seminal Vesicle	□ Seminal Vesicle	□ Seminal Vesicle	SeminalVesicle
Main sector which contains the lesion according to PI-RADS v2.1 41-sector diagram (write one , <i>e.g.</i> "PZpI"):	0			
Likert score of suspicion (1–5):	Í.			
PI-RADS v2.1 score of suspicion (1–5):				
Target appearance (select one):	Focal	Focal	🗆 Focal	Focal
The default is focal, unless there is diffuse change in the peripheral zone	Diffuse		Diffuse	Diffuse
Biaxial diameter on sequence where it was largest, in axial plane (mm x mm):		?		
	□ T2	□ T2	□ T2	□ T2
Sequence used to measure biaxial diameter (select one):	🗆 High b	🗆 High b	🗆 High b	🗆 High b

Overall patient Likert score	Overall patient PIRADS v2.1 score
Enter the highest Likert score	Enter the highest PI-RADS v2.1 score

If there are no Targets scoring \geq 3 on either scoring system, then the overall Likert and PI-RADS v2.1 score will be 1 or 2.

PARTICIPANT INITIALS:

TRIAL IDENTIFIER:

Table 2. Staging information. Complete **only if** a Target has been identified above:

Radiological stage:	🗆 T2a	□ T2b	□ T2c	🗆 T3a 🛛 T3b	□ T4		
	Radiological T3a = unequivocal extracapsular disease						
Likelihood of right -sided extracapsular spread*: 1 = highly unlikely , 3 = equivocal, 5 = highly likely	□ 1	□ 2	□ 3	□ 4	□ 5		
Likelihood of left -sided extracapsular spread*:		□ 2	□ 3	□ 4	□ 5		
Likelihood of right seminal vesicle involvement:		□ 2	□ 3	□ 4	□ 5		
Likelihood of left seminal vesicle involvement:		□ 2	□ 3	□ 4	□ 5		
Likelihood of urethral sphincter involvement:		□ 2	□ 3	□ 4	□ 5		
Likelihood of bladder neck involvement:		□ 2	□ 3	□ 4	□ 5		
Likelihood of rectal involvement:	□ 1	□ 2	□ 3	□ 4	□ 5		

*See PI-RADS v2.1 guidelines for examples of features suggestive of extracapsular spread.

MRI Quality: Please **complete** this for **all** MRIs <u>regardless</u> of whether a Target was identified:

Was there a problem with the quality of the	e T2W sequence?		□ Yes	□ No	
Was there a problem with the quality of the	e DWI sequence?		□ Yes		□ No
If there were problems, please describe these (tick all that apply):		2	7		
For T2W:	Rectal air		vement artefact	Prosthesis	□ Other
For DWI:	Rectal air		vement artefact	Prosthesis	\Box Other
If other, please describe:			2		
Was the quality of the scan sufficient for you to make a diagnostic assessment?	□ Yes] No	
Hypothetically, if this patient only had this biparametric MRI scan:					
• Would you typically have recommended a repeat bpMRI?	🗆 Yes	□ No			
• Would you typically have recommended a contrast sequence to be done?	□ Yes	□ No			
Radiologist			Date of MRI:		
(Forename, Surname):			Date of Repo	rt:	

TRIAL IDENTIFIER:	IDENTIFIER: PARTICIPANT INITIALS:				
	Reporting Proforma (mpMRI):	(mpMRI):			
Report	2 – Multiparametric MRI (mpMRI)	Report			
he same radiologist should annotate vill be used by the biopsy operator to	the diagrams below after they are unblind perform targeted biopsy .	ed to the DCE sequence. This repor			
total of maximum 8 suspicious a eport.	areas scoring \geq 3 on either Likert or PI	-RADS v2.1 can be annotated in this			
	PART ONE: TARGETS SEEN ON BPMRI				
1. First, copy any targets drawn	on Report 1 (bpMRI) onto this report (Re	port 2 – mpMRI).			
a. Draw them on the di	agram.				
b. Specify their biparam	etric MRI status (bpMRI +ve or bpMRI -ve)	when you label each lesion.			
2. Upon viewing the DCF find	nas for each of these lesions inlease spe	cify their multi-parametric MRI statu			
(mpMRI +ve or mpMRI -ve)	on the diagram then specify updated Like	rt (L) and PI-RADS v2.1 (P) scores of			
mpMRI.					
	`				
No targets seen on bpMRI or mpMRI	Target identified on bpMRI <i>but</i> Target is no longer scoring \ge 3 on Likert or PI-RADS v2 1 on mpMRI	Target identified on bpMRI and remains scoring \geq 3 on Likert or PI-RADS v2 1 on mpMRI			
bpMRI -ve, mpMRI -ve	Label Target on diagram as	Label Target on diagram as			
Leave Table 1, 2 & 3 blank	Label Target on diagram with Likert	and PI-RADS v2.1 scores on mpMRI			
Complete overall Likert and PI-RADS v2.1 score, MRI quality	Complete Table 1 and	I rest of the proforma			
information and biopsy plan					



TRIAL IDENTIFIER:



In the case of diffuse changes on **both sides** of the prostate scoring ≥3 (Likert), the diffuse changes on each side of the prostate can be arbitrarily treated as **separate Targets.** "Diffuse change" is defined as an intermediate or low T2 signal that occupies the majority of at least one side of the peripheral zone, without a defined border.



Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

PARTICIPANT INITIALS:

Patient age (years)	PSA (ng/ml):			
MRI volume of prostate (ml):	PSA Density (ne	g/ml/ml):		
able 1. Information from Targets origina	Illy identified on	the biparametr	ric MRI (if appli	cable):
TARGET SPECIFIC INFORMATION	TARGET 1	TARGET 2	TARGET 3	TARGET 4
СОРУ І	FROM REPORT	1 (BPMRI):	1	1
Location of suspicious area(s) (select one option):	□ Right □ Left □ Bilateral	□ Right □ Left □ Bilateral	□ Right □ Left □ Bilateral	RightLeftBilateral
Location in prostate according to PI-RADS v2.1 41-sector diagram (select the one main location which contains the target):	 Base Mid Apex Seminal Vesicle 			
Main sector which contains the lesion according to PI-RADS v2.1 41-sector diagram (write one sector, <i>e.g.</i> "PZpI"):	2	•		
Biparametric MRI Likert score (1–5):		4		
Biparametric MRI PI-RADS v2.1 score (1–5):		0,		
RE-ASSESS, TAKING INTO ACCOU		FION FROM DC	CE SEQUENCE ((MPMRI):
Multiparametric MRI Likert score (1–5):		3		
Multiparametric MRI PI-RADS v2.1 score (1–5):				
Target appearance (select one):	Focal Diffuse	Focal Diffuse	Focal Diffuse	□ Focal □ Diffuse
Biaxial diameter on sequence where it was largest, in axial plane (mm x mm):				
Sequence used to measure biaxial diameter	□ T2 □ High b	🗆 T2 🛛 High b	🗆 T2 🗆 High b	🗆 T2 🗆 Hiç

 \Box ADC \Box DCE



 \Box ADC \Box DCE

 \Box ADC \Box DCE

(select **one**):

TRIAL IDENTIFIER:

PARTICIPANT INITIALS:

PART TWO: NEW DCE-TARGETS ON DYNAMIC CONTRAST ENHANCED SEQUENCE New **parts** of previously identified New Target on DCE? lesion larger on DCE?* Draw and annotate as a new Target on diagram and label as a DCE-Target Label Target on diagram as bpMRI -ve, mpMRI +ve Label Target on diagram with Likert and PI-RADS v2.1 scores on mpMRI Complete Table 2 and the rest of the proforma * Please note: this is a subjective decision by the radiologist as to whether new parts of an existing lesion on bpMRI would need to be declared as a new target in order not to be missed on biopsy. A clear example of when to declare a new DCE-Target would be if the non-overlapping part of the lesion on DCE crosses into a new sector on the PI-RADSv2.1 sector diagram 5. Any new targets should be labelled **DCE-Target-x.** a. The first new, most suspicious, target should be DCE-Target-1. The second if applicable, DCE-Target-2 and so on. 6. A maximum of **4 new targets** can be drawn on this report (**Report 2**). a. Thus, a maximum of 8 targets can be drawn in total (4 carried over from Report 1 and 4 new DCE targets). 7. On the diagram on Page 2, every lesion drawn must have the following marked and labelled: a. Target number b. bpMRI status (positive or negative) c. mpMRI status (positive or negative) d. Likert score for mpMRI e. PI-RADS v2.1 score for mpMRI e.g. DCE-Target-1. bpMRI negative. mpMRI positive. Likert 4. PI-RADS 2. 8. Then complete **Table 2** and the rest of the MRI proforma.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

TRIAL IDENTIFIER:

PARTICIPANT INITIALS:

Table 2. Information from Targets identified **ONLY** by DCE, which were <u>not</u> identified on the **biparametric MRI** (if applicable). If there are no DCE-Targets then leave Table 2 blank & move onto overall patient Likert & PI-RADs scores):

TARGET SPECIFIC INFORMATION	DCE-TARGET 1	DCE-TARGET 2	DCE-TARGET 3	DCE-TARGET 4	
DCE-Target (select if new lesion or part of	□ New	□ New	□ New	□ New	
existing lesion bigger on DCE):	Existing	Existing	Existing	Existing	Prot
	🗆 Right	🗆 Right	🗆 Right	🗆 Right	ectec
Location of suspicious area(s) (select one):	🗆 Left	🗆 Left	🗆 Left	🗆 Left	
O,	Bilateral	Bilateral	Bilateral	Bilateral	pyri
	□ Base	□ Base	□ Base	□ Base	gnt, I
Location in prostate according to PI-RADS v2.1	🗆 Mid	🗆 Mid	🗆 Mid	🗆 Mid	nciuc
41-sector diagram (select the one main	□ Apex	□ Apex	□ Apex	□ Apex	r Burk
location which contains the target).	Seminal Vesicle	Seminal Vesicle	SeminalVesicle	Seminal Vesicle	or uses
Main sector which contains the lesion according to PI-RADS v2.1 41-sector diagram (write one , <i>e.g.</i> "PZpI"):	(C)	•			related to tex
Multiparametric MRI Likert score (1–5):	0	24			t and data n
Multiparametric MRI PI-RADS v2.1 score (1–5):		0			nining, Al tr
-	Focal	Focal	Focal	Focal	ainin
l'arget appearance (select one):	□ Diffuse	🗆 Diffuse	Diffuse	Diffuse	g, anc
Biaxial diameter on dominant sequence in axial plane (mm x mm):					i similar tec
Looking back again at the T2W and DWI only ,	□ No	🗆 No	🗆 No	□ No	nnolo
is the DCE-target identified here actually visible on the bpMRI?	□ Yes	□ Yes	□ Yes	□ Yes	gies.
If you answered Yes , please specify whether the lesion was missed on 1 st look <i>or</i> whether	\Box Missed on 1^{st} look	\Box Missed on 1^{st} look	□ Missed on 1 st look	\Box Missed on 1^{st} look	
it was seen but scored a 1 or 2 on PI-RADS v2.1 and Likert	 Seen on 1st look but scored a 1 or 2 	 Seen on 1st look but scored a 1 or 2 	 Seen on 1st look but scored a 1 or 2 	 Seen on 1st look but scored a 1 or 2 	

TRIAL IDENTIFIER:

PARTICIPANT INITIALS:

Please complete the **overall scores** <u>regardless</u> of whether there are any Targets identified above:

Overall patient Likert score	Overall patient PI-RADS v2.1 score
Enter the highest Likert score on either biparametric MRI or multiparametric MRI	Enter the highest PI-RADS v2.1 score on either biparametric MRI or multiparametric MRI

Please note: if a lesion was suspicious on biparametric MRI but **not** suspicious on mpMRI (*i.e.* bpMRI +ve, mpMRI -ve), it should still be biopsied if either the Likert or PI-RADS v2.1 score on bpMRI is \geq 3. This highest score on either bpMRI or mpMRI should be entered above.

Table 3. Staging information. Complete only if a Target has been identified above. Select one option each time:

Radiological stage:	□ T2a Radiolo	□ T2b □ ogical T3a = unequ	∃ T2c uivocal ext	□ T3a □ T3b racapsular disease	□ T4
Likelihood of right -sided extracapsular spread*: 1 = highly unlikely , 3 = equivocal, 5 = highly likely		□ 2	□ 3	□ 4	□ 5
Likelihood of left -sided extracapsular spread*:		□ 2	□ 3	□ 4	□ 5
Capsular involvement on DCE :	🗆 No	□Yes, on right	□Yes, o	n left 🗆 Yes, on bo	oth sides
Likelihood of right seminal vesicle involvement:		□ 2	□ 3	□ 4	□ 5
Likelihood of left seminal vesicle involvement:		□ 2	□ 3	□ 4	□ 5
Seminal vesicle involvement on DCE:	🗆 No	□Yes, on right	□Yes, o	n left	oth sides
Likelihood of urethral sphincter involvement:		🗆 2 🕻	□ 3	□ 4	□ 5
Urethral sphincter involvement on DCE:	🗆 No	□Yes, on right	□Yes, o	n left	oth sides
Likelihood of bladder neck involvement:		□ 2	□ 3	□ 4	□ 5
Bladder neck involvement on DCE:	🗆 No		□ Yes	5	
Likelihood of rectal involvement:		□ 2	□ 3	□ 4	□ 5
Rectal wall involvement on DCE:	🗆 No		□ Yes	5	

*See PI-RADS v2.1 guidelines for examples of features suggestive of extracapsular spread.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

TRIAL IDENTIFIER:

PARTICIPANT INITIALS:

MRI Quality. Please complete this for all MRIs regardless of whether a Target was identified:

Was there a problem with the quality o	the DCE sequence?		□ Yes		□ No
If problems with DCE, please specify: Tick all that apply	Rectal air		ement artefact	Prosthesis	□ Other
If other, please describe:					
Was the quality of the scan sufficient for you to make a diagnostic assessment?	□ Yes		□ No	0	
Based on the quality of the mpMRI scan and your typical practice, would you recommend a repeat multiparametric MRI be performed?	□ Yes		□ No	0	

Biopsy protocol guidelines

It is **mandatory** to follow these recommendations below:

Number of MRI targets	Location of MRI targets in prostate	Number of MRI- targeted biopsy cores	Number of contralateral systematic cores	Total number of biopsy cores
0	If PSA De	nsity is < 0.15ng/ml/ml	0	
0	If PSA Density is \geq 0.15ng/ml/ml, then 12 systematic biopsy cores are taken (6 from each side)			12
1	Unilateral	4	6	10
2	Unilateral	8	6	14
3	Unilateral	12	6	18
4-8	Unilateral	16–32	6	22–38
1	Bilateral (<i>e.g.</i> crossing midline)	4	0	4
2	Bilateral	8	0	8
3	Bilateral	12	0	12
4-8	Bilateral	16–32	0	16–32

Note: For 4–8 MRI targets, determine the number of MRI-targeted cores by using the principle of 4 cores per MRI target.



Recommended Biopsy Plan for biopsy operator to follow

The radiologist should now complete this biopsy plan which should be passed directly to the person performing biopsy (if one is required) along with the labelled diagram on Page 2:

Even if radiologists do not typically write biopsy plans, we request they do this here following the protocol in the table above, in order to reduce errors between linking the MRI information to the protocol biopsy plan.

	with MRI-targeted biopsy:		
(<i>Note:</i> Targets which are only susp targets for biopsy therefore include	icious on bpMRI should still be biopsied. T s MRI targets identified only on bpMRI, on	ne number of MRI- ly on mpMRI or on	
both bpMRI and mpMRI and on eith	er the Likert scoring system or the PIRADsv	2.1 scoring system)	
Total number of MRI-targeted b	opsy cores to be taken:		
(<i>Note:</i> 4 biopsy cores should be tak	en per lesion)		
Total number of systematic biop	sy cores to be taken:		
(Note: Systematic cores should be p	eripheral zone-focused cores)		
Number of systematic cores to t	e taken from right side of prostate:		
(Note: do not take systematic cores	from the same side as an MRI target)		
Number of systematic cores to b (<i>Note:</i> do not take systematic cores	e taken from left side of prostate: from the same side as an MRI target)		
Number of systematic cores to b (<i>Note:</i> do not take systematic cores Total number of systematic and	e taken from left side of prostate: from the same side as an MRI target) targeted cores to be taken	0,	
Number of systematic cores to b (<i>Note:</i> do not take systematic cores Total number of systematic and	e taken from left side of prostate: from the same side as an MRI target) targeted cores to be taken	0,5	
Number of systematic cores to t (<i>Note:</i> do not take systematic cores Total number of systematic and	e taken from left side of prostate: from the same side as an MRI target) targeted cores to be taken	0,52	
Number of systematic cores to t (<i>Note:</i> do not take systematic cores Total number of systematic and	e taken from left side of prostate: from the same side as an MRI target) targeted cores to be taken	0,52	



Supplementary Appendix 2: Detailed PRIME Biopsy Plans

To be pragmatic and allow results to be generalisable to biopsy practice around the world, biopsies can be performed transperineally (**Figures 1** and **2**) or transrectally (**Figures 3 and 4**) as per local practice. We split this Appendix into these sections, respectively.

If there is an MRI lesion (scores 3, 4 or 5 on *either* Likert or PI-RADS v2.1 scoring systems), then MRI-targeted biopsy and some limited contralateral systematic biopsy should be performed. MRI-targeted biopsy should be performed **first**, with 4 cores per suspicious area. Then the systematic biopsy cores should be taken but avoid taking biopsies from the same side of the prostate that targeted biopsies were taken from.

Table of Contents

Systematic Transperineal Biopsy Schema2
Non-suspicious MRI but a PSA Density of \geq 0.15ng/mL/mL scenario2
Suspicious MRI lesion scenarios4
Single lesion scenario
Bilateral lesions scenario4
Lesion crossing midline scenario5
Bilateral diffuse change on Likert scoring scenario5
New lesion is revealed on DCE sequence scenario6
New part of existing lesion is revealed on DCE sequence scenario
Systematic Transrectal Biopsy Schema7
Non-suspicious MRI but a PSA Density of \geq 0.15ng/mL/mL scenario7
Suspicious MRI lesion scenarios9
Single lesion scenario9
Bilateral lesions scenario10
Lesion crossing midline scenario11
Bilateral diffuse change on Likert scoring scenario12
New lesion is revealed on DCE sequence scenario13
New part of existing lesion is revealed on DCE sequence scenario
Summary Biopsy Guidelines16



Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.
Systematic Transperineal Biopsy Schema

Figures 1 and **2A-F** depict examples of how to perform the systematic biopsy in the **absence** of an MRI lesion and in the **presence** of MRI lesions, respectively.

Non-suspicious MRI but a PSA Density of \geq 0.15ng/mL/mL scenario

In patients with a **non-suspicious MRI but a PSA Density of** \geq **0.15ng/mL/mL**, 12-core systematic biopsy should be performed (Figure 1).

The number of systematic cores that should be taken per patient is **12**.

Systematic biopsy cores are taken from:

- Right anterior zone (2 cores)
- Right mid zone (2 cores)
- Right posterior zone (2 cores)
- Left anterior zone (2 cores)
- Left mid zone (2 cores)
- Left posterior zone (2 cores)

Systematic biopsy cores should be stored and labelled in a way that their **location** can be identified when the pathologist reports the result.

Figure 1. The transperineal biopsy schema for men with a **non-suspicious MRI** (scores 1 or 2 on both Likert and PI-RADS v2.1 scoring systems) *but* a PSA Density of \geq 0.15ng/mL/mL, undergoing 12-core systematic biopsy.







For each pair of biopsies - one core is more lateral, one core is more medial. From anteriorposterior, there are 3 planned rows of biopsies - anterior, mid zone, posterior. Avoid biopsy around the urethra.



Suspicious MRI lesion scenarios

Figure 2. Examples of how to perform transperineal biopsies in patients with an MRI Target (scores 3, 4 or 5 on *either* Likert or PI-RADS v2.1 scoring systems).

2A. Single lesion example.



This is a single lesion in the right mid-gland peripheral zone posteromedially (PZ pm) and posterolaterally (PZ pl).

- Take 4 targeted biopsies from the Target.
- Then take 6 peripheral zone focused biopsies from the contralateral side.
- Do not resample the targeted biopsy side.

2B. Bilateral peripheral zone lesions example.



There are **two lesions**: one in right mid-gland, peripheral zone posteromedially and posterolaterally (PZ pm and PZ pI); one in left mid-gland, peripheral zone posteromedially and posterolaterally (PZ pm and PZ pI).

- Take 4 targeted biopsies from *each* Target *i.e.* 8 targeted biopsies in total.
- **Do not take any systematic biopsies** as targeted biopsies are taken from both sides of the prostate.



2C. Lesion crossing midline example.



This is one lesion crossing the midline in the mid-gland, anterior fibromuscular stroma.

- Take 4 targeted biopsies from the Target. •
- Do not take any systematic biopsies as targeted biopsies are taken from both sides • of the prostate.

2D. Bilateral diffuse change on Likert scoring example.



ιple. In the circumstance where on Likert scoring, the peripheral zone gives diffuse change, scoring 3 out of 5, arbitrarily treat each peripheral zone as a different Target.

- Take 4 targeted biopsies from each half of the peripheral zone i.e. 8 biopsies in • total.
- Do not take any systematic biopsies as targeted biopsies are taken from both sides • of the prostate.



2E. A new lesion is revealed on DCE sequence example.



This is one lesion in the right mid-gland, peripheral zone posterolaterally. This **new Target** was specifically *not* suspicious (scored 1 or 2 on both Likert and PI-RADS v2.1) on bpMRI sequences (T2W and DWI). However, when the contrast sequence is revealed, the lesion appears to be suspicious (scored 3, 4 or 5 on Likert) on the dynamic contrast-enhanced (DCE) sequence than on the bpMRI.

- Thus, label the new lesion as a DCE-Target.
- Take 4 targeted biopsies from DCE-Target-1.
- Then take **6 peripheral zone focused biopsies** from the **contralateral** side of the prostate.
- Do **not** resample the targeted biopsy side.

2F. A new **part** of an *existing* lesion is revealed on DCE sequence example.



There are two lesions in this example. **Target 1** (**red**) was suspicious on **both** bpMRI and mpMRI. It is in the right mid-gland, peripheral zone, posterolaterally (PZ pl). It scores Likert 4 and PI-RADS v2.1 4.

However, when the contrast sequence is revealed, this lesion appears to be larger on the DCE sequence than on bpMRI. The part of the lesion that is **non-overlapping** would **not** have been



target biopsied if bpMRI <u>alone</u> was used. Thus, the second lesion (the non-overlapping part, **purple**) is called **DCE Target 1**. It is in the right mid-gland, peripheral zone, posteromedially (PZ pm).

Thus, the instructions are as follows in this instance:

- Take 4 targeted biopsies from Target 1.
- Take 4 targeted biopsies from DCE Target 1.
- Take 6 peripheral zone focused biopsies from the contralateral side of the prostate.
- Do **not** resample the targeted biopsy side.

Systematic Transrectal Biopsy Schema

Figures 3 and **4** depict examples of how to perform the systematic biopsy in the **absence** of an MRI lesion and in the **presence** of MRI lesions, respectively.

Non-suspicious MRI but a PSA Density of \geq 0.15ng/mL/mL scenario

In patients with a **non-suspicious MRI but a PSA Density of** \geq **0.15ng/mL/mL**, 12-core systematic biopsy should be performed (Figure 3).

If performing biopsies transrectally, systematic biopsy cores should be taken from:

- Right base (2 cores)
- Right mid gland (2 cores)
- Right apex (2 cores)
- Left base (2 cores)
- Left mid gland (2 cores)
- Left apex (2 cores)

Systematic biopsy cores should be stored and labelled in a way that their location can be identified when the pathologist reports the result.

The 12 systematic biopsies **should be focused on the peripheral zone.** The urethra should be avoided.



Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Figure 3. The transrectal biopsy schema for men with a **non-suspicious MRI** (scores 1 or 2 on both Likert and PI-RADS v2.1 scoring systems) *but* a PSA Density of \geq 0.15ng/mL/mL, undergoing 12-core systematic biopsy.





Suspicious MRI lesion scenarios

Figure 4. Examples of how to perform transrectal biopsies in patients with an MRI Target (scores 3, 4 or 5 on *either* Likert or PI-RADS v2.1 scoring systems).

4A. Single lesion example.



This is a single lesion in the right mid-gland peripheral zone posteromedially (PZ pm) and posterolaterally (PZ pl).

- Take **4 targeted biopsies** from the Target.
- Then take 6 peripheral zone focused biopsies from the contralateral side.





4B. Bilateral peripheral zone lesions example.



There are **two lesions**: one in right mid-gland, peripheral zone posteromedially and posterolaterally (PZ pm and PZ pl); one in left mid-gland, peripheral zone posteromedially and posterolaterally (PZ pm and PZ pl).

• Take 4 targeted biopsies from *each* Target – *i.e.* 8 targeted biopsies in total.



• **Do not take any systematic biopsies** as targeted biopsies are taken from both sides of the prostate.

4C. Lesion crossing midline example.



This is one lesion crossing the midline in the mid-gland, anterior fibromuscular stroma.

• Take **4 targeted biopsies** from the Target.



- **Do not take any systematic biopsies** as targeted biopsies are taken from both sides of the prostate.
- 4D. Bilateral diffuse change on Likert scoring example.



In the circumstance where on Likert scoring, the peripheral zone gives diffuse change, scoring 3 out of 5, arbitrarily **treat each peripheral zone** as a **different Target**.



- Take **4 targeted biopsies** from *each half* of the peripheral zone *i.e.* **8 biopsies** in total.
- **Do not take any systematic biopsies** as targeted biopsies are taken from both sides of the prostate.

4E. A new lesion is revealed on DCE sequence example.



This is one lesion in the right mid-gland, peripheral zone posterolaterally. This **new Target** was specifically *not* suspicious (scored 1 or 2 on both Likert and PI-RADS v2.1) on bpMRI sequences (T2W and DWI). However, when the contrast sequence is revealed, the lesion



Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

appears to be suspicious (scored 3, 4 or 5 on Likert) on the dynamic contrast-enhanced (DCE) sequence than on the bpMRI.

- Thus, label the **new lesion** as a **DCE-Target**.
- Take 4 targeted biopsies from DCE-Target-1.
- Then take **6 peripheral zone focused biopsies** from the **contralateral** side of the prostate.
- Do **not** resample the targeted biopsy side.

4F. A new **part** of an *existing* lesion is revealed on DCE sequence example.

There are two lesions in this example. **Target 1** (**red**) was suspicious on **both** bpMRI and mpMRI. It is in the right mid-gland, peripheral zone, posterolaterally (PZ pl). It scores Likert 4 and PI-RADS v2.1 4.

However, when the contrast sequence is revealed, this lesion appears to be larger on the DCE sequence than on bpMRI. The part of the lesion that is **non-overlapping** would **not** have been target biopsied if bpMRI <u>alone</u> was used. Thus, the second lesion (the non-overlapping part, **purple**) is called **DCE Target 1**. It is in the right mid-gland, peripheral zone, posteromedially (PZ pm).

Thus, the instructions are as follows in this instance:

- Take 4 targeted biopsies from Target 1.
- Take 4 targeted biopsies from DCE Target 1.
- Take 6 peripheral zone focused biopsies from the contralateral side of the prostate.
- Do **not** resample the targeted biopsy side.





Summary	Biopsy	Guide	lines
Sammary	Diopsy	ourac	mics

Number of MRI targets	Location of MRI targets in prostate	Number of MRI- targeted biopsy cores	Number of contralateral systematic cores	Total number of biopsy cores				
0	If P	0						
0	If PSA Density is ≥ (f PSA Density is ≥ 0.15ng/ml/ml, then 12 systematic biopsy cores are taken (6 from each side)						
1	Unilateral	4	6	10				
2	Unilateral	8	6	14				
3	Unilateral	12	6	18				
4–8	Unilateral	16–32	6	22–38				
1	Bilateral (<i>e.g</i> . crossing midline)	4	0	4				
2	Bilateral	8	0	8				
3	Bilateral	12	0	12				
4–8	Bilateral	16–32	0	16–32				



1

Please present on local headed paper

REC Number: IRAS Number: 282789

Subject Identification: _____ Study Number ;_____

CONSENT FORM

Title of Project: PRostate Imaging using MRI +/- contrast Enhancement (PRIME)

Name of Researcher:

Please initial box

1. I confirm that I have read and understand the information sheet dated...... (version.....) for the above study. I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.

I understand that my participation is voluntary and that I am free to withdraw at any time without giving any reason, without my medical care or legal rights being affected.

3. I understand that relevant sections of my medical notes and data collected during the study, may be looked at by individuals from the sponsor of the trial (University College London), responsible persons authorised by the sponsor, from regulatory authorities, from the NHS Trust and from PRIME study researchers who may be outside of my local centre, where it is relevant to my taking part in this research. I give permission for these individuals to have access to my records.

4. I agree to my GP being informed of my participation in the study.

5. I give my permission for the PRIME research team at my local centre to hold identifiable information such as my name, address, date of birth, email address, mobile phone number, NHS number or other applicable hospital identifier. I understand this may be used to collect longer term healthcare information on me from national records, such as the Office for National Statistics, NHS Digital, Public Health England, and other applicable NHS information systems, or other relevant national databases. This data may be linked to my data from the PRIME study in future research.

IRAS Reference Number 282789 PRIME Consent Form Version 2.0 Dated 27APR2021











BMJ Open

6. I give permission to be contacted for further information in the future. This may include requests to complete quality of life questionnaires or for ascertaining future health status, if required. 7. I give permission for my samples to be sent to UCL by courier for quality control assessments. 8. I give permission for my anonymized data to be used for teaching and educational purposes for healthcare professionals. 9. I give my permission for my anonymized data to be shared with affiliated researchers and commercial partners who are approved by the PRIME study team for future research if deemed suitable by the PRIME Chief Investigator 10. I give my permission to be approached for other studies in the future that may be relevant to me, and for my study data collected in PRIME to be used for this purpose. 11. I agree to take part in the above study and to complete study procedures outlined in the patient information sheet provided. All boxes above must be initialed for consent to be valid

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Name of Participant	Date	Signature	-
Name of Person	Date	Signature	-

When completed: 1 for participant; 1 (original) for researcher site file; 1 to be kept in medical notes.

IRAS Reference Number 282789 PRIME Consent Form Version 2.0 Dated 27APR2021

taking consent

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

PLACE HOSPITAL LETTER HEAD ON FIRST PAGE ONLY.

Affix patient sticker / details here

Version 3.0 8 June 2021

This is the Patient Information Sheet for a Health Research Study called PRIME

Study Short Title: Prostate Imaging using MRI +/- contrast Enhancement

Study acronym: PRIME

Chief Investigator: Mr Veeru Kasivisvanathan

UCL Reference number: <u>135819</u>

REC Reference number: 21/WM/0091

IRAS Number: 282789

We would like to invite you to take part in our research study. Before you decide we would like you to understand why you are being invited, why the research is being done and what it would involve for you. One of our team will go through the information sheet with you and answer any questions you have. Talk to others about the study if you wish.

Part 1 tells you the purpose of this study and what will happen to you if you take part. Part 2 gives you more detailed information about the conduct of the study.

Ask us if there is anything that is not clear. Please take as much time as you need to consider the study.

Part 1

1. Why have I been invited?

You are being invited because you may require further investigation of your prostate with an MRI scan and / or a prostate biopsy. You have not been diagnosed with cancer but an MRI and / or a biopsy may be required to establish whether you do or do not have cancer. The clinical Urology team that you have been referred to has informed us that you may be eligible for this study.

2. What is the purpose of the study?

The standard way of diagnosing prostate cancer is to carry out a multiparametric prostate MRI scan and prostate biopsy. This type of MRI scan normally involves an injection of contrast into one of your veins.

Another type of MRI scan (biparametric) can be performed that does not require contrast, and therefore does not require the insertion of a cannula. We currently do not know for certain whether using this type of MRI will allow us to detect the same, more or less prostate cancer than if we use the standard (multiparametric) type of MRI. Current evidence supports the idea that using biparametric MRI may detect a similar amount of cancer to when it is not used but one advantage is it may allow a man to have a scan without contrast.

The main purpose of this study is to assess if biparametric MRI can provide similar information to multiparametric MRI. You will undergo a multiparametric MRI with a contrast injection, which is the typical method used for investigating the prostate for the presence of cancer. The doctor reviewing your scan will be asked to review the MRI scan in a particular order so that they can tell whether the additional information given by the contrast injection helps identifies prostate cancer.

If there is a suspicious area in the prostate on the MRI, a few biopsies can be directed at where the suspicious area is thought to be, also using an ultrasound probe in the back passage. If there is no suspicious area on the MRI and if you at low risk of harbouring cancer, which occurs in about 30% of men, then no biopsy will be taken at all.

3. Do I have to take part?

It is up to you to decide to join the study. We will describe the study and go through this information sheet. If you agree to take part, we will then ask you to sign a consent form. You are free to withdraw at any time without giving a reason. This will not affect the standard of care you receive.

4. What are the benefits to me of taking part in this study?

The healthcare team carrying out the tests in the study are experienced in carrying out and interpreting these tests. The research team will ensure your tests are carried out as quickly as possible and will be a point of contact for you should you have any concerns or questions.

The information we get from this study will help improve the diagnosis of prostate cancer for men in the future.

5. What type of study is this?

This is a study evaluating the accuracy of diagnostic tests. In this trial, you will have the same investigation (multiparametric MRI) as your hospital normally does to investigate the prostate, but the doctor interpreting your scan will be asked to report this in a particular order. The full information will be available to the doctors as it would normally be available if you were not taking part in the study.

You will be required to attend a screening visit with a member of the research team who will spend around 40 minutes explaining what is involved in the study and making sure you are

eligible for the study. Where possible, all study visits that do not require a journey to the hospital will be performed remotely (e.g. over the phone or video call).

6. What will happen to me if I take part?

After you have attended the screening visit, if you are eligible to take part in the study, you will asked to visit the hospital 2-3 times in total, which is the same as if you were not taking part in the study. After you consent to participating in the study, you will be asked to complete two short questionnaires which will ask about any symptoms related to your prostate that you may be having. These are questionnaires that are typically used as part of routine care. You would only undergo tests that you would normally have as part of routine care if you were not taking part in the study.

If you have not already had a prostate MRI, you will have one within a few weeks after the screening visit. The MRI takes about 40 minutes. Alternatively, it is possible that you are approached for the study after you have had your prostate MRI.

If you have an MRI with a high enough suspicion (MRI Score 3, 4 or 5) you will be booked for a biopsy following the MRI. If the MRI is non-suspicious but you are at high risk of having cancer because of a blood test result, (called your prostate specific antigen density) you will also undergo a prostate biopsy. If you do not need a biopsy (if your MRI is non-suspicious and your prostate specific antigen density is low) then you do not need to undergo a biopsy and we will explain this to you once your MRI results is available.

The biopsy procedure itself takes about 40 minutes and is typically carried out under local or general anaesthetic. Prostate biopsies, which take very small samples of prostate tissue, are taken from the prostate gland and sent to the lab to determine whether there is cancer there or not. If there is a suspicious area on the MRI scan, the MRI information will be used to influence where the biopsies are taken from. Software may be used to transfer additional information from the original MRI onto the screen when the biopsies are taken. In some centres, this would be exactly what you would normally get, and there would be no difference to standard of care. In other centres, their usual practice may be slightly different to this, and you may be required to have a few extra or fewer biopsies than what is typical in your usual centre. After the procedure, we then wait for the results and discuss treatment options with you in clinic at approximately 2-3 weeks after the biopsies.

Please note that the above time frames are suggested time frames and depending on clinical workload within the hospital, the time frame may be shorter or longer. This would be no different than if you were not part of the study.

Being involved in the study does not limit subsequent tests or treatment you may receive. If you do undergo further tests or treatment after the study is complete we may check the results of these on your records. We use the research data we have gathered from your involvement in the study to help us determine how good the diagnostic tests you have had are. We will work with other research teams to do this. We also ask your permission to use research data for teaching and education of other healthcare professionals. After completing the study, we also ask your permission to check your health through national databases. We may also contact you for further information in the future. This may include requests to complete quality of life questionnaires or for ascertaining future health status. All information which is collected about you during the course of the research will be kept strictly confidential, and any information about you which leaves the hospital will have your name and address removed so that you cannot be recognised. Please see Part 2 for further information on this.

7. What data will be collected and use of data

We will need to use information from your medical records for this research project. Your hospital will hold personal identifiable data on you. This information will include information such as age, PSA level, family history of medical conditions such as prostate cancer and examination findings. We allow the PRIME research team at your local site to hold

identifiable data on you, which will be for 10 years. Longer term data that may be requested from you include information on whether or not you have had further investigations or treatment for prostate problems and what the outcomes of those were as well as quality of life assessments. Non-identifiable data will be stored in the MARVIN database and the database will be transferred and stored at UCL within UCL's data safe haven. You will be given a subject number and a subject identifier, and this will be used on all your study records. The code for this number will be known to the investigators at your site so that the link between your name and the data we hold on the study database is not completely broken. Any paperwork for the study will be kept in locked cupboards, staff access to these cupboards is strictly controlled.

In general, UCL, as a university and a study sponsor, uses personally-identifiable information to conduct research to improve health, care and services. As a publicly-funded organisation, we have to ensure that it is in the public interest when we use personally-identifiable information from people who have agreed to take part in research. This means that when you agree to take part in a research study, we will use your data in the ways needed to conduct and analyse the research study. Your rights to access, change or move your information are limited, as we need to manage your information in specific ways in order for the research to be reliable and accurate. If you withdraw from the study, we will use the minimum personally-identifiable information possible.

Health and care research should serve the public interest, which means that we have to demonstrate that our research serves the interests of society as a whole. We do this by following the UK Policy Framework for Health and Social Care Research.

All data is managed in line with the Data Protection Act (2018) & General Data Protection Regulations (GDPR).

If you wish to raise a complaint on how we have handled your personal data, you can contact our Data Protection Officer who will investigate the matter. If you are not satisfied with our response or believe we are processing your personal data in a way that is not lawful you can complain to the Information Commissioner's Office (ICO).

UCL Data Protection Officer can be contacted on data-protection@ucl.ac.uk

8. What will I have to do?

You should attend your screening visit and if eligible for the study, await contact from the hospital for further dates of investigations. Unless otherwise advised by a doctor you should carry on with your normal activities and medication. Sometimes before a biopsy your doctor will prescribe you antibiotics and may ask you to stop blood-thinning medications.

You should undergo the necessary tests and biopsy procedures that you are advised to have by your doctor.

You should attend your follow up clinic appointment where we discuss your results. Treatment options will be discussed with you at the results clinic. In total you will typically be required to attend the hospital 2-3 times.

9. What are the alternatives for diagnosis?

An MRI scan and biopsies of the prostate if required are the standard ways in which prostate cancer is diagnosed.

10. What are the possible disadvantages and risks of taking part?

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Being involved in the study is unlikely to expose you to additional risk than if you were not involved in the study but underwent the normal procedures for men referred for further investigation of prostate disease.

Risks of prostate biopsy include:

- Temporary discomfort in the back passage (most men)
- Blood in the urine up to 2 weeks (most men)
- Blood in the semen up to 3 months (most men)
- Blood in the back passage up to 1 week (most men)
- Infection in the blood stream 1-4 out of 100 men
- Urinary tract infection 4 out of 100 men
- Urinary retention 1 out of 100 men
- Adverse reaction to antibiotics less than 1 in 100 men

Risks of MRI include:

- Discomfort from cannulation
- Allergic reaction:
 - o Mild reaction e.g. rash, itching less than 1 in 250 men
 - Moderate reaction e.g. nausea, omitting less than 1 in 2000 men
 - Severe reaction e.g. breathing problems less than 1 in 10000 men

In some centres, you would receive exactly what you would normally get outside of the study. In other centres, their usual practice may be slightly different to this, and you may be required to have a few extra or fewer biopsies than what is typical in your usual centre. However, there is no evidence that a few extra or fewer biopsies within the proposed study would result in additional adverse effects for you.

Before participating you should consider if this will affect any insurance you have and seek advice if necessary.

11. What should you do if you experience any problems during the study?

Though the risk is very low, if you do experience any possible signs of infection after biopsies (fevers and feeling generally unwell) then you should urgently go to your nearest accident and emergency department which is open 24 hours a day. If you are not able to pass urine you should urgently go to your nearest accident and emergency. If you are unsure about what to do or have any questions please call 0207 679 9092 between 9am and 5pm and a member of our team may be able to offer you advice or direct you to someone who can offer you advice.

If you experience any other untoward complication or need to see a doctor we would like to know about this so please let us know on the above number as soon as possible after the complication. For any emergencies at any time or if you are unable to contact a member of the research team, please attend your local accident and emergency for an assessment.

12. What happens when the research study stops?

Once the results of the MRI and, if required, biopsy are available you will be called to clinic to discuss them. Once a treatment decision is made, most men in the study will complete the study and your normal clinical team will continue to look after your care. Being part of the study does not prevent you from undergoing any further diagnostic test or treatment that your clinician would normally recommend.

13. What if there is a problem?

Any complaint about the way you have been dealt with during the clinical study or any possible harm you might suffer will be addressed. The detailed information concerning this is given in Part 2 of this information sheet. If you have any concerns or complaints you should contact a member of the research team in the first instance.

14. Will my taking part in the study be kept confidential?

Yes. We will follow ethical and legal practice and all information about you will be handled in confidence. The details are included in Part 2.

15. Will any costs I incur in travelling to study visits be reimbursed to me?

Reasonable transport costs that you incur to get to additional study visits (if any further visits are necessary) that are above what you would normally need if you were not part of the study may be reimbursed. Please contact your local study nurse or doctor or the Study Coordinator (details below) for further information on claiming.

16. Contact Details

If you have any further questions or need any further information please do no hesitate to contact the research team.

or the Chief Investigator:

Mr Veeru Kasivisvanathan MBBS BSc FRCS MSc PGCert PhD Division of Surgery and Interventional Science, University College London 3rd floor Charles Bell House, 43-45 Foley Street London W1W 7TS T: 0207 679 9092 F: 0207 679 9511 E: veeru.kasi@ucl.ac.uk

This completes Part 1 of the Information Sheet.

If the information in Part 1 has interested you and you are considering participation, please read the additional information in Part 2 before making any decision.

review only

Part 2

17. What if relevant new information becomes available?

Sometimes we get new information about the procedures being studied. If this happens and we feel it is important to your participation in the study, we will tell you about it and discuss whether you want to or should continue in the study. If you decide not to carry on, we will make arrangements for your care to continue. If you decide to continue in the study, we may ask you to sign an updated consent form. You can also find out if there is any new relevant information by visiting www.ncita.org.uk.

18. What will happen if I don't want to carry on with the study?

You can withdraw from the study at any point and it will not affect the care that you are given. We will use information collected about you up until your withdrawal. Kindly keep in contact with us to let us know your progress.

19. What if there is a problem?

If you have a concern about any aspect of this study, you should ask to speak to your research team who will do their best to answer your questions, please see point number 24. You can also contact the Chief Investigators on the number or address given earlier in this document. If you wish to complain by other means or have any concerns about any aspect of the way you have been approached or treated by members of staff or about any side effects (adverse events) you may have experienced due to your participation in the clinical study, the normal National Health Service complaints mechanisms are available to you. You can contact the hospital Patient Advice and Liaison Service (PALS). Your local PALS team can be contacted at the following number:

Local team to insert contact details of local PALS office here:

You can also contact NHS helpline at 111 which will be able to give you the number of your local PALS office if you are concerned.

Every care will be taken in the course of this clinical study. However in the unlikely event that you are injured by taking part, compensation may be available.

If you suspect that the injury is the result of the Sponsor's (University College London) or the hospital's negligence, then you may be able to claim compensation. After discussing with your study doctor, please make the claim in writing to Mr Veeru Kasivisvanathan who is the Chief Investigator for the clinical study and is based at University College London. The Chief Investigator will then pass the claim to the Sponsor's Insurers, via the Sponsor's office. You may have to bear the costs of the legal action initially, and you should consult a lawyer about this.

20. Will my taking part in this study be kept confidential?

If you consent to take part in this study, the records obtained while you are in this study as well as related health records will remain strictly confidential at all times. The information will be held securely on paper and electronically at your treating hospital under the provisions of the Data Protection Act 2018 and the General Data Protection Regulations 2018. The information will be made available to persons in the clinical and research teams treating you. Your name and personal details will not be passed to anyone else outside the clinical team, research team or the Sponsor, who is not involved in the study. No additional samples will be taken specially for research in this study. All The research team may verify results of tests carried out at your local hospital (for example MRI results or prostate biopsy results) by transferring and analysing a small number of samples collected to UCL. samples and information collected will be de-identified to you prior to transfer to UCL, so only non-identifiable data will be transferred to UCL. This includes some pathology glass slides, which will be reviewed at Dr Alex Freeman's laboratory at University College London (UCL), for quality control. Slides sent to UCL will be

 not have your name assigned. Samples will be sent using one of UCL's preferred couriers, for both pick up and return.

Any data stored by the research team outside of your treating hospital will be kept at a secure location and will not contain information that can directly identify you. You will be allocated a study number, which will be used as a code to identify you on all study forms and data. The information will be linked to you so that if we did need to identify you for your safety or to clarify some information we would be able to by using a unique key, which will be known only to your local hospital team.

Your records will be available to people authorised to work on the study but may also need to be made available to people authorised by the Sponsor, which is the organisation responsible for ensuring that the study is carried out correctly. By signing the consent form, you agree to this access for the current study and any further research that may be conducted in relation to it, even if you withdraw from the current study. All will have a duty of confidentiality to you as a research participant.

If you withdraw consent from further study treatment, your data and samples will remain on file and will be included in the final study analysis.

In line with the regulations, at the end of the study your data will be securely archived for 20 years. Arrangements for confidential destruction will then be made.

Anonymised data collected during the study may be transferred for the purpose of processing or analysis to approved associated researchers and commercial partners within/outside the European Economic Area. The Sponsor of the study will take all reasonable steps to protect your privacy.

In the future we may publish our findings from the study in scientific journals, but you will not be identifiable in any publications.

21. Will my GP be informed of my involvement?

Because this study is not being carried out by your GP, we would like to inform them of your participation. If you agree to take part and agree to us contacting your GP, we will give him or her details of the study and inform them that you have chosen to participate in it. You will not be able to participate in this study if you do not give us this permission to inform your GP.

22. What will happen to the results of the research study?

The results of the study will be available after it finishes and will usually be published online in a medical journal and presented at a scientific conference, they will also be posted to. The data will be anonymous and it will not be possible to identify you in any report or publication. Sometimes the data may be used to teach other healthcare professionals how to treat patients in a similar position to you.

Should you wish to see the results, or the publication, please ask your study doctor or see the trial website on <u>https://www.ucl.ac.uk/surgery/research/research-department-targeted-intervention/prime-trial-information</u>, or the clinical trials units website www.ncita.org.uk.

23. Who is organising and funding the research?

The governance sponsor is University College London. The study is funded by Prostate Cancer UK, the European Association of Urology Research Foundation, the UK National Institute for Health Research via an Academic Clinical Lectureship to Dr Veeru Kasivisvanathan and the UK National Cancer Imaging Translational Accelerator.

24. Who has reviewed the study?

All research in the NHS is looked at by an independent group of people, called a Research Ethics Committee, to protect your interests. This study has been reviewed and given favorable opinion by National Research Ethics Service Committee _West Midlands - Black Country Research Ethics Committee. Patients and members of the public have also reviewed the study documents to ensure they are appropriate and well written.

25. Further information

You are encouraged to ask any questions you wish, before, during or after your investigations. If you have any questions about the study, please speak to your study nurse or doctor on the numbers specified below, who will be able to provide you with up to date information about the procedures involved. If you wish to read the research on which this study is based, please ask your study nurse or doctor.

Site Study staff contact details:

Principal Investigator (site) details:

Alternatively, if you or your relatives have any questions about this study you may wish to contact one of the following organisations that are independent of the hospital at which you are being treated:

Prostate Cancer UK - 0800 082 1616 - http://prostatecanceruk.org

Macmillan Cancer Support - 0808 808 0000 - http://www.macmillan.org.uk

If you decide you would like to take part then please read and sign the consent form. You will be given a copy of this information sheet and the consent form to keep. A copy of the consent form will be filed in your patient notes, one will be filed with the study records and one may be sent to the Research Sponsor.

You can have more time to think this over if you are at all unsure.

Thank you for taking the time to read this information sheet and to consider this study.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and

provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRITreporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A,

Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D, SPIRIT 2013 Explanation and

Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586

m as: text and data mining, Al training, and similar technologies. Reporting Item **Administrative** information

- Descriptive title identifying the study design, Title #1 population, interventions, and, if applicable, trial acronym
- Trial registration #2a Trial identifier and registry name. If not yet

BMJ Open		

1 2			registered, name of intended registry	
3 4	Trial registration:	<u>#2b</u>	All items from the World Health Organization Trial	Table 3
5 6 7	data set		Registration Data Set	
8 9 10 11	Protocol version	<u>#3</u>	Date and version identifier	Table 4
12 13	Funding	<u>#4</u>	Sources and types of financial, material, and other	#13ted
14 15			support	by сор
16 17 18	Roles and	<u>#5a</u>	Names, affiliations, and roles of protocol	vright #13t
19 20	responsibilities:		contributors	includ
21 22 23	contributorship			ling for us
24 25 26	Roles and	<u>#5b</u>	Name and contact information for the trial sponsor	Table 5
27 28	responsibilities:			ited to
29 30	sponsor contact			text ar
32 33	information			nd data r
34 35 36	Roles and	<u>#5c</u>	Role of study sponsor and funders, if any, in study	Table 5
37 38	responsibilities:		design; collection, management, analysis, and	Al trai
39 40	sponsor and funder		interpretation of data; writing of the report; and the	ning, a
41 42 43			decision to submit the report for publication,	and sin
44 45			including whether they will have ultimate authority	nilar te
46 47 48			over any of these activities	chnolog
49 50	Roles and	<u>#5d</u>	Composition, roles, and responsibilities of the	Table 5 [.]
51 52	responsibilities:		coordinating centre, steering committee, endpoint	
55 55	committees		adjudication committee, data management team,	
56 57 58			and other individuals or groups overseeing the trial,	
59 60		For peer	review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

		if applicable (see Item 21a for data monitoring committee)
Introduction		
Background and	<u>#6a</u>	Description of research question and justification for
rationale		undertaking the trial, including summary of relevant
		studies (published and unpublished) examining
		benefits and harms for each intervention
Background and	<u>#6b</u>	Explanation for choice of comparators
rationale: choice of		
comparators		
Objectives	<u>#7</u>	Specific objectives or hypotheses
Trial design	<u>#8</u>	Description of trial design including type of trial (eg,
		parallel group, crossover, factorial, single group),
		allocation ratio, and framework (eg, superiority,
		equivalence, non-inferiority, exploratory)
Methods:		
Participants,		
interventions, and		
outcomes		
Study setting	<u>#9</u>	Description of study settings (eg, community clinic,
		academic hospital) and list of countries where data
		will be collected. Reference to where list of study
		sites can be obtained
	For peer	review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2022-070280 on 5 April 2023. Downloaded from http://bmjopen.bmj.com/ on May 20, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1 2	Eligibility criteria	<u>#10</u>	Inclusion and exclusion criteria for participants. If
3 4			applicable, eligibility criteria for study centres and
5 6 7			individuals who will perform the interventions (eg,
7 8 9			surgeons, psychotherapists)
10 11 12	Interventions:	<u>#11a</u>	Interventions for each group with sufficient detail to
13 14	description		allow replication, including how and when they will
15 16 17			be administered
18 19 20	Interventions:	<u>#11b</u>	Criteria for discontinuing or modifying allocated
20 21 22	modifications		interventions for a given trial participant (eg, drug
23 24			dose change in response to harms, participant
25 26 27			request, or improving / worsening disease)
28 29	Interventions:	<u>#11c</u>	Strategies to improve adherence to intervention
30 31 32	adherance		protocols, and any procedures for monitoring
33 34 35			adherence (eg, drug tablet return; laboratory tests)
36 37	Interventions:	<u>#11d</u>	Relevant concomitant care and interventions that
38 39 40	concomitant care		are permitted or prohibited during the trial
41 42	Outcomes	<u>#12</u>	Primary, secondary, and other outcomes, including
43 44 45			the specific measurement variable (eg, systolic
46 47			blood pressure), analysis metric (eg, change from
48 49			baseline, final value, time to event), method of
50 51			aggregation (eg, median, proportion), and time point
52 53			for each outcome. Explanation of the clinical
55 56			relevance of chosen efficacy and harm outcomes is
57 58			strongly recommended
59 60		For peer r	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2	Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions	Table 2 and	BMU
3 4			(including any run-ins and washouts), assessments,	Figure 1	Open
5 6 7			and visits for participants. A schematic diagram is		: first
7 8 9			highly recommended (see Figure)		publish
10 11 12	Sample size	<u>#14</u>	Estimated number of participants needed to achieve	Protec #9tec	ied as 1
13 14			study objectives and how it was determined,	ted by	0.1136
15 16			including clinical and statistical assumptions	соруг	i/bmjop
17 18 19			supporting any sample size calculations	ight, incl	en-2022-
20 21 22	Recruitment	<u>#15</u>	Strategies for achieving adequate participant	uding f #9g f	-07028(
23 24 25			enrolment to reach target sample size	or uses r) on 5 Ap
26 27	Methods:			elated	ril 2023 Erasm
28 29 30	Assignment of			to text	3. Dowr
31 32	interventions (for			and di	nloade Iescho
33 34 35	controlled trials)			ata minir	d from h
36 37	Allocation:	<u>#16a</u>	Method of generating the allocation sequence (eg,	ng, N/A ⊨	ttp://br
38 39 40	sequence		computer-generated random numbers), and list of	raining	njopen
40 41 42	generation		any factors for stratification. To reduce predictability	, and s	.bmj.c
43 44			of a random sequence, details of any planned	similar	om/ or
45 46			restriction (eg, blocking) should be provided in a	techn	ר May
47 48			separate document that is unavailable to those who	ologie	20, 20:
49 50 51			enrol participants or assign interventions	Ň	25 at Dep
52 53 54	Allocation	<u>#16b</u>	Mechanism of implementing the allocation	N/A	bartmen
55 56	concealment		sequence (eg, central telephone; sequentially		t GEZ-
57 58 50	mechanism		numbered, opaque, sealed envelopes), describing		·LTA
60 59		For peer r	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml		

1			any steps to conceal the sequence until	
2 3 4			interventions are assigned	
5 6 7	Allocation:	<u>#16c</u>	Who will generate the allocation sequence, who will	N/A
, B 9	implementation		enrol participants, and who will assign participants	
10 11			to interventions	Protec
2 3 4	Blinding (masking)	<u>#17a</u>	Who will be blinded after assignment to	N/Ay
5 5			interventions (eg, trial participants, care providers,	copyri
/ 8 9			outcome assessors, data analysts), and how	ght, incl
) <u>2</u>	Blinding (masking):	<u>#17b</u>	If blinded, circumstances under which unblinding is	N/Ag
3 1	emergency		permissible, and procedure for revealing a	or use
5	unblinding		participant's allocated intervention during the trial	s relate
;	Methods: Data			d to text
))	collection,			and c
2 3 4	management, and			lata mi
5	analysis			ning, Al
3	Data collection plan	<u>#18a</u>	Plans for assessment and collection of outcome,	#9 and
•			baseline, and other trial data, including any related	Supplementary
			processes to promote data quality (eg, duplicate	Appendix 1
			measurements, training of assessors) and a	r techr
,			description of study instruments (eg,	nologie
)			questionnaires, laboratory tests) along with their	Ň
2 3			reliability and validity, if known. Reference to where	
4 5			data collection forms can be found, if not in the	
6 7 8			protocol	
9 0		For peer r	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Data collection plan:	<u>#18b</u>	Plans to promote participant retention and complete	#9
3 4	retention		follow-up, including list of any outcome data to be	
5 6 7			collected for participants who discontinue or deviate	
, 8 9			from intervention protocols	
10 11 12	Data management	<u>#19</u>	Plans for data entry, coding, security, and storage,	#9
13 14			including any related processes to promote data	
15 16 17			quality (eg, double data entry; range checks for data	
17 18 19			values). Reference to where details of data	
20 21			management procedures can be found, if not in the	
22 23 24			protocol	
25 26	Statistics: outcomes	<u>#20a</u>	Statistical methods for analysing primary and	#1(
27 28 29			secondary outcomes. Reference to where other	
30 31			details of the statistical analysis plan can be found,	
32 33			if not in the protocol	
35 36	Statistics: additional	<u>#20b</u>	Methods for any additional analyses (eg, subgroup	#10
37 38 39	analyses		and adjusted analyses)	
40 41	Statistics: analysis	<u>#20c</u>	Definition of analysis population relating to protocol	#10
42 43 44	population and		non-adherence (eg, as randomised analysis), and	
45 46	missing data		any statistical methods to handle missing data (eg,	
47 48 49			multiple imputation)	
49 50 51 52	Methods: Monitoring			
53 54 55	Data monitoring:	<u>#21a</u>	Composition of data monitoring committee (DMC);	#1 ⁻
56 57	formal committee		summary of its role and reporting structure;	
58 59 60	1	For peer r	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

		statement of whether it is independent from the	
		sponsor and competing interests; and reference to	
		where further details about its charter can be found,	
		if not in the protocol. Alternatively, an explanation of	
		why a DMC is not needed	Ţ
Data manitarina:	#216	Description of any interim analyses and stanning	otecte
	<u>#210</u>		#11ă 94 04
interim analysis		guidelines, including who will have access to these	соруги
		interim results and make the final decision to	gnt, In
		terminate the trial	
Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and	ق #119 ل
		managing solicited and spontaneously reported	ises re
		adverse events and other unintended effects of trial	lated t
		interventions or trial conduct	o text a
Auditing	<u>#23</u>	Frequency and procedures for auditing trial	Table 5
		conduct, if any, and whether the process will be	
		independent from investigators and the sponsor	9, Al t
			rainin
Ethics and			g, ano
dissemination			SIMI
Research ethics	<u>#24</u>	Plans for seeking research ethics committee /	#111 #11
approval		institutional review board (REC / IRB) approval	loop
Protocol	<u>#25</u>	Plans for communicating important protocol	Table 4
amendments		modifications (eg, changes to eligibility criteria,	
		outcomes, analyses) to relevant parties (eg,	
		investigators, REC / IRBs, trial participants, trial	
	For peer r	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1			registries, journals, regulators)	B
3	Consent or assent	<u>#26a</u>	Who will obtain informed consent or assent from	#12 pp
5 6 7			potential trial participants or authorised surrogates,	: first
7 8 9			and how (see Item 32)	publish
10 11 12	Consent or assent:	<u>#26b</u>	Additional consent provisions for collection and use	Supplementarytect 10.
13 14 15	ancillary studies		of participant data and biological specimens in	Appendix 3
15 16 17			ancillary studies, if applicable	:opyrig
18 19 20	Confidentiality	<u>#27</u>	How personal information about potential and	10-2022-0 #12inclu #12lu
21 22			enrolled participants will be collected, shared, and	ding f
23 24			maintained in order to protect confidentiality before,	or use
25 26 27			during, and after the trial	April 202 Eras s relatec
28 29 30	Declaration of	<u>#28</u>	Financial and other competing interests for principal	1 to tshog #12 text #12 text
31 32	interests		investigators for the overall trial and each study site	and dat
33 34 35	Data access	<u>#29</u>	Statement of who will have access to the final trial	a - from #12mi - m
36 37			dataset, and disclosure of contractual agreements	ng, Al t
38 39 40			that limit such access for investigators	mjopen.t
41 42 42	Ancillary and post	<u>#30</u>	Provisions, if any, for ancillary and post-trial care,	#111 sir
43 44 45	trial care		and for compensation to those who suffer harm	n/ on l nilar te
46 47			from trial participation	schnolog
48 49 50	Dissemination	<u>#31a</u>	Plans for investigators and sponsor to communicate	gies: #12 [:] at
51 52	policy: trial results		trial results to participants, healthcare professionals,	Depari
53 54 55			the public, and other relevant groups (eg, via	tment
56 57 58			publication, reporting in results databases, or other	GEZ-LTA
59 60		For peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

		data sharing arrangements), including any	
		publication restrictions	
Dissemination	<u>#31b</u>	Authorship eligibility guidelines and any intended	#12
policy: authorship		use of professional writers	
Dissemination	<u>#31c</u>	Plans, if any, for granting public access to the full	Protect #12ect
policy: reproducible		protocol, participant-level dataset, and statistical	ed by
research		code	copyri
Appendices			ght, includi
Informed consent	<u>#32</u>	Model consent form and other related	ی Supplementary
materials		documentation given to participants and authorised	Appendix 3
		surrogates	elated to
Biological	<u>#33</u>	Plans for collection, laboratory evaluation, and	Supplementary
specimens		storage of biological specimens for genetic or	ط Appendix 1 and 2
		molecular analysis in the current trial and for future	minir
		use in ancillary studies, if applicable	ηg, Al t
Notes:			raining,
18a: #11 and Supplementary Appendix 1			
26b: Supplementary Appendix 3			
• 32: Supplementary Appendix 3			
33: Supplementary Appendix 1 and 2			
• The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative			
Commons Attribution License CC-BY-NC. This checklist was completed on 16. November 2022			
BMJ Open

1 2 3 4 5	using https://www.goodreports.org/ , a tool made by the EQUATOR Network in collaboration with Penelope.ai
$ \begin{array}{c} 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 20 \\ 21 \\ 22 \\ 23 \\ 24 \\ 25 \\ 26 \\ 27 \\ 28 \\ 29 \\ 30 \\ 31 \\ 32 \\ 33 \\ 34 \\ 35 \\ 36 \\ 37 \\ 38 \\ 39 \\ 40 \\ 41 \\ 42 \\ 43 \\ 44 \\ 45 \\ 46 \\ 47 \\ 48 \\ 49 \\ 50 \\ 51 \\ 52 \\ 53 \\ 54 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ 55 \\ $	Procedure reproduced in the pr
56 57 58 59 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml